



PATENT
Customer No. 22,852
Attorney Docket No. 3495.0010-20

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Marc ALIZON et al.) Group Art Unit: 1637
)
Application No.: 08/308,219) Examiner: Jeffrey Norman Fredman
)
Filed: September 19, 1994) Confirmation No.: 4832
)
For: DNA SEQUENCE OF THE LTR REGION OF HUMAN IMMUNODEFICIENCY
VIRUS TYPE 1 (HIV-1) (as amended)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

REQUEST TO CORRECT INVENTORSHIP

Pursuant to 37 C.F.R. § 1.48, applicants request that the inventorship in this application be corrected as follows.

Pursuant to 37 C.F.R. § 1.48 (c), please add the following inventors to this application:

Robert C. Gallo,
Milkulas Popovic,
Mangalasseril G. Sarngadharan,
Solange Chamaret,
Claudine Axler-Bin,
Francoise Rey,
Marie-Therese Nugeyre,
Jacqueline Gruet,
Charles Dauget,
Willy Rozenbaum,
Christine Rouzioux,
Francoise Brun-Vezinet,
Luc Montagnier,
Jean-Claude Chermann,

06/06/2006 JADD01 00000001 08308219
06 FC:1464 130.00 OP

BEST AVAILABLE COPY

Francoise Barre-Sinoussi, and
Pierre Tiollais.

The addition of the above-named inventors is necessitated by amendment of the claims during prosecution of this application.

A statement from each person being added as an inventor that the addition is necessitated by amendment of the claims and that the inventorship error occurred without deceptive intent is enclosed.

A Declaration by each of the actual inventors is enclosed. One copy of the application is enclosed although each Declaration was attached to a copy of the application when it was executed. The duplicate copies of the application have been removed to reduce the size of the submission, but will be provided by applicants if the Examiner requires them.

The written consent of each of the assignees is enclosed.

A check for the required fee of \$130.00 under § 1.17(c) is enclosed.


Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: June 5, 2006

By: _____


Salvatore J. Arrigo
Registration No. 46,063
Telephone: 202-408-4160
Facsimile: 202-408-4400
E-mail: arrigos@finnegan.com

DECLARATION

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; I believe I am an original, first, and joint inventor of the subject matter of claims 25, 29, and 32, which is claimed and for which a patent is sought on the invention entitled: DNA SEQUENCE OF THE LTR REGION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) the specification of which was filed on September 19, 1994, as United States Application No. 08/308,219 and Confirmation No. 4832.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims. I acknowledge the duty to disclose information, which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate or § 365(a) of any PCT international application(s) designating at least one country other than the United States, listed below and have also identified below, any foreign application(s) for patent or inventor's certificate, or any PCT International application(s) having a filing date before that of the application(s) of which priority is claimed:

Country	Application Number	Date of Filing	Priority Claimed Under 35 U.S.C. 119
UNITED KINGDOM	84 29099	November 16, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
FRANCE	84 16013	October 18, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	84 23659	September 19, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	83 24800	September 15, 1983	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO


I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional applications listed below:

Application Number	Date of Filing

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) or § 365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of claims 25, 29, and 32 of this application is not disclosed in the prior United States or PCT International application(s) in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application(s) and the national or PCT International filing date of this application:

Application Number	Date of Filing	Status (Patented, Pending, Abandoned)
06/771,248	August 30, 1985	Abandoned
07/999,410	December 31, 1992	Pending
07/499,210	March 19, 1990	Pending
06/771,230	August 30, 1985	Abandoned
06/706,562	February 28, 1985	Abandoned
06/558,109	December 5, 1983	Abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full Name of First Inventor: Robert C. Gallo	Inventor's Signature 	Date May 31, '06
Residence 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		Citizenship United States
Post Office Address 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		
Full Name of Second Inventor Mikulas Popovic	Inventor's Signature	Date
Residence 9917 Holmhurst Road, Bethesda, Maryland 20817		Citizenship United States
Post Office Address 9917 Holmhurst Road, Bethesda, Maryland 20817		
Full Name of Third Inventor: Mangalasseril G. Sarngadharan	Inventor's Signature	Date
Residence 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		Citizenship United States
Post Office Address 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		
Full Name of Fourth Inventor: Solange Chamaret	Inventor's Signature	Date
Residence 138 boulevard Voltaire, 750M Paris, France		Citizenship French
Post Office Address 138 boulevard Voltaire, 750M Paris, France		
Full Name of Fifth Inventor: Claudine Axler-Blin	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Sixth Inventor Francoise Rey	Inventor's Signature	Date
Residence 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		Citizenship French
Post Office Address 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		
Full Name of Seventh Inventor: Marie-Therese Nugeyre	Inventor's Signature	Date
Residence 92130 Issy-les-Moulineaux, France		Citizenship French
Post Office Address 92130 Issy-les-Moulineaux, France		
Full Name of Eighth Inventor Jacqueline Gruet (Deceased) Jacques Gruet (Legal Successor)	Inventor's Signature	Date
Residence Grue du Gué, 94240 L'Hay les Roses, France		Citizenship French
Post Office Address Grue du Gué, 94240 L'Hay les Roses, France		

Full Name of Ninth Inventor: Charles Dauguet	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Tenth Inventor Willy Rozenbaum	Inventor's Signature	Date
Residence 20 rue de Sucy, 94430 Chennnevières-sur-Marne, France		Citizenship French
Post Office Address 20 rue de Sucy, 94430 Chennnevières-sur-Marne, France		
Full Name of Eleventh Inventor: Christine Rouzioux	Inventor's Signature	Date
Residence 21 rue de Dantzig, 75015 Paris, France		Citizenship French
Post Office Address 21 rue de Dantzig, 75015 Paris, France		
Full Name of Twelfth Inventor Francois Brun-Vezinet	Inventor's Signature	Date
Residence 24 boulevard Saint Germain, 75005 Paris, France		Citizenship French
Post Office Address 24 boulevard Saint Germain, 75005 Paris, France		
Full Name of Thirteenth Inventor: Luc Montagnier	Inventor's Signature	Date
Residence 21 rue de Malabry, 92350 Le Plessis-Robinson, France		Citizenship French
Post Office Address 21 rue de Malabry, 92350 Le Plessis-Robinson, France		
Full Name of Fourteenth Inventor Jean-Claude Chermann	Inventor's Signature	Date
Residence Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		Citizenship French
Post Office Address Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		
Full Name of Fifteenth Inventor: Francoise Barre-Sinoussi	Inventor's Signature	Date
Residence 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		Citizenship French
Post Office Address 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		
Full Name of Sixteenth Inventor Pierre Tiollais	Inventor's Signature	Date
Residence 16 rue de la Glaciere, 75013 Paris, France		Citizenship French
Post Office Address 16 rue de la Glaciere, 75013 Paris, France		

Full Name of Seventeenth Inventor: Marc Alizon	Inventor's Signature	Date
Residence 26 rue Censier, 75005 Paris, France		Citizenship French
Post Office Address 26 rue Censier, 75005 Paris, France		
Full Name of Eighteenth Inventor Pierre Sonigo	Inventor's Signature	Date
Residence 21 rue Gutenberg, 75015 Paris, France		Citizenship French
Post Office Address 21 rue Gutenberg, 75015 Paris, France		
Full Name of Nineteenth Inventor: Simon Wain-Hobson	Inventor's Signature	Date
Residence 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		Citizenship United Kingdom
Post Office Address 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		
Full Name of Twentieth Inventor Stewart Cole	Inventor's Signature	Date
Residence 23 bis rue Cécile Dunant, 92140 Clahart, France		Citizenship United Kingdom
Post Office Address 23 bis rue Cécile Dunant, 92140 Clahart, France		
Full Name of Twenty-First Inventor: Oliver Danos	Inventor's Signature	Date
Residence 173 rue Saint Merry, 7730 Fontainebleau, France		Citizenship French
Post Office Address 173 rue Saint Merry, 7730 Fontainebleau, France		



DECLARATION

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; I believe I am an original, first, and joint inventor of the subject matter of claims 25, 29, and 32, which is claimed and for which a patent is sought on the invention entitled: DNA SEQUENCE OF THE LTR REGION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) the specification of which was filed on September 19, 1994, as United States Application No. 08/308,219 and Confirmation No. 4832.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims. I acknowledge the duty to disclose information, which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate or § 365(a) of any PCT international application(s) designating at least one country other than the United States, listed below and have also identified below, any foreign application(s) for patent or inventor's certificate, or any PCT International application(s) having a filing date before that of the application(s) of which priority is claimed:

Country	Application Number	Date of Filing	Priority Claimed Under 35 U.S.C. 119
UNITED KINGDOM	84 29099	November 16, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
FRANCE	84 16013	October 18, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	84 23659	September 19, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	83 24800	September 15, 1983	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO


I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional applications listed below:

Application Number	Date of Filing

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) or § 365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of claims 25, 29, and 32 of this application is not disclosed in the prior United States or PCT International application(s) in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application(s) and the national or PCT International filing date of this application:


Application Number	Date of Filing	Status (Patented, Pending, Abandoned)
06/771,248	August 30, 1985	Abandoned
07/999,410	December 31, 1992	Pending
07/499,210	March 19, 1990	Pending
06/771,230	August 30, 1985	Abandoned
06/706,562	February 28, 1985	Abandoned
06/558,109	December 5, 1983	Abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full Name of First Inventor: Robert C. Gallo	Inventor's Signature	Date
Residence 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		Citizenship United States
Post Office Address 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		
Full Name of Second Inventor Mikulas Popovic	Inventor's Signature 	Date 6.1.2006
Residence 9917 Holmhurst Road, Bethesda, Maryland 20817		Citizenship United States
Post Office Address 9917 Holmhurst Road, Bethesda, Maryland 20817		
Full Name of Third Inventor: Mangalasseril G. Samgadharan	Inventor's Signature	Date
Residence 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		Citizenship United States
Post Office Address 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		
Full Name of Fourth Inventor: Solange Chamaret	Inventor's Signature	Date
Residence 138 boulevard Voltaire, 750M Paris, France		Citizenship French
Post Office Address 138 boulevard Voltaire, 750M Paris, France		
Full Name of Fifth Inventor: Claudine Axler-Blin	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Sixth Inventor Francoise Rey	Inventor's Signature	Date
Residence 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		Citizenship French
Post Office Address 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		
Full Name of Seventh Inventor: Marie-Therese Nugeyre	Inventor's Signature	Date
Residence 92130 Issy-les-Moulineaux, France		Citizenship French
Post Office Address 92130 Issy-les-Moulineaux, France		
Full Name of Eighth Inventor Jacqueline Gruet (Deceased) Jacques Gruet (Legal Successor)	Inventor's Signature	Date
Residence Grue du Gué, 94240 L'Hay les Roses, France		Citizenship French
Post Office Address Grue du Gué, 94240 L'Hay les Roses, France		

Full Name of Ninth Inventor: Charles Dauguet	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Tenth Inventor Willy Rozenbaum	Inventor's Signature	Date
Residence 20 rue de Sucy, 94430 Chennnevières-sur-Marne, France		Citizenship French
Post Office Address 20 rue de Sucy, 94430 Chennnevières-sur-Marne, France		
Full Name of Eleventh Inventor: Christine Rouzioux	Inventor's Signature	Date
Residence 21 rue de Dantzig, 75015 Paris, France		Citizenship French
Post Office Address 21 rue de Dantzig, 75015 Paris, France		
Full Name of Twelfth Inventor Francois Brun-Vezinet	Inventor's Signature	Date
Residence 24 boulevard Saint Germain, 75005 Paris, France		Citizenship French
Post Office Address 24 boulevard Saint Germain, 75005 Paris, France		
Full Name of Thirteenth Inventor: Luc Montagnier	Inventor's Signature	Date
Residence 21 rue de Malabry, 92350 Le Plessis-Robinson, France		Citizenship French
Post Office Address 21 rue de Malabry, 92350 Le Plessis-Robinson, France		
Full Name of Fourteenth Inventor Jean-Claude Chermann	Inventor's Signature	Date
Residence Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		Citizenship French
Post Office Address Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		
Full Name of Fifteenth Inventor: Francoise Barre-Sinoussi	Inventor's Signature	Date
Residence 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		Citizenship French
Post Office Address 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		
Full Name of Sixteenth Inventor Pierre Tiollais	Inventor's Signature	Date
Residence 16 rue de la Glaciere, 75013 Paris, France		Citizenship French
Post Office Address 16 rue de la Glaciere, 75013 Paris, France		

Full Name of Seventeenth Inventor: Marc Alizon	Inventor's Signature	Date
Residence 26 rue Censier, 75005 Paris, France		Citizenship French
Post Office Address 26 rue Censier, 75005 Paris, France		
Full Name of Eighteenth Inventor Pierre Sonigo	Inventor's Signature	Date
Residence 21 rue Gutenberg, 75015 Paris, France		Citizenship French
Post Office Address 21 rue Gutenberg, 75015 Paris, France		
Full Name of Nineteenth Inventor: Simon Wain-Hobson	Inventor's Signature	Date
Residence 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		Citizenship United Kingdom
Post Office Address 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		
Full Name of Twentieth Inventor Stewart Cole	Inventor's Signature	Date
Residence 23 bis rue Cécile Dunant, 92140 Clahart, France		Citizenship United Kingdom
Post Office Address 23 bis rue Cécile Dunant, 92140 Clahart, France		
Full Name of Twenty-First Inventor: Oliver Danos	Inventor's Signature	Date
Residence 173 rue Saint Merry, 7730 Fontainebleau, France		Citizenship French
Post Office Address 173 rue Saint Merry, 7730 Fontainebleau, France		



DECLARATION

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; I believe I am an original, first, and joint inventor of the subject matter of claims 25, 29, and 32, which is claimed, and for which a patent is sought on the invention entitled: DNA SEQUENCE OF THE LTR REGION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) the specification of which was filed on September 19, 1994, as United States Application No. 08/308,219 and Confirmation No. 4832.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims. I acknowledge the duty to disclose information, which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate or § 365(a) of any PCT international application(s) designating at least one country other than the United States, listed below and have also identified below, any foreign application(s) for patent or inventor's certificate, or any PCT International application(s) having a filing date before that of the application(s) of which priority is claimed:

Country	Application Number	Date of Filing	Priority Claimed Under 35 U.S.C. 119
UNITED KINGDOM	84 29099	November 16, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
FRANCE	84 16013	October 18, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	84 23659	September 19, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	83 24800	September 15, 1983	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional applications listed below:

Application Number	Date of Filing

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) or § 365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of claims 25, 29, and 32 of this application is not disclosed in the prior United States or PCT International application(s) in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application(s) and the national or PCT International filing date of this application:


Application Number	Date of Filing	Status (Patented, Pending, Abandoned)
06/771,248	August 30, 1985	Abandoned
07/999,410	December 31, 1992	Pending
07/499,210	March 19, 1990	Pending
06/771,230	August 30, 1985	Abandoned
06/706,562	February 28, 1985	Abandoned
06/558,109	December 5, 1983	Abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full Name of First Inventor: Robert C. Gallo	Inventor's Signature	Date
Residence 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		Citizenship United States
Post Office Address 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		
Full Name of Second Inventor Mikulas Popovic	Inventor's Signature	Date
Residence 9917 Holmhurst Road, Bethesda, Maryland 20817		Citizenship United States
Post Office Address 9917 Holmhurst Road, Bethesda, Maryland 20817		
Full Name of Third Inventor: Mangalasseril G. Samgadharan	Inventor's Signature <i>Mangalasseril G. Samgadharan</i>	Date <i>June 4, 2006</i>
Residence 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		Citizenship United States
Post Office Address 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		
Full Name of Fourth Inventor: Solange Chamaret	Inventor's Signature	Date
Residence 138 boulevard Voltaire, 750M Paris, France		Citizenship French
Post Office Address 138 boulevard Voltaire, 750M Paris, France		
Full Name of Fifth Inventor: Claudine Axler-Blin	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Sixth Inventor Francoise Rey	Inventor's Signature	Date
Residence 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		Citizenship French
Post Office Address 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		
Full Name of Seventh Inventor: Marie-Therese Nugeyre	Inventor's Signature	Date
Residence 92130 Issy-les-Moulineaux, France		Citizenship French
Post Office Address 92130 Issy-les-Moulineaux, France		
Full Name of Eighth Inventor Jacqueline Gruet (Deceased) Jacques Gruet (Legal Successor)	Inventor's Signature	Date
Residence Grue du Gué, 94240 L'Hay les Roses, France		Citizenship French
Post Office Address Grue du Gué, 94240 L'Hay les Roses, France		

Full Name of Ninth Inventor: Charles Dauguet	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Tenth Inventor Willy Rozenbaum	Inventor's Signature	Date
Residence 20 rue de Sucy, 94430 Chennnevières-sur-Marne, France		Citizenship French
Post Office Address 20 rue de Sucy, 94430 Chennnevières-sur-Marne, France		
Full Name of Eleventh Inventor: Christine Rouzioux	Inventor's Signature	Date
Residence 21 rue de Dantzig, 75015 Paris, France		Citizenship French
Post Office Address 21 rue de Dantzig, 75015 Paris, France		
Full Name of Twelfth Inventor Francois Brun-Vezinet	Inventor's Signature	Date
Residence 24 boulevard Saint Germain, 75005 Paris, France		Citizenship French
Post Office Address 24 boulevard Saint Germain, 75005 Paris, France		
Full Name of Thirteenth Inventor: Luc Montagnier	Inventor's Signature	Date
Residence 21 rue de Malabry, 92350 Le Plessis-Robinson, France		Citizenship French
Post Office Address 21 rue de Malabry, 92350 Le Plessis-Robinson, France		
Full Name of Fourteenth Inventor Jean-Claude Chermann	Inventor's Signature	Date
Residence Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		Citizenship French
Post Office Address Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		
Full Name of Fifteenth Inventor: Francoise Barre-Sinoussi	Inventor's Signature	Date
Residence 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		Citizenship French
Post Office Address 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		
Full Name of Sixteenth Inventor Pierre Tiollais	Inventor's Signature	Date
Residence 16 rue de la Glaciere, 75013 Paris, France		Citizenship French
Post Office Address 16 rue de la Glaciere, 75013 Paris, France		

Full Name of Seventeenth Inventor: Marc Alizon	Inventor's Signature	Date
Residence 26 rue Censier, 75005 Paris, France		Citizenship French
Post Office Address 26 rue Censier, 75005 Paris, France		
Full Name of Eighteenth Inventor Pierre Sonigo	Inventor's Signature	Date
Residence 21 rue Gutenberg, 75015 Paris, France		Citizenship French
Post Office Address 21 rue Gutenberg, 75015 Paris, France		
Full Name of Nineteenth Inventor: Simon Wain-Hobson	Inventor's Signature	Date
Residence 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		Citizenship United Kingdom
Post Office Address 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		
Full Name of Twentieth Inventor Stewart Cole	Inventor's Signature	Date
Residence 23 bis rue Cécile Dunant, 92140 Clahart, France		Citizenship United Kingdom
Post Office Address 23 bis rue Cécile Dunant, 92140 Clahart, France		
Full Name of Twenty-First Inventor: Oliver Danos	Inventor's Signature	Date
Residence 173 rue Saint Merry, 7730 Fontainebleau, France		Citizenship French
Post Office Address 173 rue Saint Merry, 7730 Fontainebleau, France		



DECLARATION

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name. I am an original, first, and joint inventor of the subject matter, which is claimed and for which a patent is sought on the invention entitled: DNA SEQUENCE OF THE LTR REGION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) the specification of which was filed on September 19, 1994, as United States Application No. 08/308,219 and Confirmation No. 4832.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims. I acknowledge the duty to disclose information, which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate or § 365(a) of any PCT international application(s) designating at least one country other than the United States, listed below and have also identified below, any foreign application(s) for patent or inventor's certificate, or any PCT International application(s) having a filing date before that of the application(s) of which priority is claimed:

Country	Application Number	Date of Filing	Priority Claimed Under 35 U.S.C. 119
UNITED KINGDOM	84 29099	November 16, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
FRANCE	84 16013	October 18, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	84 23659	September 19, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	83 24800	September 15, 1983	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional applications listed below:

Application Number	Date of Filing

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) or § 365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application(s) in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application(s) and the national or PCT International filing date of this application:

Application Number	Date of Filing	Status (Patented, Pending, Abandoned)
06/771,248	August 30, 1985	Abandoned
07/999,410	December 31, 1992	Pending
07/499,210	March 19, 1990	Pending
06/771,230	August 30, 1985	Abandoned
06/706,562	February 28, 1985	Abandoned
06/558,109	December 5, 1983	Abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full Name of First Inventor: Robert C. Gallo	Inventor's Signature	Date
Residence 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		Citizenship United States
Post Office Address 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		
Full Name of Second Inventor Mikulas Popovic	Inventor's Signature	Date
Residence 9917 Holmhurst Road, Bethesda, Maryland 20817		Citizenship United States
Post Office Address 9917 Holmhurst Road, Bethesda, Maryland 20817		
Full Name of Third Inventor: Mangalasseril G. Samgadharan	Inventor's Signature	Date
Residence 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		Citizenship United States
Post Office Address 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		
Full Name of Fourth Inventor: Solange Chamaret	Inventor's Signature <i>S Chamaret</i>	Date 24-05-06
Residence 138 boulevard Voltaire, 750M Paris, France		Citizenship French
Post Office Address 138 boulevard Voltaire, 750M Paris, France		
Full Name of Fifth Inventor: Claudine Axler-Blin	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Sixth Inventor Francoise Rey	Inventor's Signature	Date
Residence 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		Citizenship French
Post Office Address 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		
Full Name of Seventh Inventor: Marie-Therese Nugeyre	Inventor's Signature	Date
Residence 92130 Issy-les-Moulineaux, France		Citizenship French
Post Office Address 92130 Issy-les-Moulineaux, France		
Full Name of Eighth Inventor Jacqueline Gruet (Deceased) Jacques Gruet (Legal Successor)	Inventor's Signature	Date
Residence Grue du Gué, 94240 L'Hay les Roses, France		Citizenship French
Post Office Address Grue du Gué, 94240 L'Hay les Roses, France		

Full Name of Ninth Inventor: Charles Dauguet	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Tenth Inventor Willy Rozenbaum	Inventor's Signature	Date
Residence 20 rue de Sucy, 94430 Chennnevières-sur-Marne, France		Citizenship French
Post Office Address 20 rue de Sucy, 94430 Chennnevières-sur-Marne, France		
Full Name of Eleventh Inventor: Christine Rouzioux	Inventor's Signature	Date
Residence 21 rue de Dantzig, 75015 Paris, France		Citizenship French
Post Office Address 21 rue de Dantzig, 75015 Paris, France		
Full Name of Twelfth Inventor Francois Brun-Vezinet	Inventor's Signature	Date
Residence 24 boulevard Saint Germain, 75005 Paris, France		Citizenship French
Post Office Address 24 boulevard Saint Germain, 75005 Paris, France		
Full Name of Thirteenth Inventor: Luc Montagnier	Inventor's Signature	Date
Residence 21 rue de Malabry, 92350 Le Plessis-Robinson, France		Citizenship French
Post Office Address 21 rue de Malabry, 92350 Le Plessis-Robinson, France		
Full Name of Fourteenth Inventor Jean-Claude Chermann	Inventor's Signature	Date
Residence Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		Citizenship French
Post Office Address Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		
Full Name of Fifteenth Inventor: Francoise Barre-Sinoussi	Inventor's Signature	Date
Residence 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		Citizenship French
Post Office Address 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		
Full Name of Sixteenth Inventor Pierre Tiollais	Inventor's Signature	Date
Residence 16 rue de la Glaciere, 75013 Paris, France		Citizenship French
Post Office Address 16 rue de la Glaciere, 75013 Paris, France		

Full Name of Seventeenth Inventor: Marc Alizon	Inventor's Signature	Date
Residence 26 rue Censier, 75005 Paris, France		Citizenship French
Post Office Address 26 rue Censier, 75005 Paris, France		
Full Name of Eighteenth Inventor Pierre Sonigo	Inventor's Signature	Date
Residence 21 rue Gutenberg, 75015 Paris, France		Citizenship French
Post Office Address 21 rue Gutenberg, 75015 Paris, France		
Full Name of Nineteenth Inventor: Simon Wain-Hobson	Inventor's Signature	Date
Residence 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		Citizenship United Kingdom
Post Office Address 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		
Full Name of Twentieth Inventor Stewart Cole	Inventor's Signature	Date
Residence 23 bis rue Cécile Dunant, 92140 Clahart, France		Citizenship United Kingdom
Post Office Address 23 bis rue Cécile Dunant, 92140 Clahart, France		
Full Name of Twenty-First Inventor: Oliver Danos	Inventor's Signature	Date
Residence 173 rue Saint Merry, 7730 Fontainebleau, France		Citizenship French
Post Office Address 173 rue Saint Merry, 7730 Fontainebleau, France		



DECLARATION

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; I believe I am an original, first, and joint inventor of the subject matter, which is claimed and for which a patent is sought on the invention entitled: DNA SEQUENCE OF THE LTR REGION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) the specification of which was filed on September 19, 1994, as United States Application No. 08/308,219 and Confirmation No. 4832.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims. I acknowledge the duty to disclose information, which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate or § 365(a) of any PCT international application(s) designating at least one country other than the United States, listed below and have also identified below, any foreign application(s) for patent or inventor's certificate, or any PCT International application(s) having a filing date before that of the application(s) of which priority is claimed:

Country	Application Number	Date of Filing	Priority Claimed Under 35 U.S.C. 119
UNITED KINGDOM	84 29099	November 16, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
FRANCE	84 16013	October 18, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	84 23659	September 19, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	83 24800	September 15, 1983	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional applications listed below:

Application Number	Date of Filing

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) or § 365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application(s) in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application(s) and the national or PCT International filing date of this application:

Application Number	Date of Filing	Status (Patented, Pending, Abandoned)
06/771,248	August 30, 1985	Abandoned
07/999,410	December 31, 1992	Pending
07/499,210	March 19, 1990	Pending
06/771,230	August 30, 1985	Abandoned
06/706,562	February 28, 1985	Abandoned
06/558,109	December 5, 1983	Abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full Name of First Inventor: Robert C. Gallo	Inventor's Signature	Date
Residence 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		Citizenship United States
Post Office Address 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		
Full Name of Second Inventor Mikulas Popovic	Inventor's Signature	Date
Residence 9917 Holmhurst Road, Bethesda, Maryland 20817		Citizenship United States
Post Office Address 9917 Holmhurst Road, Bethesda, Maryland 20817		
Full Name of Third Inventor: Mangalasseril G. Samgadharan	Inventor's Signature	Date
Residence 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		Citizenship United States
Post Office Address 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		
Full Name of Fourth Inventor: Solange Chamaret	Inventor's Signature	Date
Residence 138 boulevard Voltaire, 750M Paris, France		Citizenship French
Post Office Address 138 boulevard Voltaire, 750M Paris, France		
Full Name of Fifth Inventor: Claudine Axler-Blin	Inventor's Signature <i>C. Axler-Blin</i>	Date 26 Mar 2006
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Sixth Inventor Francoise Rey	Inventor's Signature	Date
Residence 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		Citizenship French
Post Office Address 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		
Full Name of Seventh Inventor: Marie-Therese Nugeyre	Inventor's Signature	Date
Residence 92130 Issy-les-Moulineaux, France		Citizenship French
Post Office Address 92130 Issy-les-Moulineaux, France		
Full Name of Eighth Inventor Jacqueline Gruet (Deceased) Jacques Gruet (Legal Successor)	Inventor's Signature	Date
Residence Grue du Gué, 94240 L'Hay les Roses, France		Citizenship French
Post Office Address Grue du Gué, 94240 L'Hay les Roses, France		

Full Name of Ninth Inventor: Charles Dauguet	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Tenth Inventor Willy Rozenbaum	Inventor's Signature	Date
Residence 20 rue de Sucy, 94430 Chennnevières-sur-Marne, France		Citizenship French
Post Office Address 20 rue de Sucy, 94430 Chennnevières-sur-Marne, France		
Full Name of Eleventh Inventor: Christine Rouzioux	Inventor's Signature	Date
Residence 21 rue de Dantzig, 75015 Paris, France		Citizenship French
Post Office Address 21 rue de Dantzig, 75015 Paris, France		
Full Name of Twelfth Inventor Francois Brun-Vezinet	Inventor's Signature	Date
Residence 24 boulevard Saint Germain, 75005 Paris, France		Citizenship French
Post Office Address 24 boulevard Saint Germain, 75005 Paris, France		
Full Name of Thirteenth Inventor: Luc Montagnier	Inventor's Signature	Date
Residence 21 rue de Malabry, 92350 Le Plessis-Robinson, France		Citizenship French
Post Office Address 21 rue de Malabry, 92350 Le Plessis-Robinson, France		
Full Name of Fourteenth Inventor Jean-Claude Chermann	Inventor's Signature	Date
Residence Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		Citizenship French
Post Office Address Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		
Full Name of Fifteenth Inventor: Francoise Barre-Sinoussi	Inventor's Signature	Date
Residence 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		Citizenship French
Post Office Address 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		
Full Name of Sixteenth Inventor Pierre Tiollais	Inventor's Signature	Date
Residence 16 rue de la Glaciere, 75013 Paris, France		Citizenship French
Post Office Address 16 rue de la Glaciere, 75013 Paris, France		

Full Name of Seventeenth Inventor: Marc Alizon	Inventor's Signature	Date
Residence 26 rue Censier, 75005 Paris, France		Citizenship French
Post Office Address 26 rue Censier, 75005 Paris, France		
Full Name of Eighteenth Inventor Pierre Sonigo	Inventor's Signature	Date
Residence 21 rue Gutenberg, 75015 Paris, France		Citizenship French
Post Office Address 21 rue Gutenberg, 75015 Paris, France		
Full Name of Nineteenth Inventor: Simon Wain-Hobson	Inventor's Signature	Date
Residence 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		Citizenship United Kingdom
Post Office Address 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		
Full Name of Twentieth Inventor Stewart Cole	Inventor's Signature	Date
Residence 23 bis rue Cécile Dunant, 92140 Clahart, France		Citizenship United Kingdom
Post Office Address 23 bis rue Cécile Dunant, 92140 Clahart, France		
Full Name of Twenty-First Inventor: Oliver Danos	Inventor's Signature	Date
Residence 173 rue Saint Merry, 7730 Fontainebleau, France		Citizenship French
Post Office Address 173 rue Saint Merry, 7730 Fontainebleau, France		



DECLARATION

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; I believe I am an original, first, and joint inventor of the subject matter, which is claimed and for which a patent is sought on the invention entitled: DNA SEQUENCE OF THE LTR REGION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) the specification of which was filed on September 19, 1994, as United States Application No. 08/308,219 and Confirmation No. 4832.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims. I acknowledge the duty to disclose information, which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate or § 365(a) of any PCT international application(s) designating at least one country other than the United States, listed below and have also identified below, any foreign application(s) for patent or inventor's certificate, or any PCT International application(s) having a filing date before that of the application(s) of which priority is claimed:

Country	Application Number	Date of Filing	Priority Claimed Under 35 U.S.C. 119
UNITED KINGDOM	84 29099	November 16, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
FRANCE	84 16013	October 18, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	84 23659	September 19, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	83 24800	September 15, 1983	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO


I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional applications listed below:

Application Number	Date of Filing

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) or § 365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application(s) in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application(s) and the national or PCT International filing date of this application:

Application Number	Date of Filing	Status (Patented, Pending, Abandoned)
06/771,248	August 30, 1985	Abandoned
07/999,410	December 31, 1992	Pending
07/499,210	March 19, 1990	Pending
06/771,230	August 30, 1985	Abandoned
06/706,562	February 28, 1985	Abandoned
06/558,109	December 5, 1983	Abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full Name of First Inventor: Robert C. Gallo	Inventor's Signature	Date
Residence 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		Citizenship United States
Post Office Address 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		
Full Name of Second Inventor Mikulas Popovic	Inventor's Signature	Date
Residence 9917 Holmhurst Road, Bethesda, Maryland 20817		Citizenship United States
Post Office Address 9917 Holmhurst Road, Bethesda, Maryland 20817		
Full Name of Third Inventor: Mangalasseril G. Samgadharan	Inventor's Signature	Date
Residence 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		Citizenship United States
Post Office Address 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		
Full Name of Fourth Inventor: Solange Chamaret	Inventor's Signature	Date
Residence 138 boulevard Voltaire, 750M Paris, France		Citizenship French
Post Office Address 138 boulevard Voltaire, 750M Paris, France		
Full Name of Fifth Inventor: Claudine Axler-Blin	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Sixth Inventor Francoise Rey	Inventor's Signature 	Date 9.5.2006
Residence 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		Citizenship French
Post Office Address 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		
Full Name of Seventh Inventor: Marie-Therese Nugeyre	Inventor's Signature	Date
Residence 92130 Issy-les-Moulineaux, France		Citizenship French
Post Office Address 92130 Issy-les-Moulineaux, France		
Full Name of Eighth Inventor Jacqueline Gruet (Deceased) Jacques Gruet (Legal Successor)	Inventor's Signature	Date
Residence Grue du Gué, 94240 L'Hay les Roses, France		Citizenship French
Post Office Address Grue du Gué, 94240 L'Hay les Roses, France		

Full Name of Ninth Inventor: Charles Dauguet	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Tenth Inventor Willy Rozenbaum	Inventor's Signature	Date
Residence 20 rue de Sucy, 94430 Chennnevières-sur-Mame, France		Citizenship French
Post Office Address 20 rue de Sucy, 94430 Chennnevières-sur-Mame, France		
Full Name of Eleventh Inventor: Christine Rouzioux	Inventor's Signature	Date
Residence 21 rue de Dantzig, 75015 Paris, France		Citizenship French
Post Office Address 21 rue de Dantzig, 75015 Paris, France		
Full Name of Twelfth Inventor Francois Brun-Vezinet	Inventor's Signature	Date
Residence 24 boulevard Saint Germain, 75005 Paris, France		Citizenship French
Post Office Address 24 boulevard Saint Germain, 75005 Paris, France		
Full Name of Thirteenth Inventor: Luc Montagnier	Inventor's Signature	Date
Residence 21 rue de Malabry, 92350 Le Plessis-Robinson, France		Citizenship French
Post Office Address 21 rue de Malabry, 92350 Le Plessis-Robinson, France		
Full Name of Fourteenth Inventor Jean-Claude Chermann	Inventor's Signature	Date
Residence Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		Citizenship French
Post Office Address Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		
Full Name of Fifteenth Inventor: Francoise Barre-Sinoussi	Inventor's Signature	Date
Residence 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		Citizenship French
Post Office Address 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		
Full Name of Sixteenth Inventor Pierre Tiollais	Inventor's Signature	Date
Residence 16 rue de la Glaciere, 75013 Paris, France		Citizenship French
Post Office Address 16 rue de la Glaciere, 75013 Paris, France		

Full Name of Seventeenth Inventor: Marc Alizon	Inventor's Signature	Date
Residence 26 rue Censier, 75005 Paris, France		Citizenship French
Post Office Address 26 rue Censier, 75005 Paris, France		
Full Name of Eighteenth Inventor Pierre Sonigo	Inventor's Signature	Date
Residence 21 rue Gutenberg, 75015 Paris, France		Citizenship French
Post Office Address 21 rue Gutenberg, 75015 Paris, France		
Full Name of Nineteenth Inventor: Simon Wain-Hobson	Inventor's Signature	Date
Residence 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		Citizenship United Kingdom
Post Office Address 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		
Full Name of Twentieth Inventor Stewart Cole	Inventor's Signature	Date
Residence 23 bis rue Cécile Dunant, 92140 Clahart, France		Citizenship United Kingdom
Post Office Address 23 bis rue Cécile Dunant, 92140 Clahart, France		
Full Name of Twenty-First Inventor: Oliver Danos	Inventor's Signature	Date
Residence 173 rue Saint Merry, 7730 Fontainebleau, France		Citizenship French
Post Office Address 173 rue Saint Merry, 7730 Fontainebleau, France		



DECLARATION

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; I believe I am an original, first, and joint inventor of the subject matter, which is claimed and for which a patent is sought on the invention entitled: DNA SEQUENCE OF THE LTR REGION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) the specification of which was filed on September 19, 1994, as United States Application No. 08/308,219 and Confirmation No. 4832.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims. I acknowledge the duty to disclose information, which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate or § 365(a) of any PCT international application(s) designating at least one country other than the United States, listed below and have also identified below, any foreign application(s) for patent or inventor's certificate, or any PCT International application(s) having a filing date before that of the application(s) of which priority is claimed:

Country	Application Number	Date of Filing	Priority Claimed Under 35 U.S.C. 119
UNITED KINGDOM	84 29099	November 16, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
FRANCE	84 16013	October 18, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	84 23659	September 19, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	83 24800	September 15, 1983	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO


I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional applications listed below:

Application Number	Date of Filing

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) or § 365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application(s) in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application(s) and the national or PCT International filing date of this application:

Application Number	Date of Filing	Status (Patented, Pending, Abandoned)
06/771,248	August 30, 1985	Abandoned
07/999,410	December 31, 1992	Pending
07/499,210	March 19, 1990	Pending
06/771,230	August 30, 1985	Abandoned
06/706,562	February 28, 1985	Abandoned
06/558,109	December 5, 1983	Abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full Name of First Inventor: Robert C. Gallo	Inventor's Signature	Date
Residence 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		Citizenship United States
Post Office Address 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		
Full Name of Second Inventor Mikulas Popovic	Inventor's Signature	Date
Residence 9917 Holmhurst Road, Bethesda, Maryland 20817		Citizenship United States
Post Office Address 9917 Holmhurst Road, Bethesda, Maryland 20817		
Full Name of Third Inventor: Mangalasseril G. Samgadharan	Inventor's Signature	Date
Residence 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		Citizenship United States
Post Office Address 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		
Full Name of Fourth Inventor: Solange Chamaret	Inventor's Signature	Date
Residence 138 boulevard Voltaire, 750M Paris, France		Citizenship French
Post Office Address 138 boulevard Voltaire, 750M Paris, France		
Full Name of Fifth Inventor: Claudine Axler-Blin	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Sixth Inventor Francoise Rey	Inventor's Signature	Date
Residence 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		Citizenship French
Post Office Address 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		
Full Name of Seventh Inventor: Marie-Therese Nugeyre	Inventor's Signature 	Date May 29 2006
Residence 92130 Issy-les-Moulineaux, France		Citizenship French
Post Office Address 92130 Issy-les-Moulineaux, France		
Full Name of Eighth Inventor Jacqueline Gruet (Deceased) Jacques Gruet (Legal Successor)	Inventor's Signature	Date
Residence Grue du Gué, 94240 L'Hay les Roses, France		Citizenship French
Post Office Address Grue du Gué, 94240 L'Hay les Roses, France		

Full Name of Ninth Inventor: Charles Dauguet	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Tenth Inventor Willy Rozenbaum	Inventor's Signature	Date
Residence 20 rue de Sucy, 94430 Chennnevières-sur-Marne, France		Citizenship French
Post Office Address 20 rue de Sucy, 94430 Chennnevières-sur-Marne, France		
Full Name of Eleventh Inventor: Christine Rouzioux	Inventor's Signature	Date
Residence 21 rue de Dantzig, 75015 Paris, France		Citizenship French
Post Office Address 21 rue de Dantzig, 75015 Paris, France		
Full Name of Twelfth Inventor Francois Brun-Vezinet	Inventor's Signature	Date
Residence 24 boulevard Saint Germain, 75005 Paris, France		Citizenship French
Post Office Address 24 boulevard Saint Germain, 75005 Paris, France		
Full Name of Thirteenth Inventor: Luc Montagnier	Inventor's Signature	Date
Residence 21 rue de Malabry, 92350 Le Plessis-Robinson, France		Citizenship French
Post Office Address 21 rue de Malabry, 92350 Le Plessis-Robinson, France		
Full Name of Fourteenth Inventor Jean-Claude Chermann	Inventor's Signature	Date
Residence Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		Citizenship French
Post Office Address Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		
Full Name of Fifteenth Inventor: Francoise Barre-Sinoussi	Inventor's Signature	Date
Residence 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		Citizenship French
Post Office Address 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		
Full Name of Sixteenth Inventor Pierre Tiollais	Inventor's Signature	Date
Residence 16 rue de la Glaciere, 75013 Paris, France		Citizenship French
Post Office Address 16 rue de la Glaciere, 75013 Paris, France		

Full Name of Seventeenth Inventor: Marc Alizon	Inventor's Signature	Date
Residence 26 rue Censier, 75005 Paris, France		Citizenship French
Post Office Address 26 rue Censier, 75005 Paris, France		
Full Name of Eighteenth Inventor Pierre Sonigo	Inventor's Signature	Date
Residence 21 rue Gutenberg, 75015 Paris, France		Citizenship French
Post Office Address 21 rue Gutenberg, 75015 Paris, France		
Full Name of Nineteenth Inventor: Simon Wain-Hobson	Inventor's Signature	Date
Residence 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		Citizenship United Kingdom
Post Office Address 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		
Full Name of Twentieth Inventor Stewart Cole	Inventor's Signature	Date
Residence 23 bis rue Cécile Dunant, 92140 Clahart, France		Citizenship United Kingdom
Post Office Address 23 bis rue Cécile Dunant, 92140 Clahart, France		
Full Name of Twenty-First Inventor: Oliver Danos	Inventor's Signature	Date
Residence 173 rue Saint Merry, 7730 Fontainebleau, France		Citizenship French
Post Office Address 173 rue Saint Merry, 7730 Fontainebleau, France		



DECLARATION

I, JACQUELINE GRUEST, as the heir of JACQUELINE GRUEST, who is deceased, do hereby make the following declaration on her behalf:

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; I believe I am an original, first, and joint inventor of the subject matter, which is claimed and for which a patent is sought on the invention entitled: DNA SEQUENCE OF THE LTR REGION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) the specification of which was filed on September 19, 1994, as United States Application No. 08/308,219 and Confirmation No. 4832.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims. I acknowledge the duty to disclose information, which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate or § 365(a) of any PCT international application(s) designating at least one country other than the United States, listed below and have also identified below, any foreign application(s) for patent or inventor's certificate, or any PCT International application(s) having a filing date before that of the application(s) of which priority is claimed:

Country	Application Number	Date of Filing	Priority Claimed Under 35 U.S.C. 119
UNITED KINGDOM	84 29099	November 16, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
FRANCE	84 16013	October 18, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	84 23659	September 19, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	83 24800	September 15, 1983	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional applications listed below:

Application Number	Date of Filing


I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) or § 365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application(s) in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application(s) and the national or PCT International filing date of this application:

Application Number	Date of Filing	Status (Patented, Pending, Abandoned)
06/771,248	August 30, 1985	Abandoned
07/999,410	December 31, 1992	Pending
07/499,210	March 19, 1990	Pending
06/771,230	August 30, 1985	Abandoned
06/706,562	February 28, 1985	Abandoned
06/558,109	December 5, 1983	Abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both,

under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full Name of First Inventor: Robert C. Gallo	Inventor's Signature	Date
Residence 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		Citizenship United States
Post Office Address 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		
Full Name of Second Inventor Mikulas Popovic	Inventor's Signature	Date
Residence 9917 Holmhurst Road, Bethesda, Maryland 20817		Citizenship United States
Post Office Address 9917 Holmhurst Road, Bethesda, Maryland 20817		
Full Name of Third Inventor: Mangalasseril G. Sarngadharan	Inventor's Signature	Date
Residence 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		Citizenship United States
Post Office Address 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		
Full Name of Fourth Inventor: Solange Chamaret	Inventor's Signature	Date
Residence 138 boulevard Voltaire, 750M Paris, France		Citizenship French
Post Office Address 138 boulevard Voltaire, 750M Paris, France		
Full Name of Fifth Inventor: Claudine Axler-Blin	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Sixth Inventor Francoise Rey	Inventor's Signature	Date
Residence 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		Citizenship French
Post Office Address 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		
Full Name of Seventh Inventor: Marie-Therese Nugeyre	Inventor's Signature	Date
Residence 92130 Issy-les-Moulineaux, France		Citizenship French
Post Office Address 92130 Issy-les-Moulineaux, France		

Full Name of Eighth Inventor Jacqueline Gruet (Deceased) Jacques Gruet (Legal Successor)	Inventor's Signature 	Date 25.05.2006
Residence Grue du Gué, 94240 L'Hay les Roses, France		Citizenship French
Post Office Address Grue du Gué, 94240 L'Hay les Roses, France		
Full Name of Ninth Inventor: Charles Dauguet	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Tenth Inventor Willy Rozenbaum	Inventor's Signature	Date
Residence 20 rue de Sucy, 94430 Chennnevières-sur-Marne, France		Citizenship French
Post Office Address 20 rue de Sucy, 94430 Chennnevières-sur-Marne, France		
Full Name of Eleventh Inventor: Christine Rouzioux	Inventor's Signature	Date
Residence 21 rue de Dantzig, 75015 Paris, France		Citizenship French
Post Office Address 21 rue de Dantzig, 75015 Paris, France		
Full Name of Twelfth Inventor Francois Brun-Vezinet	Inventor's Signature	Date
Residence 24 boulevard Saint Germain, 75005 Paris, France		Citizenship French
Post Office Address 24 boulevard Saint Germain, 75005 Paris, France		
Full Name of Thirteenth Inventor: Luc Montagnier	Inventor's Signature	Date
Residence 21 rue de Malabry, 92350 Le Plessis-Robinson, France		Citizenship French
Post Office Address 21 rue de Malabry, 92350 Le Plessis-Robinson, France		
Full Name of Fourteenth Inventor Jean-Claude Chermann	Inventor's Signature	Date
Residence Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		Citizenship French
Post Office Address Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		
Full Name of Fifteenth Inventor: Francoise Barre-Sinoussi	Inventor's Signature	Date
Residence 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		Citizenship French
Post Office Address 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		

Full Name of Sixteenth Inventor Pierre Tiollais	Inventor's Signature	Date
Residence 16 rue de la Glaciere, 75013 Paris, France		Citizenship French
Post Office Address 16 rue de la Glaciere, 75013 Paris, France		
Full Name of Seventeenth Inventor: Marc Alizon	Inventor's Signature	Date
Residence 26 rue Censier, 75005 Paris, France		Citizenship French
Post Office Address 26 rue Censier, 75005 Paris, France		
Full Name of Eighteenth Inventor Pierre Sonigo	Inventor's Signature	Date
Residence 21 rue Gutenberg, 75015 Paris, France		Citizenship French
Post Office Address 21 rue Gutenberg, 75015 Paris, France		
Full Name of Nineteenth Inventor: Simon Wain-Hobson	Inventor's Signature	Date
Residence 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		Citizenship United Kingdom
Post Office Address 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		
Full Name of Twentieth Inventor Stewart Cole	Inventor's Signature	Date
Residence 23 bis rue Cécile Dunant, 92140 Clahart, France		Citizenship United Kingdom
Post Office Address 23 bis rue Cécile Dunant, 92140 Clahart, France		
Full Name of Twenty-First Inventor: Oliver Danos	Inventor's Signature	Date
Residence 173 rue Saint Merry, 7730 Fontainebleau, France		Citizenship French
Post Office Address 173 rue Saint Merry, 7730 Fontainebleau, France		



DECLARATION

As a below-named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; I believe I am an original, first, and joint inventor of the subject matter, which is claimed and for which a patent is sought on the invention entitled: DNA SEQUENCE OF THE LTR REGION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) the specification of which was filed on September 19, 1994, as United States Application No. 08/308,219 and Confirmation No. 4832.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims. I acknowledge the duty to disclose information, which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate or § 365(a) of any PCT international application(s) designating at least one country other than the United States, listed below and have also identified below, any foreign application(s) for patent or inventor's certificate, or any PCT International application(s) having a filing date before that of the application(s) of which priority is claimed:

Country	Application Number	Date of Filing	Priority Claimed Under 35 U.S.C. 119
UNITED KINGDOM	84 29099	November 16, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
FRANCE	84 16013	October 18, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	84 23659	September 19, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	83 24800	September 15, 1983	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional applications listed below:

Application Number	Date of Filing

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) or § 365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application(s) in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application(s) and the national or PCT International filing date of this application:


Application Number	Date of Filing	Status (Patented, Pending, Abandoned)
06/771,248	August 30, 1985	Abandoned
07/999,410	December 31, 1992	Pending
07/499,210	March 19, 1990	Pending
06/771,230	August 30, 1985	Abandoned
06/706,562	February 28, 1985	Abandoned
06/558,109	December 5, 1983	Abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full Name of First Inventor: Robert C. Gallo	Inventor's Signature	Date
Residence 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		Citizenship United States
Post Office Address 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		
Full Name of Second Inventor Mikulas Popovic	Inventor's Signature	Date
Residence 9917 Holmhurst Road, Bethesda, Maryland 20817		Citizenship United States
Post Office Address 9917 Holmhurst Road, Bethesda, Maryland 20817		
Full Name of Third Inventor: Mangalasseril G. Samgadharan	Inventor's Signature	Date
Residence 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		Citizenship United States
Post Office Address 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		
Full Name of Fourth Inventor: Solange Chamaret	Inventor's Signature	Date
Residence 138 boulevard Voltaire, 750M Paris, France		Citizenship French
Post Office Address 138 boulevard Voltaire, 750M Paris, France		
Full Name of Fifth Inventor: Claudine Axler-Blin	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Sixth Inventor Francoise Rey	Inventor's Signature	Date
Residence 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		Citizenship French
Post Office Address 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		
Full Name of Seventh Inventor: Marie-Therese Nugeyre	Inventor's Signature	Date
Residence 92130 Issy-les-Moulineaux, France		Citizenship French
Post Office Address 92130 Issy-les-Moulineaux, France		
Full Name of Eighth Inventor Jacqueline Gruet (Deceased) Jacques Gruet (Legal Successor)	Inventor's Signature	Date
Residence Grue du Gué, 94240 L'Hay les Roses, France		Citizenship French
Post Office Address Grue du Gué, 94240 L'Hay les Roses, France		

Full Name of Ninth Inventor: Charles Dauguet	Inventor's Signature <i>Charles Dauguet</i>	Date 26 May 2006
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Tenth Inventor Willy Rozenbaum	Inventor's Signature	Date
Residence 20 rue de Sucy, 94430 Chennnevières-sur-Marne, France		Citizenship French
Post Office Address 20 rue de Sucy, 94430 Chennnevières-sur-Marne, France		
Full Name of Eleventh Inventor: Christine Rouzioux	Inventor's Signature	Date
Residence 21 rue de Dantzig, 75015 Paris, France		Citizenship French
Post Office Address 21 rue de Dantzig, 75015 Paris, France		
Full Name of Twelfth Inventor Francois Brun-Vezinet	Inventor's Signature	Date
Residence 24 boulevard Saint Germain, 75005 Paris, France		Citizenship French
Post Office Address 24 boulevard Saint Germain, 75005 Paris, France		
Full Name of Thirteenth Inventor: Luc Montagnier	Inventor's Signature	Date
Residence 21 rue de Malabry, 92350 Le Plessis-Robinson, France		Citizenship French
Post Office Address 21 rue de Malabry, 92350 Le Plessis-Robinson, France		
Full Name of Fourteenth Inventor Jean-Claude Chermann	Inventor's Signature	Date
Residence Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		Citizenship French
Post Office Address Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		
Full Name of Fifteenth Inventor: Francoise Barre-Sinoussi	Inventor's Signature	Date
Residence 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		Citizenship French
Post Office Address 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		
Full Name of Sixteenth Inventor Pierre Tiollais	Inventor's Signature	Date
Residence 16 rue de la Glaciere, 75013 Paris, France		Citizenship French
Post Office Address 16 rue de la Glaciere, 75013 Paris, France		

Full Name of Seventeenth Inventor: Marc Alizon	Inventor's Signature	Date
Residence 26 rue Censier, 75005 Paris, France		Citizenship French
Post Office Address 26 rue Censier, 75005 Paris, France		
Full Name of Eighteenth Inventor Pierre Sonigo	Inventor's Signature	Date
Residence 21 rue Gutenberg, 75015 Paris, France		Citizenship French
Post Office Address 21 rue Gutenberg, 75015 Paris, France		
Full Name of Nineteenth Inventor: Simon Wain-Hobson	Inventor's Signature	Date
Residence 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		Citizenship United Kingdom
Post Office Address 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		
Full Name of Twentieth Inventor Stewart Cole	Inventor's Signature	Date
Residence 23 bis rue Cécile Dunant, 92140 Clahart, France		Citizenship United Kingdom
Post Office Address 23 bis rue Cécile Dunant, 92140 Clahart, France		
Full Name of Twenty-First Inventor: Oliver Danos	Inventor's Signature	Date
Residence 173 rue Saint Merry, 7730 Fontainebleau, France		Citizenship French
Post Office Address 173 rue Saint Merry, 7730 Fontainebleau, France		



DECLARATION

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below and my name; I believe I am an original, first, and joint inventor of the subject matter, which is claimed and for which a patent is sought on the invention entitled: DNA SEQUENCE OF THE LTR REGION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) the specification of which was filed on September 19, 1994, as United States Application No. 08/308,219 and Confirmation No. 4832.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims. I acknowledge the duty to disclose information, which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate or § 365(a) of any PCT international application(s) designating at least one country other than the United States, listed below and have also identified below, any foreign application(s) for patent or inventor's certificate, or any PCT International application(s) having a filing date before that of the application(s) of which priority is claimed:

Country	Application Number	Date of Filing	Priority Claimed Under 35 U.S.C. 119
UNITED KINGDOM	84 29099	November 16, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
FRANCE	84 16013	October 18, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	84 23659	September 19, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	83 24800	September 15, 1983	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional applications listed below:


Application Number	Date of Filing

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) or § 365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application(s) in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application(s) and the national or PCT International filing date of this application:

Application Number	Date of Filing	Status (Patented, Pending, Abandoned)
06/771,248	August 30, 1985	Abandoned
07/999,410	December 31, 1992	Pending
07/499,210	March 19, 1990	Pending
06/771,230	August 30, 1985	Abandoned
06/706,562	February 28, 1985	Abandoned
06/558,109	December 5, 1983	Abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full Name of First Inventor: Robert C. Gallo	Inventor's Signature	Date
Residence 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		Citizenship United States
Post Office Address 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		
Full Name of Second Inventor Mikulas Popovic	Inventor's Signature	Date
Residence 9917 Holmhurst Road, Bethesda, Maryland 20817		Citizenship United States
Post Office Address 9917 Holmhurst Road, Bethesda, Maryland 20817		
Full Name of Third Inventor: Mangalasseril G. Samgadharan	Inventor's Signature	Date
Residence 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		Citizenship United States
Post Office Address 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		
Full Name of Fourth Inventor: Solange Chamaret	Inventor's Signature	Date
Residence 138 boulevard Voltaire, 750M Paris, France		Citizenship French
Post Office Address 138 boulevard Voltaire, 750M Paris, France		
Full Name of Fifth Inventor: Claudine Axler-Blin	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Sixth Inventor Francoise Rey	Inventor's Signature	Date
Residence 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		Citizenship French
Post Office Address 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		
Full Name of Seventh Inventor: Marie-Therese Nugeyre	Inventor's Signature	Date
Residence 92130 Issy-les-Moulineaux, France		Citizenship French
Post Office Address 92130 Issy-les-Moulineaux, France		
Full Name of Eighth Inventor Jacqueline Gruet (Deceased) Jacques Gruet (Legal Successor)	Inventor's Signature	Date
Residence Grue du Gué, 94240 L'Hay les Roses, France		Citizenship French
Post Office Address Grue du Gué, 94240 L'Hay les Roses, France		

Full Name of Ninth Inventor: Charles Dauguet	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Tenth Inventor Willy Rozenbaum	Inventor's Signature 	Date 25 May 2004
Residence 20 rue de Sucy, 94430 Chennnevières-sur-Marne, France		Citizenship French
Post Office Address 20 rue de Sucy, 94430 Chennnevières-sur-Marne, France		
Full Name of Eleventh Inventor: Christine Rouzioux	Inventor's Signature	Date
Residence 21 rue de Dantzig, 75015 Paris, France		Citizenship French
Post Office Address 21 rue de Dantzig, 75015 Paris, France		
Full Name of Twelfth Inventor Francois Brun-Vezinet	Inventor's Signature	Date
Residence 24 boulevard Saint Germain, 75005 Paris, France		Citizenship French
Post Office Address 24 boulevard Saint Germain, 75005 Paris, France		
Full Name of Thirteenth Inventor: Luc Montagnier	Inventor's Signature	Date
Residence 21 rue de Malabry, 92350 Le Plessis-Robinson, France		Citizenship French
Post Office Address 21 rue de Malabry, 92350 Le Plessis-Robinson, France		
Full Name of Fourteenth Inventor Jean-Claude Chermann	Inventor's Signature	Date
Residence Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		Citizenship French
Post Office Address Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		
Full Name of Fifteenth Inventor: Francoise Barre-Sinoussi	Inventor's Signature	Date
Residence 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		Citizenship French
Post Office Address 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		
Full Name of Sixteenth Inventor Pierre Tiollais	Inventor's Signature	Date
Residence 16 rue de la Glaciere, 75013 Paris, France		Citizenship French
Post Office Address 16 rue de la Glaciere, 75013 Paris, France		

Full Name of Seventeenth Inventor: Marc Alizon	Inventor's Signature	Date
Residence 26 rue Censier, 75005 Paris, France		Citizenship French
Post Office Address 26 rue Censier, 75005 Paris, France		
Full Name of Eighteenth Inventor Pierre Sonigo	Inventor's Signature	Date
Residence 21 rue Gutenberg, 75015 Paris, France		Citizenship French
Post Office Address 21 rue Gutenberg, 75015 Paris, France		
Full Name of Nineteenth Inventor: Simon Wain-Hobson	Inventor's Signature	Date
Residence 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		Citizenship United Kingdom
Post Office Address 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		
Full Name of Twentieth Inventor Stewart Cole	Inventor's Signature	Date
Residence 23 bis rue Cécile Dunant, 92140 Clahart, France		Citizenship United Kingdom
Post Office Address 23 bis rue Cécile Dunant, 92140 Clahart, France		
Full Name of Twenty-First Inventor: Oliver Danos	Inventor's Signature	Date
Residence 173 rue Saint Merry, 7730 Fontainebleau, France		Citizenship French
Post Office Address 173 rue Saint Merry, 7730 Fontainebleau, France		



DECLARATION

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; I believe I am an original, first, and joint inventor of the subject matter, which is claimed and for which a patent is sought on the invention entitled: DNA SEQUENCE OF THE LTR REGION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) the specification of which was filed on September 19, 1994, as United States Application No. 08/308,219 and Confirmation No. 4832.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims. I acknowledge the duty to disclose information, which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate or § 365(a) of any PCT international application(s) designating at least one country other than the United States, listed below and have also identified below, any foreign application(s) for patent or inventor's certificate, or any PCT International application(s) having a filing date before that of the application(s) of which priority is claimed:

Country	Application Number	Date of Filing	Priority Claimed Under 35 U.S.C. 119
UNITED KINGDOM	84 29099	November 16, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
FRANCE	84 16013	October 18, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	84 23659	September 19, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	83 24800	September 15, 1983	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional applications listed below:


Application Number	Date of Filing

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) or § 365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application(s) in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application(s) and the national or PCT International filing date of this application:

Application Number	Date of Filing	Status (Patented, Pending, Abandoned)
06/771,248	August 30, 1985	Abandoned
07/999,410	December 31, 1992	Pending
07/499,210	March 19, 1990	Pending
06/771,230	August 30, 1985	Abandoned
06/706,562	February 28, 1985	Abandoned
06/558,109	December 5, 1983	Abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full Name of First Inventor: Robert C. Gallo	Inventor's Signature	Date
Residence 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		Citizenship United States
Post Office Address 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		
Full Name of Second Inventor Mikulas Popovic	Inventor's Signature	Date
Residence 9917 Holmhurst Road, Bethesda, Maryland 20817		Citizenship United States
Post Office Address 9917 Holmhurst Road, Bethesda, Maryland 20817		
Full Name of Third Inventor: Mangalasseril G. Samgadharan	Inventor's Signature	Date
Residence 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		Citizenship United States
Post Office Address 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		
Full Name of Fourth Inventor: Solange Chamaret	Inventor's Signature	Date
Residence 138 boulevard Voltaire, 750M Paris, France		Citizenship French
Post Office Address 138 boulevard Voltaire, 750M Paris, France		
Full Name of Fifth Inventor: Claudine Axler-Blin	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Sixth Inventor Francoise Rey	Inventor's Signature	Date
Residence 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		Citizenship French
Post Office Address 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		
Full Name of Seventh Inventor: Marie-Therese Nugeyre	Inventor's Signature	Date
Residence 92130 Issy-les-Moulineaux, France		Citizenship French
Post Office Address 92130 Issy-les-Moulineaux, France		
Full Name of Eighth Inventor Jacqueline Gruet (Deceased) Jacques Gruet (Legal Successor)	Inventor's Signature	Date
Residence Grue du Gué, 94240 L'Hay les Roses, France		Citizenship French
Post Office Address Grue du Gué, 94240 L'Hay les Roses, France		

Full Name of Ninth Inventor: Charles Dauguet	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Tenth Inventor Willy Rozenbaum	Inventor's Signature	Date
Residence 20 rue de Sucy, 94430 Chennnevières-sur-Marne, France		Citizenship French
Post Office Address 20 rue de Sucy, 94430 Chennnevières-sur-Marne, France		
Full Name of Eleventh Inventor: Christine Rouzioux	Inventor's Signature 	Date 20 05 2006
Residence 21 rue de Dantzig, 75015 Paris, France		Citizenship French
Post Office Address 21 rue de Dantzig, 75015 Paris, France		
Full Name of Twelfth Inventor Francois Brun-Vezinet	Inventor's Signature	Date
Residence 24 boulevard Saint Germain, 75005 Paris, France		Citizenship French
Post Office Address 24 boulevard Saint Germain, 75005 Paris, France		
Full Name of Thirteenth Inventor: Luc Montagnier	Inventor's Signature	Date
Residence 21 rue de Malabry, 92350 Le Plessis-Robinson, France		Citizenship French
Post Office Address 21 rue de Malabry, 92350 Le Plessis-Robinson, France		
Full Name of Fourteenth Inventor Jean-Claude Chermann	Inventor's Signature	Date
Residence Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		Citizenship French
Post Office Address Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		
Full Name of Fifteenth Inventor: Francoise Barre-Sinoussi	Inventor's Signature	Date
Residence 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		Citizenship French
Post Office Address 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		
Full Name of Sixteenth Inventor Pierre Tiollais	Inventor's Signature	Date
Residence 16 rue de la Glaciere, 75013 Paris, France		Citizenship French
Post Office Address 16 rue de la Glaciere, 75013 Paris, France		

Full Name of Seventeenth Inventor: Marc Alizon	Inventor's Signature	Date
Residence 26 rue Censier, 75005 Paris, France		Citizenship French
Post Office Address 26 rue Censier, 75005 Paris, France		
Full Name of Eighteenth Inventor Pierre Sonigo	Inventor's Signature	Date
Residence 21 rue Gutenberg, 75015 Paris, France		Citizenship French
Post Office Address 21 rue Gutenberg, 75015 Paris, France		
Full Name of Nineteenth Inventor: Simon Wain-Hobson	Inventor's Signature	Date
Residence 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		Citizenship United Kingdom
Post Office Address 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		
Full Name of Twentieth Inventor Stewart Cole	Inventor's Signature	Date
Residence 23 bis rue Cécile Dunant, 92140 Clahart, France		Citizenship United Kingdom
Post Office Address 23 bis rue Cécile Dunant, 92140 Clahart, France		
Full Name of Twenty-First Inventor: Oliver Danos	Inventor's Signature	Date
Residence 173 rue Saint Merry, 7730 Fontainebleau, France		Citizenship French
Post Office Address 173 rue Saint Merry, 7730 Fontainebleau, France		



Customer Number 22,852
Attorney Docket No. 3495.0010-20

DECLARATION

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; I believe I am an original, first, and joint inventor of the subject matter, which is claimed and for which a patent is sought on the invention entitled: DNA SEQUENCE OF THE LTR REGION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) the specification of which was filed on September 19, 1994, as United States Application No. 08/308,219 and Confirmation No. 4832.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims. I acknowledge the duty to disclose information, which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate or § 365(a) of any PCT international application(s) designating at least one country other than the United States, listed below and have also identified below, any foreign application(s) for patent or inventor's certificate, or any PCT International application(s) having a filing date before that of the application(s) of which priority is claimed:

Country	Application Number	Date of Filing	Priority Claimed Under 35 U.S.C. 119
UNITED KINGDOM	84 29099	November 16, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
FRANCE	84 16013	October 18, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	84 23659	September 19, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	83 24800	September 15, 1983	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional applications listed below:



Application Number	Date of Filing

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) or § 365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application(s) in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application(s) and the national or PCT International filing date of this application:

Application Number	Date of Filing	Status (Patented, Pending, Abandoned)
06/771,248	August 30, 1985	Abandoned
07/999,410	December 31, 1992	Pending
07/499,210	March 19, 1990	Pending
06/771,230	August 30, 1985	Abandoned
06/706,562	February 28, 1985	Abandoned
06/558,109	December 5, 1983	Abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full Name of First Inventor: Robert C. Gallo	Inventor's Signature	Date
Residence 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		Citizenship United States
Post Office Address 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		
Full Name of Second Inventor Mikulas Popovic	Inventor's Signature	Date
Residence 9917 Holmhurst Road, Bethesda, Maryland 20817		Citizenship United States
Post Office Address 9917 Holmhurst Road, Bethesda, Maryland 20817		
Full Name of Third Inventor: Mangalasseril G. Samgadharan	Inventor's Signature	Date
Residence 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		Citizenship United States
Post Office Address 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		
Full Name of Fourth Inventor: Solange Chamaret	Inventor's Signature	Date
Residence 138 boulevard Voltaire, 750M Paris, France		Citizenship French
Post Office Address 138 boulevard Voltaire, 750M Paris, France		
Full Name of Fifth Inventor: Claudine Axler-Blin	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Sixth Inventor Francoise Rey	Inventor's Signature	Date
Residence 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		Citizenship French
Post Office Address 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		
Full Name of Seventh Inventor: Marie-Therese Nugeyre	Inventor's Signature	Date
Residence 92130 Issy-les-Moulineaux, France		Citizenship French
Post Office Address 92130 Issy-les-Moulineaux, France		
Full Name of Eighth Inventor Jacqueline Gruet (Deceased) Jacques Gruet (Legal Successor)	Inventor's Signature	Date
Residence Grue du Gué, 94240 L'Hay les Roses, France		Citizenship French
Post Office Address Grue du Gué, 94240 L'Hay les Roses, France		

Full Name of Ninth Inventor: Charles Dauguet	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France	Citizenship French	
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Tenth Inventor Willy Rozenbaum	Inventor's Signature	Date
Residence 20 rue de Sucy, 94430 Chennnevières-sur-Marne, France	Citizenship French	
Post Office Address 20 rue de Sucy, 94430 Chennnevières-sur-Marne, France		
Full Name of Eleventh Inventor: Christine Rouzioux	Inventor's Signature	Date
Residence 21 rue de Dantzig, 75015 Paris, France	Citizenship French	
Post Office Address 21 rue de Dantzig, 75015 Paris, France		
Full Name of Twelfth Inventor Francois Brun-Vezinet	Inventor's Signature 	Date 30/05/05
Residence 24 boulevard Saint Germain, 75005 Paris, France	Citizenship French	
Post Office Address 24 boulevard Saint Germain, 75005 Paris, France		
Full Name of Thirteenth Inventor: Luc Montagnier	Inventor's Signature	Date
Residence 21 rue de Malabry, 92350 Le Plessis-Robinson, France	Citizenship French	
Post Office Address 21 rue de Malabry, 92350 Le Plessis-Robinson, France		
Full Name of Fourteenth Inventor Jean-Claude Chermann	Inventor's Signature	Date
Residence Le Messuguet, 22 rue Cardalino, 13260 Cassis, France	Citizenship French	
Post Office Address Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		
Full Name of Fifteenth Inventor: Francoise Barre-Sinoussi	Inventor's Signature 	Date 05.24.2006
Residence 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch	Citizenship French	
Post Office Address 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		
Full Name of Sixteenth Inventor Pierre Tiollais	Inventor's Signature	Date
Residence 16 rue de la Glaciere, 75013 Paris, France	Citizenship French	
Post Office Address 16 rue de la Glaciere, 75013 Paris, France		

Full Name of Seventeenth Inventor: Marc Alizon	Inventor's Signature	Date
Residence 26 rue Censier, 75005 Paris, France		Citizenship French
Post Office Address 26 rue Censier, 75005 Paris, France		
Full Name of Eighteenth Inventor Pierre Sonigo	Inventor's Signature	Date
Residence 21 rue Gutenberg, 75015 Paris, France		Citizenship French
Post Office Address 21 rue Gutenberg, 75015 Paris, France		
Full Name of Nineteenth Inventor: Simon Wain-Hobson	Inventor's Signature	Date
Residence 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		Citizenship United Kingdom
Post Office Address 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		
Full Name of Twentieth Inventor Stewart Cole	Inventor's Signature	Date
Residence 23 bis rue Cécile Dunant, 92140 Clahart, France		Citizenship United Kingdom
Post Office Address 23 bis rue Cécile Dunant, 92140 Clahart, France		
Full Name of Twenty-First Inventor: Oliver Danos	Inventor's Signature	Date
Residence 173 rue Saint Merry, 7730 Fontainebleau, France		Citizenship French
Post Office Address 173 rue Saint Merry, 7730 Fontainebleau, France		



DECLARATION

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; I believe I am an original, first, and joint inventor of the subject matter, which is claimed and for which a patent is sought on the invention entitled: DNA SEQUENCE OF THE LTR REGION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) the specification of which was filed on September 19, 1994, as United States Application No. 08/308,219 and Confirmation No. 4832.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims. I acknowledge the duty to disclose information, which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate or § 365(a) of any PCT international application(s) designating at least one country other than the United States, listed below and have also identified below, any foreign application(s) for patent or inventor's certificate, or any PCT International application(s) having a filing date before that of the application(s) of which priority is claimed:

Country	Application Number	Date of Filing	Priority Claimed Under 35 U.S.C. 119
UNITED KINGDOM	84 29099	November 16, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
FRANCE	84 16013	October 18, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	84 23659	September 19, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	83 24800	September 15, 1983	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional applications listed below:


Application Number	Date of Filing

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) or § 365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application(s) in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application(s) and the national or PCT International filing date of this application:


Application Number	Date of Filing	Status (Patented, Pending, Abandoned)
06/771,248	August 30, 1985	Abandoned
07/999,410	December 31, 1992	Pending
07/499,210	March 19, 1990	Pending
06/771,230	August 30, 1985	Abandoned
06/706,562	February 28, 1985	Abandoned
06/558,109	December 5, 1983	Abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full Name of First Inventor: Robert C. Gallo	Inventor's Signature	Date
Residence 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		Citizenship United States
Post Office Address 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		
Full Name of Second Inventor Mikulas Popovic	Inventor's Signature	Date
Residence 9917 Holmhurst Road, Bethesda, Maryland 20817		Citizenship United States
Post Office Address 9917 Holmhurst Road, Bethesda, Maryland 20817		
Full Name of Third Inventor: Mangalasseril G. Samgadharan	Inventor's Signature	Date
Residence 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		Citizenship United States
Post Office Address 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		
Full Name of Fourth Inventor: Solange Chamaret	Inventor's Signature	Date
Residence 138 boulevard Voltaire, 750M Paris, France		Citizenship French
Post Office Address 138 boulevard Voltaire, 750M Paris, France		
Full Name of Fifth Inventor: Claudine Axler-Blin	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Sixth Inventor Francoise Rey	Inventor's Signature	Date
Residence 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		Citizenship French
Post Office Address 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		
Full Name of Seventh Inventor: Marie-Therese Nugeyre	Inventor's Signature	Date
Residence 92130 Issy-les-Moulineaux, France		Citizenship French
Post Office Address 92130 Issy-les-Moulineaux, France		
Full Name of Eighth Inventor Jacqueline Gruet (Deceased) Jacques Gruet (Legal Successor)	Inventor's Signature	Date
Residence Grue du Gué, 94240 L'Hay les Roses, France		Citizenship French
Post Office Address Grue du Gué, 94240 L'Hay les Roses, France		

Full Name of Ninth Inventor: Charles Dauguet	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Tenth Inventor Willy Rozenbaum	Inventor's Signature	Date
Residence 20 rue de Sucy, 94430 Chennnevières-sur-Marne, France		Citizenship French
Post Office Address 20 rue de Sucy, 94430 Chennnevières-sur-Marne, France		
Full Name of Eleventh Inventor: Christine Rouzioux	Inventor's Signature	Date
Residence 21 rue de Dantzig, 75015 Paris, France		Citizenship French
Post Office Address 21 rue de Dantzig, 75015 Paris, France		
Full Name of Twelfth Inventor Francois Brun-Vezinet	Inventor's Signature	Date
Residence 24 boulevard Saint Germain, 75005 Paris, France		Citizenship French
Post Office Address 24 boulevard Saint Germain, 75005 Paris, France		
Full Name of Thirteenth Inventor: Luc Montagnier	Inventor's Signature 	Date May 24 2006
Residence 21 rue de Malabry, 92350 Le Plessis-Robinson, France		Citizenship French
Post Office Address 21 rue de Malabry, 92350 Le Plessis-Robinson, France		
Full Name of Fourteenth Inventor Jean-Claude Chermann	Inventor's Signature	Date
Residence Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		Citizenship French
Post Office Address Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		
Full Name of Fifteenth Inventor: Francoise Barre-Sinoussi	Inventor's Signature	Date
Residence 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		Citizenship French
Post Office Address 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		
Full Name of Sixteenth Inventor Pierre Tiollais	Inventor's Signature	Date
Residence 16 rue de la Glaciere, 75013 Paris, France		Citizenship French
Post Office Address 16 rue de la Glaciere, 75013 Paris, France		

Full Name of Seventeenth Inventor: Marc Alizon	Inventor's Signature	Date
Residence 26 rue Censier, 75005 Paris, France		Citizenship French
Post Office Address 26 rue Censier, 75005 Paris, France		
Full Name of Eighteenth Inventor Pierre Sonigo	Inventor's Signature	Date
Residence 21 rue Gutenberg, 75015 Paris, France		Citizenship French
Post Office Address 21 rue Gutenberg, 75015 Paris, France		
Full Name of Nineteenth Inventor: Simon Wain-Hobson	Inventor's Signature	Date
Residence 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		Citizenship United Kingdom
Post Office Address 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		
Full Name of Twentieth Inventor Stewart Cole	Inventor's Signature	Date
Residence 23 bis rue Cécile Dunant, 92140 Clahart, France		Citizenship United Kingdom
Post Office Address 23 bis rue Cécile Dunant, 92140 Clahart, France		
Full Name of Twenty-First Inventor: Oliver Danos	Inventor's Signature	Date
Residence 173 rue Saint Merry, 7730 Fontainebleau, France		Citizenship French
Post Office Address 173 rue Saint Merry, 7730 Fontainebleau, France		



DECLARATION

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; I believe I am an original, first, and joint inventor of the subject matter, which is claimed and for which a patent is sought on the invention entitled: DNA SEQUENCE OF THE LTR REGION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) the specification of which was filed on September 19, 1994, as United States Application No. 08/308,219 and Confirmation No. 4832.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims. I acknowledge the duty to disclose information, which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate or § 365(a) of any PCT international application(s) designating at least one country other than the United States, listed below and have also identified below, any foreign application(s) for patent or inventor's certificate, or any PCT International application(s) having a filing date before that of the application(s) of which priority is claimed:

Country	Application Number	Date of Filing	Priority Claimed Under 35 U.S.C. 119
UNITED KINGDOM	84 29099	November 16, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
FRANCE	84 16013	October 18, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	84 23659	September 19, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	83 24800	September 15, 1983	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional applications listed below:

Application Number	Date of Filing

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) or § 365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application(s) in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application(s) and the national or PCT International filing date of this application:

Application Number	Date of Filing	Status (Patented, Pending, Abandoned)
06/771,248	August 30, 1985	Abandoned
07/999,410	December 31, 1992	Pending
07/499,210	March 19, 1990	Pending
06/771,230	August 30, 1985	Abandoned
06/706,562	February 28, 1985	Abandoned
06/558,109	December 5, 1983	Abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full Name of First Inventor: Robert C. Gallo	Inventor's Signature	Date
Residence 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		Citizenship United States
Post Office Address 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		
Full Name of Second Inventor Mikulas Popovic	Inventor's Signature	Date
Residence 9917 Holmhurst Road, Bethesda, Maryland 20817		Citizenship United States
Post Office Address 9917 Holmhurst Road, Bethesda, Maryland 20817		
Full Name of Third Inventor: Mangalasseril G. Samgadharan	Inventor's Signature	Date
Residence 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		Citizenship United States
Post Office Address 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		
Full Name of Fourth Inventor: Solange Chamaret	Inventor's Signature	Date
Residence 138 boulevard Voltaire, 750M Paris, France		Citizenship French
Post Office Address 138 boulevard Voltaire, 750M Paris, France		
Full Name of Fifth Inventor: Claudine Axler-Blin	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Sixth Inventor Francoise Rey	Inventor's Signature	Date
Residence 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		Citizenship French
Post Office Address 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		
Full Name of Seventh Inventor: Marie-Therese Nugeyre	Inventor's Signature	Date
Residence 92130 Issy-les-Moulineaux, France		Citizenship French
Post Office Address 92130 Issy-les-Moulineaux, France		
Full Name of Eighth Inventor Jacqueline Gruet (Deceased) Jacques Gruet (Legal Successor)	Inventor's Signature	Date
Residence Grue du Gué, 94240 L'Hay les Roses, France		Citizenship French
Post Office Address Grue du Gué, 94240 L'Hay les Roses, France		

Full Name of Ninth Inventor: Charles Dauguet	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France	Citizenship French	
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Tenth Inventor Willy Rozenbaum	Inventor's Signature	Date
Residence 20 rue de Sucy, 94430 Chennnevières-sur-Marne, France	Citizenship French	
Post Office Address 20 rue de Sucy, 94430 Chennnevières-sur-Marne, France		
Full Name of Eleventh Inventor: Christine Rouzioux	Inventor's Signature	Date
Residence 21 rue de Dantzig, 75015 Paris, France	Citizenship French	
Post Office Address 21 rue de Dantzig, 75015 Paris, France		
Full Name of Twelfth Inventor Francois Brun-Vezinet	Inventor's Signature	Date
Residence 24 boulevard Saint Germain, 75005 Paris, France	Citizenship French	
Post Office Address 24 boulevard Saint Germain, 75005 Paris, France		
Full Name of Thirteenth Inventor: Luc Montagnier	Inventor's Signature	Date
Residence 21 rue de Malabry, 92350 Le Plessis-Robinson, France	Citizenship French	
Post Office Address 21 rue de Malabry, 92350 Le Plessis-Robinson, France		
Full Name of Fourteenth Inventor Jean-Claude Chermann	Inventor's Signature <i>Jean Claude Chermann</i>	Date May 26. 06
Residence Le Messuguet, 22 rue Cardalino, 13260 Cassis, France	Citizenship French	
Post Office Address Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		
Full Name of Fifteenth Inventor: Francoise Barre-Sinoussi	Inventor's Signature	Date
Residence 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch	Citizenship French	
Post Office Address 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		
Full Name of Sixteenth Inventor Pierre Tiollais	Inventor's Signature	Date
Residence 16 rue de la Glaciere, 75013 Paris, France	Citizenship French	
Post Office Address 16 rue de la Glaciere, 75013 Paris, France		

Full Name of Seventeenth Inventor: Marc Alizon	Inventor's Signature	Date
Residence 26 rue Censier, 75005 Paris, France		Citizenship French
Post Office Address 26 rue Censier, 75005 Paris, France		
Full Name of Eighteenth Inventor Pierre Sonigo	Inventor's Signature	Date
Residence 21 rue Gutenberg, 75015 Paris, France		Citizenship French
Post Office Address 21 rue Gutenberg, 75015 Paris, France		
Full Name of Nineteenth Inventor: Simon Wain-Hobson	Inventor's Signature	Date
Residence 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		Citizenship United Kingdom
Post Office Address 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		
Full Name of Twentieth Inventor Stewart Cole	Inventor's Signature	Date
Residence 23 bis rue Cécile Dunant, 92140 Clahart, France		Citizenship United Kingdom
Post Office Address 23 bis rue Cécile Dunant, 92140 Clahart, France		
Full Name of Twenty-First Inventor: Oliver Danos	Inventor's Signature	Date
Residence 173 rue Saint Merry, 7730 Fontainebleau, France		Citizenship French
Post Office Address 173 rue Saint Merry, 7730 Fontainebleau, France		



DECLARATION

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; I believe I am an original, first, and joint inventor of the subject matter, which is claimed and for which a patent is sought on the invention entitled: DNA SEQUENCE OF THE LTR REGION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) the specification of which was filed on September 19, 1994, as United States Application No. 08/308,219 and Confirmation No. 4832.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims. I acknowledge the duty to disclose information, which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate or § 365(a) of any PCT international application(s) designating at least one country other than the United States, listed below and have also identified below, any foreign application(s) for patent or inventor's certificate, or any PCT International application(s) having a filing date before that of the application(s) of which priority is claimed:

Country	Application Number	Date of Filing	Priority Claimed Under 35 U.S.C. 119
UNITED KINGDOM	84 29099	November 16, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
FRANCE	84 16013	October 18, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	84 23659	September 19, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	83 24800	September 15, 1983	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional applications listed below:


Application Number	Date of Filing

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) or § 365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application(s) in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application(s) and the national or PCT International filing date of this application:


Application Number	Date of Filing	Status (Patented, Pending, Abandoned)
06/771,248	August 30, 1985	Abandoned
07/999,410	December 31, 1992	Pending
07/499,210	March 19, 1990	Pending
06/771,230	August 30, 1985	Abandoned
06/706,562	February 28, 1985	Abandoned
06/558,109	December 5, 1983	Abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full Name of First Inventor: Robert C. Gallo	Inventor's Signature	Date
Residence 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		Citizenship United States
Post Office Address 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		
Full Name of Second Inventor Mikulas Popovic	Inventor's Signature	Date
Residence 9917 Holmhurst Road, Bethesda, Maryland 20817		Citizenship United States
Post Office Address 9917 Holmhurst Road, Bethesda, Maryland 20817		
Full Name of Third Inventor: Mangalasseril G. Sarngadharan	Inventor's Signature	Date
Residence 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		Citizenship United States
Post Office Address 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		
Full Name of Fourth Inventor: Solange Chamaret	Inventor's Signature	Date
Residence 138 boulevard Voltaire, 750M Paris, France		Citizenship French
Post Office Address 138 boulevard Voltaire, 750M Paris, France		
Full Name of Fifth Inventor: Claudine Axler-Blin	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Sixth Inventor Francoise Rey	Inventor's Signature	Date
Residence 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		Citizenship French
Post Office Address 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		
Full Name of Seventh Inventor: Marie-Therese Nugeyre	Inventor's Signature	Date
Residence 92130 Issy-les-Moulineaux, France		Citizenship French
Post Office Address 92130 Issy-les-Moulineaux, France		
Full Name of Eighth Inventor Jacqueline Gruet (Deceased) Jacques Gruet (Legal Successor)	Inventor's Signature	Date
Residence Grue du Gué, 94240 L'Hay les Roses, France		Citizenship French
Post Office Address Grue du Gué, 94240 L'Hay les Roses, France		

Full Name of Ninth Inventor: Charles Dauguet	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Tenth Inventor Willy Rozenbaum	Inventor's Signature	Date
Residence 20 rue de Sucy, 94430 Chennnevières-sur-Marne, France		Citizenship French
Post Office Address 20 rue de Sucy, 94430 Chennnevières-sur-Marne, France		
Full Name of Eleventh Inventor: Christine Rouzioux	Inventor's Signature	Date
Residence 21 rue de Dantzig, 75015 Paris, France		Citizenship French
Post Office Address 21 rue de Dantzig, 75015 Paris, France		
Full Name of Twelfth Inventor Francois Brun-Vezinet	Inventor's Signature	Date
Residence 24 boulevard Saint Germain, 75005 Paris, France		Citizenship French
Post Office Address 24 boulevard Saint Germain, 75005 Paris, France		
Full Name of Thirteenth Inventor: Luc Montagnier	Inventor's Signature	Date
Residence 21 rue de Malabry, 92350 Le Plessis-Robinson, France		Citizenship French
Post Office Address 21 rue de Malabry, 92350 Le Plessis-Robinson, France		
Full Name of Fourteenth Inventor Jean-Claude Chemann	Inventor's Signature	Date
Residence Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		Citizenship French
Post Office Address Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		
Full Name of Fifteenth Inventor: Francoise Barre-Sinoussi	Inventor's Signature 	Date 05.24.2006
Residence 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		Citizenship French
Post Office Address 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		
Full Name of Sixteenth Inventor Pierre Tiollais	Inventor's Signature	Date
Residence 16 rue de la Glaciere, 75013 Paris, France		Citizenship French
Post Office Address 16 rue de la Glaciere, 75013 Paris, France		

Full Name of Seventeenth Inventor: Marc Alizon	Inventor's Signature	Date
Residence 26 rue Censier, 75005 Paris, France		Citizenship French
Post Office Address 26 rue Censier, 75005 Paris, France		
Full Name of Eighteenth Inventor Pierre Sonigo	Inventor's Signature	Date
Residence 21 rue Gutenberg, 75015 Paris, France		Citizenship French
Post Office Address 21 rue Gutenberg, 75015 Paris, France		
Full Name of Nineteenth Inventor: Simon Wain-Hobson	Inventor's Signature	Date
Residence 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		Citizenship United Kingdom
Post Office Address 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		
Full Name of Twentieth Inventor Stewart Cole	Inventor's Signature	Date
Residence 23 bis rue Cécile Dunant, 92140 Clahart, France		Citizenship United Kingdom
Post Office Address 23 bis rue Cécile Dunant, 92140 Clahart, France		
Full Name of Twenty-First Inventor: Oliver Danos	Inventor's Signature	Date
Residence 173 rue Saint Merry, 7730 Fontainebleau, France		Citizenship French
Post Office Address 173 rue Saint Merry, 7730 Fontainebleau, France		



DECLARATION

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; I believe I am an original, first, and joint inventor of the subject matter, which is claimed and for which ~~priority~~ is sought on the invention entitled: DNA SEQUENCE OF THE LTR REGION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) the specification of which was filed on September 19, 1994, as United States Application No. 08/308,219 and Confirmation No. 4832.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims. I acknowledge the duty to disclose information, which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate or § 365(a) of any PCT international application(s) designating at least one country other than the United States, listed below and have also identified below, any foreign application(s) for patent or inventor's certificate, or any PCT International application(s) having a filing date before that of the application(s) of which priority is claimed:

Country	Application Number	Date of Filing	Priority Claimed Under 35 U.S.C. 119
UNITED KINGDOM	84 29099	November 16, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
FRANCE	84 16013	October 18, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	84 23659	September 19, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	83 24800	September 15, 1983	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional applications listed below:


Application Number	Date of Filing

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) or § 365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application(s) in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application(s) and the national or PCT International filing date of this application:


Application Number	Date of Filing	Status (Patented, Pending, Abandoned)
06/771,248	August 30, 1985	Abandoned
07/999,410	December 31, 1992	Pending
07/499,210	March 19, 1990	Pending
06/771,230	August 30, 1985	Abandoned
06/706,562	February 28, 1985	Abandoned
06/558,109	December 5, 1983	Abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full Name of First Inventor: Robert C. Gallo	Inventor's Signature	Date
Residence 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		Citizenship United States
Post Office Address 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		
Full Name of Second Inventor Mikulas Popovic	Inventor's Signature	Date
Residence 9917 Holmhurst Road, Bethesda, Maryland 20817		Citizenship United States
Post Office Address 9917 Holmhurst Road, Bethesda, Maryland 20817		
Full Name of Third Inventor: Mangalasseril G. Samgadharan	Inventor's Signature	Date
Residence 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		Citizenship United States
Post Office Address 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		
Full Name of Fourth Inventor: Solange Chamaret	Inventor's Signature	Date
Residence 138 boulevard Voltaire, 750M Paris, France		Citizenship French
Post Office Address 138 boulevard Voltaire, 750M Paris, France		
Full Name of Fifth Inventor: Claudine Axler-Blin	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Sixth Inventor Francoise Rey	Inventor's Signature	Date
Residence 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		Citizenship French
Post Office Address 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		
Full Name of Seventh Inventor: Marie-Therese Nugeyre	Inventor's Signature	Date
Residence 92130 Issy-les-Moulineaux, France		Citizenship French
Post Office Address 92130 Issy-les-Moulineaux, France		
Full Name of Eighth Inventor Jacqueline Gruet (Deceased) Jacques Gruet (Legal Successor)	Inventor's Signature	Date
Residence Grue du Gué, 94240 L'Hay les Roses, France		Citizenship French
Post Office Address Grue du Gué, 94240 L'Hay les Roses, France		

Full Name of Ninth Inventor: Charles Dauguet	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Tenth Inventor Willy Rozenbaum	Inventor's Signature	Date
Residence 20 rue de Sucy, 94430 Chennnevières-sur-Marne, France		Citizenship French
Post Office Address 20 rue de Sucy, 94430 Chennnevières-sur-Marne, France		
Full Name of Eleventh Inventor: Christine Rouzioux	Inventor's Signature	Date
Residence 21 rue de Dantzig, 75015 Paris, France		Citizenship French
Post Office Address 21 rue de Dantzig, 75015 Paris, France		
Full Name of Twelfth Inventor Francois Brun-Vezinet	Inventor's Signature	Date
Residence 24 boulevard Saint Germain, 75005 Paris, France		Citizenship French
Post Office Address 24 boulevard Saint Germain, 75005 Paris, France		
Full Name of Thirteenth Inventor: Luc Montagnier	Inventor's Signature	Date
Residence 21 rue de Malabry, 92350 Le Plessis-Robinson, France		Citizenship French
Post Office Address 21 rue de Malabry, 92350 Le Plessis-Robinson, France		
Full Name of Fourteenth Inventor Jean-Claude Chermann	Inventor's Signature	Date
Residence Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		Citizenship French
Post Office Address Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		
Full Name of Fifteenth Inventor: Francoise Barre-Sinoussi	Inventor's Signature	Date
Residence 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		Citizenship French
Post Office Address 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		
Full Name of Sixteenth Inventor Pierre Tiollais	Inventor's Signature 	Date 24 mai 06
Residence 16 rue de la Glaciere, 75013 Paris, France		Citizenship French
Post Office Address 16 rue de la Glaciere, 75013 Paris, France		

Full Name of Seventeenth Inventor: Marc Alizon	Inventor's Signature	Date
Residence 26 rue Censier, 75005 Paris, France		Citizenship French
Post Office Address 26 rue Censier, 75005 Paris, France		
Full Name of Eighteenth Inventor Pierre Sonigo	Inventor's Signature	Date
Residence 21 rue Gutenberg, 75015 Paris, France		Citizenship French
Post Office Address 21 rue Gutenberg, 75015 Paris, France		
Full Name of Nineteenth Inventor: Simon Wain-Hobson	Inventor's Signature	Date
Residence 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		Citizenship United Kingdom
Post Office Address 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		
Full Name of Twentieth Inventor Stewart Cole	Inventor's Signature	Date
Residence 23 bis rue Cécile Dunant, 92140 Clahart, France		Citizenship United Kingdom
Post Office Address 23 bis rue Cécile Dunant, 92140 Clahart, France		
Full Name of Twenty-First Inventor: Oliver Danos	Inventor's Signature	Date
Residence 173 rue Saint Merry, 7730 Fontainebleau, France		Citizenship French
Post Office Address 173 rue Saint Merry, 7730 Fontainebleau, France		



DECLARATION

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; I believe I am an original, first, and joint inventor of the subject matter, which is claimed and for which a patent is sought on the invention entitled: DNA SEQUENCE OF THE LTR REGION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) the specification of which was filed on September 19, 1994, as United States Application No. 08/308,219 and Confirmation No. 4832.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims. I acknowledge the duty to disclose information, which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate or § 365(a) of any PCT international application(s) designating at least one country other than the United States, listed below and have also identified below, any foreign application(s) for patent or inventor's certificate, or any PCT International application(s) having a filing date before that of the application(s) of which priority is claimed:

Country	Application Number	Date of Filing	Priority Claimed Under 35 U.S.C. 119
UNITED KINGDOM	84 29099	November 16, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
FRANCE	84 16013	October 18, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	84 23659	September 19, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	83 24800	September 15, 1983	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional applications listed below:

Application Number	Date of Filing


I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) or § 365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application(s) in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application(s) and the national or PCT International filing date of this application:


Application Number	Date of Filing	Status (Patented, Pending, Abandoned)
06/771,248	August 30, 1985	Abandoned
07/999,410	December 31, 1992	Pending
07/499,210	March 19, 1990	Pending
06/771,230	August 30, 1985	Abandoned
06/706,562	February 28, 1985	Abandoned
06/558,109	December 5, 1983	Abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full Name of First Inventor: Robert C. Gallo	Inventor's Signature	Date
Residence 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		Citizenship United States
Post Office Address 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		
Full Name of Second Inventor Mikulas Popovic	Inventor's Signature	Date
Residence 9917 Holmhurst Road, Bethesda, Maryland 20817		Citizenship United States
Post Office Address 9917 Holmhurst Road, Bethesda, Maryland 20817		
Full Name of Third Inventor: Mangalasseril G. Samgadharan	Inventor's Signature	Date
Residence 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		Citizenship United States
Post Office Address 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		
Full Name of Fourth Inventor: Solange Chamaret	Inventor's Signature	Date
Residence 138 boulevard Voltaire, 750M Paris, France		Citizenship French
Post Office Address 138 boulevard Voltaire, 750M Paris, France		
Full Name of Fifth Inventor: Claudine Axler-Blin	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Sixth Inventor Francoise Rey	Inventor's Signature	Date
Residence 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		Citizenship French
Post Office Address 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		
Full Name of Seventh Inventor: Marie-Therese Nugeyre	Inventor's Signature	Date
Residence 92130 Issy-les-Moulineaux, France		Citizenship French
Post Office Address 92130 Issy-les-Moulineaux, France		
Full Name of Eighth Inventor Jacqueline Gruet (Deceased) Jacques Gruet (Legal Successor)	Inventor's Signature	Date
Residence Grue du Gué, 94240 L'Hay les Roses, France		Citizenship French
Post Office Address Grue du Gué, 94240 L'Hay les Roses, France		

Full Name of Ninth Inventor: Charles Dauguet	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Tenth Inventor Willy Rozenbaum	Inventor's Signature	Date
Residence 20 rue de Sucy, 94430 Chennnevières-sur-Marne, France		Citizenship French
Post Office Address 20 rue de Sucy, 94430 Chennnevières-sur-Marne, France		
Full Name of Eleventh Inventor: Christine Rouzioux	Inventor's Signature	Date
Residence 21 rue de Dantzig, 75015 Paris, France		Citizenship French
Post Office Address 21 rue de Dantzig, 75015 Paris, France		
Full Name of Twelfth Inventor Francois Brun-Vezinet	Inventor's Signature	Date
Residence 24 boulevard Saint Germain, 75005 Paris, France		Citizenship French
Post Office Address 24 boulevard Saint Germain, 75005 Paris, France		
Full Name of Thirteenth Inventor: Luc Montagnier	Inventor's Signature	Date
Residence 21 rue de Malabry, 92350 Le Plessis-Robinson, France		Citizenship French
Post Office Address 21 rue de Malabry, 92350 Le Plessis-Robinson, France		
Full Name of Fourteenth Inventor Jean-Claude Chermann	Inventor's Signature	Date
Residence Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		Citizenship French
Post Office Address Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		
Full Name of Fifteenth Inventor: Francoise Barre-Sinoussi	Inventor's Signature	Date
Residence 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		Citizenship French
Post Office Address 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		
Full Name of Sixteenth Inventor Pierre Tiollais	Inventor's Signature	Date
Residence 16 rue de la Glaciere, 75013 Paris, France		Citizenship French
Post Office Address 16 rue de la Glaciere, 75013 Paris, France		

Full Name of Seventeenth Inventor: Marc Alizon	Inventor's Signature 	Date 31.5.2006
Residence 26 rue Censier, 75005 Paris, France		Citizenship French
Post Office Address 26 rue Censier, 75005 Paris, France		
Full Name of Eighteenth Inventor Pierre Sonigo	Inventor's Signature	Date
Residence 21 rue Gutenberg, 75015 Paris, France		Citizenship French
Post Office Address 21 rue Gutenberg, 75015 Paris, France		
Full Name of Nineteenth Inventor: Simon Wain-Hobson	Inventor's Signature	Date
Residence 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		Citizenship United Kingdom
Post Office Address 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		
Full Name of Twentieth Inventor Stewart Cole	Inventor's Signature	Date
Residence 23 bis rue Cécile Dunant, 92140 Clahart, France		Citizenship United Kingdom
Post Office Address 23 bis rue Cécile Dunant, 92140 Clahart, France		
Full Name of Twenty-First Inventor: Oliver Danos	Inventor's Signature	Date
Residence 173 rue Saint Merry, 7730 Fontainebleau, France		Citizenship French
Post Office Address 173 rue Saint Merry, 7730 Fontainebleau, France		



DECLARATION

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; I believe I am an original, first, and joint inventor of the subject matter, which is claimed and for which a patent is sought on the invention entitled: DNA SEQUENCE OF THE LTR REGION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) the specification of which was filed on September 19, 1994, as United States Application No. 08/308,219 and Confirmation No. 4832.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims. I acknowledge the duty to disclose information, which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate or § 365(a) of any PCT international application(s) designating at least one country other than the United States, listed below and have also identified below, any foreign application(s) for patent or inventor's certificate, or any PCT International application(s) having a filing date before that of the application(s) of which priority is claimed:

Country	Application Number	Date of Filing	Priority Claimed Under 35 U.S.C. 119
UNITED KINGDOM	84 29099	November 16, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
FRANCE	84 16013	October 18, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	84 23659	September 19, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	83 24800	September 15, 1983	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional applications listed below:

Application Number	Date of Filing


I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) or § 365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application(s) in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application(s) and the national or PCT International filing date of this application:

Application Number	Date of Filing	Status (Patented, Pending, Abandoned)
06/771,248	August 30, 1985	Abandoned
07/999,410	December 31, 1992	Pending
07/499,210	March 19, 1990	Pending
06/771,230	August 30, 1985	Abandoned
06/706,562	February 28, 1985	Abandoned
06/558,109	December 5, 1983	Abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full Name of First Inventor: Robert C. Gallo	Inventor's Signature	Date
Residence 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		Citizenship United States
Post Office Address 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		
Full Name of Second Inventor Mikulas Popovic	Inventor's Signature	Date
Residence 9917 Holmhurst Road, Bethesda, Maryland 20817		Citizenship United States
Post Office Address 9917 Holmhurst Road, Bethesda, Maryland 20817		
Full Name of Third Inventor: Mangalasseril G. Samgadharan	Inventor's Signature	Date
Residence 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		Citizenship United States
Post Office Address 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		
Full Name of Fourth Inventor: Solange Chamaret	Inventor's Signature	Date
Residence 138 boulevard Voltaire, 750M Paris, France		Citizenship French
Post Office Address 138 boulevard Voltaire, 750M Paris, France		
Full Name of Fifth Inventor: Claudine Axler-Blin	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Sixth Inventor Francoise Rey	Inventor's Signature	Date
Residence 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		Citizenship French
Post Office Address 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		
Full Name of Seventh Inventor: Marie-Therese Nugeyre	Inventor's Signature	Date
Residence 92130 Issy-les-Moulineaux, France		Citizenship French
Post Office Address 92130 Issy-les-Moulineaux, France		
Full Name of Eighth Inventor Jacqueline Gruet (Deceased) Jacques Gruet (Legal Successor)	Inventor's Signature	Date
Residence Grue du Gué, 94240 L'Hay les Roses, France		Citizenship French
Post Office Address Grue du Gué, 94240 L'Hay les Roses, France		

Full Name of Ninth Inventor: Charles Dauguet	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Tenth Inventor Willy Rozenbaum	Inventor's Signature	Date
Residence 20 rue de Sucy, 94430 Chennnevières-sur-Marne, France		Citizenship French
Post Office Address 20 rue de Sucy, 94430 Chennnevières-sur-Marne, France		
Full Name of Eleventh Inventor: Christine Rouzioux	Inventor's Signature	Date
Residence 21 rue de Dantzig, 75015 Paris, France		Citizenship French
Post Office Address 21 rue de Dantzig, 75015 Paris, France		
Full Name of Twelfth Inventor Francois Brun-Vezinet	Inventor's Signature	Date
Residence 24 boulevard Saint Germain, 75005 Paris, France		Citizenship French
Post Office Address 24 boulevard Saint Germain, 75005 Paris, France		
Full Name of Thirteenth Inventor: Luc Montagnier	Inventor's Signature	Date
Residence 21 rue de Malabry, 92350 Le Plessis-Robinson, France		Citizenship French
Post Office Address 21 rue de Malabry, 92350 Le Plessis-Robinson, France		
Full Name of Fourteenth Inventor Jean-Claude Chermann	Inventor's Signature	Date
Residence Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		Citizenship French
Post Office Address Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		
Full Name of Fifteenth Inventor: Francoise Barre-Sinoussi	Inventor's Signature	Date
Residence 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		Citizenship French
Post Office Address 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		
Full Name of Sixteenth Inventor Pierre Tiollais	Inventor's Signature	Date
Residence 16 rue de la Glaciere, 75013 Paris, France		Citizenship French
Post Office Address 16 rue de la Glaciere, 75013 Paris, France		

Full Name of Seventeenth Inventor: Marc Alizon	Inventor's Signature	Date
Residence 26 rue Censier, 75005 Paris, France		Citizenship French
Post Office Address 26 rue Censier, 75005 Paris, France		
Full Name of Eighteenth Inventor Pierre Sonigo	Inventor's Signature 	Date 29 MAY 06
Residence 21 rue Gutenberg, 75015 Paris, France		Citizenship French
Post Office Address 21 rue Gutenberg, 75015 Paris, France		
Full Name of Nineteenth Inventor: Simon Wain-Hobson	Inventor's Signature	Date
Residence 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		Citizenship United Kingdom
Post Office Address 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		
Full Name of Twentieth Inventor Stewart Cole	Inventor's Signature	Date
Residence 23 bis rue Cécile Dunant, 92140 Clahart, France		Citizenship United Kingdom
Post Office Address 23 bis rue Cécile Dunant, 92140 Clahart, France		
Full Name of Twenty-First Inventor: Oliver Danos	Inventor's Signature	Date
Residence 173 rue Saint Merry, 7730 Fontainebleau, France		Citizenship French
Post Office Address 173 rue Saint Merry, 7730 Fontainebleau, France		



DECLARATION

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below ~~is~~ my name; I believe I am an original, first, and joint inventor of the subject matter, which is claimed and for which a patent is sought on the invention entitled: DNA SEQUENCE OF THE LTR REGION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) the specification of which was filed on September 19, 1994, as United States Application No. 08/308,219 and Confirmation No. 4832.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims. I acknowledge the duty to disclose information, which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate or § 365(a) of any PCT international application(s) designating at least one country other than the United States, listed below and have also identified below, any foreign application(s) for patent or inventor's certificate, or any PCT International application(s) having a filing date before that of the application(s) of which priority is claimed:

Country	Application Number	Date of Filing	Priority Claimed Under 35 U.S.C. 119
UNITED KINGDOM	84 29099	November 16, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
FRANCE	84 16013	October 18, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	84 23659	September 19, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	83 24800	September 15, 1983	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional applications listed below:

Application Number	Date of Filing

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) or § 365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application(s) in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application(s) and the national or PCT International filing date of this application:

Application Number	Date of Filing	Status (Patented, Pending, Abandoned)
06/771,248	August 30, 1985	Abandoned
07/999,410	December 31, 1992	Pending
07/499,210	March 19, 1990	Pending
06/771,230	August 30, 1985	Abandoned
06/706,562	February 28, 1985	Abandoned
06/558,109	December 5, 1983	Abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full Name of First Inventor: Robert C. Gallo	Inventor's Signature	Date
Residence 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		Citizenship United States
Post Office Address 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		
Full Name of Second Inventor Mikulas Popovic	Inventor's Signature	Date
Residence 9917 Holmhurst Road, Bethesda, Maryland 20817		Citizenship United States
Post Office Address 9917 Holmhurst Road, Bethesda, Maryland 20817		
Full Name of Third Inventor: Mangalasseril G. Samgadharan	Inventor's Signature	Date
Residence 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		Citizenship United States
Post Office Address 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		
Full Name of Fourth Inventor: Solange Chamaret	Inventor's Signature	Date
Residence 138 boulevard Voltaire, 750M Paris, France		Citizenship French
Post Office Address 138 boulevard Voltaire, 750M Paris, France		
Full Name of Fifth Inventor: Claudine Axler-Blin	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Sixth Inventor Francoise Rey	Inventor's Signature	Date
Residence 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		Citizenship French
Post Office Address 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		
Full Name of Seventh Inventor: Marie-Therese Nugeyre	Inventor's Signature	Date
Residence 92130 Issy-les-Moulineaux, France		Citizenship French
Post Office Address 92130 Issy-les-Moulineaux, France		
Full Name of Eighth Inventor Jacqueline Gruet (Deceased) Jacques Gruet (Legal Successor)	Inventor's Signature	Date
Residence Grue du Gué, 94240 L'Hay les Roses, France		Citizenship French
Post Office Address Grue du Gué, 94240 L'Hay les Roses, France		

Full Name of Ninth Inventor: Charles Dauguet	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Tenth Inventor Willy Rozenbaum	Inventor's Signature	Date
Residence 20 rue de Sucy, 94430 Chennnevières-sur-Marne, France		Citizenship French
Post Office Address 20 rue de Sucy, 94430 Chennnevières-sur-Marne, France		
Full Name of Eleventh Inventor: Christine Rouzioux	Inventor's Signature	Date
Residence 21 rue de Dantzig, 75015 Paris, France		Citizenship French
Post Office Address 21 rue de Dantzig, 75015 Paris, France		
Full Name of Twelfth Inventor Francois Brun-Vezinet	Inventor's Signature	Date
Residence 24 boulevard Saint Germain, 75005 Paris, France		Citizenship French
Post Office Address 24 boulevard Saint Germain, 75005 Paris, France		
Full Name of Thirteenth Inventor: Luc Montagnier	Inventor's Signature	Date
Residence 21 rue de Malabry, 92350 Le Plessis-Robinson, France		Citizenship French
Post Office Address 21 rue de Malabry, 92350 Le Plessis-Robinson, France		
Full Name of Fourteenth Inventor Jean-Claude Chermann	Inventor's Signature	Date
Residence Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		Citizenship French
Post Office Address Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		
Full Name of Fifteenth Inventor: Francoise Barre-Sinoussi	Inventor's Signature	Date
Residence 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		Citizenship French
Post Office Address 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		
Full Name of Sixteenth Inventor Pierre Tiollais	Inventor's Signature	Date
Residence 16 rue de la Glaciere, 75013 Paris, France		Citizenship French
Post Office Address 16 rue de la Glaciere, 75013 Paris, France		

Full Name of Seventeenth Inventor: Marc Alizon	Inventor's Signature	Date
Residence 26 rue Censier, 75005 Paris, France		Citizenship French
Post Office Address 26 rue Censier, 75005 Paris, France		
Full Name of Eighteenth Inventor Pierre Sonigo	Inventor's Signature	Date
Residence 21 rue Gutenberg, 75015 Paris, France		Citizenship French
Post Office Address 21 rue Gutenberg, 75015 Paris, France		
Full Name of Nineteenth Inventor: Simon Wain-Hobson	Inventor's Signature <i>Simon Wain-Hobson</i>	Date <i>24 May 2006</i>
Residence 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		Citizenship United Kingdom
Post Office Address 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		
Full Name of Twentieth Inventor Stewart Cole	Inventor's Signature	Date
Residence 23 bis rue Cécile Dunant, 92140 Clahart, France		Citizenship United Kingdom
Post Office Address 23 bis rue Cécile Dunant, 92140 Clahart, France		
Full Name of Twenty-First Inventor: Oliver Danos	Inventor's Signature	Date
Residence 173 rue Saint Merry, 7730 Fontainebleau, France		Citizenship French
Post Office Address 173 rue Saint Merry, 7730 Fontainebleau, France		



DECLARATION

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; I believe I am an original, first, and joint inventor of the subject matter, which is claimed and for which a patent is sought on the invention entitled: DNA SEQUENCE OF THE LTR REGION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) the specification of which was filed on September 19, 1994, as United States Application No. 08/308,219 and Confirmation No. 4832.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims. I acknowledge the duty to disclose information, which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate or § 365(a) of any PCT international application(s) designating at least one country other than the United States, listed below and have also identified below, any foreign application(s) for patent or inventor's certificate, or any PCT International application(s) having a filing date before that of the application(s) of which priority is claimed:

Country	Application Number	Date of Filing	Priority Claimed Under 35 U.S.C. 119
UNITED KINGDOM	84 29099	November 16, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
FRANCE	84 16013	October 18, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	84 23659	September 19, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	83 24800	September 15, 1983	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional applications listed below:

Application Number	Date of Filing


I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) or § 365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application(s) in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application(s) and the national or PCT International filing date of this application:


Application Number	Date of Filing	Status (Patented, Pending, Abandoned)
06/771,248	August 30, 1985	Abandoned
07/999,410	December 31, 1992	Pending
07/499,210	March 19, 1990	Pending
06/771,230	August 30, 1985	Abandoned
06/706,562	February 28, 1985	Abandoned
06/558,109	December 5, 1983	Abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full Name of First Inventor: Robert C. Gallo	Inventor's Signature	Date
Residence 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		Citizenship United States
Post Office Address 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		
Full Name of Second Inventor Mikulas Popovic	Inventor's Signature	Date
Residence 9917 Holmhurst Road, Bethesda, Maryland 20817		Citizenship United States
Post Office Address 9917 Holmhurst Road, Bethesda, Maryland 20817		
Full Name of Third Inventor: Mangalasseril G. Samgadharan	Inventor's Signature	Date
Residence 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		Citizenship United States
Post Office Address 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		
Full Name of Fourth Inventor: Solange Chamaret	Inventor's Signature	Date
Residence 138 boulevard Voltaire, 750M Paris, France		Citizenship French
Post Office Address 138 boulevard Voltaire, 750M Paris, France		
Full Name of Fifth Inventor: Claudine Axler-Blin	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Sixth Inventor Francoise Rey	Inventor's Signature	Date
Residence 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		Citizenship French
Post Office Address 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		
Full Name of Seventh Inventor: Marie-Therese Nugeyre	Inventor's Signature	Date
Residence 92130 Issy-les-Moulineaux, France		Citizenship French
Post Office Address 92130 Issy-les-Moulineaux, France		
Full Name of Eighth Inventor Jacqueline Gruet (Deceased) Jacques Gruet (Legal Successor)	Inventor's Signature	Date
Residence Grue du Gué, 94240 L'Hay les Roses, France		Citizenship French
Post Office Address Grue du Gué, 94240 L'Hay les Roses, France		

Full Name of Ninth Inventor: Charles Dauguet	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Tenth Inventor Willy Rozenbaum	Inventor's Signature	Date
Residence 20 rue de Sucy, 94430 Chennnevières-sur-Marne, France		Citizenship French
Post Office Address 20 rue de Sucy, 94430 Chennnevières-sur-Marne, France		
Full Name of Eleventh Inventor: Christine Rouzioux	Inventor's Signature	Date
Residence 21 rue de Dantzig, 75015 Paris, France		Citizenship French
Post Office Address 21 rue de Dantzig, 75015 Paris, France		
Full Name of Twelfth Inventor Francois Brun-Vezinet	Inventor's Signature	Date
Residence 24 boulevard Saint Germain, 75005 Paris, France		Citizenship French
Post Office Address 24 boulevard Saint Germain, 75005 Paris, France		
Full Name of Thirteenth Inventor: Luc Montagnier	Inventor's Signature	Date
Residence 21 rue de Malabry, 92350 Le Plessis-Robinson, France		Citizenship French
Post Office Address 21 rue de Malabry, 92350 Le Plessis-Robinson, France		
Full Name of Fourteenth Inventor Jean-Claude Chermann	Inventor's Signature	Date
Residence Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		Citizenship French
Post Office Address Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		
Full Name of Fifteenth Inventor: Francoise Barre-Sinoussi	Inventor's Signature	Date
Residence 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		Citizenship French
Post Office Address 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		
Full Name of Sixteenth Inventor Pierre Tiollais	Inventor's Signature	Date
Residence 16 rue de la Glaciere, 75013 Paris, France		Citizenship French
Post Office Address 16 rue de la Glaciere, 75013 Paris, France		

Full Name of Seventeenth Inventor: Marc Alizon	Inventor's Signature	Date
Residence 26 rue Censier, 75005 Paris, France		Citizenship French
Post Office Address 26 rue Censier, 75005 Paris, France		
Full Name of Eighteenth Inventor Pierre Sonigo	Inventor's Signature	Date
Residence 21 rue Gutenberg, 75015 Paris, France		Citizenship French
Post Office Address 21 rue Gutenberg, 75015 Paris, France		
Full Name of Nineteenth Inventor: Simon Wain-Hobson	Inventor's Signature	Date
Residence 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		Citizenship United Kingdom
Post Office Address 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		
Full Name of Twentieth Inventor Stewart Cole	Inventor's Signature 	Date 29.04.06
Residence 23 bis rue Cécile Dunant, 92140 Clahart, France		Citizenship United Kingdom
Post Office Address 23 bis rue Cécile Dunant, 92140 Clahart, France		
Full Name of Twenty-First Inventor: Oliver Danos	Inventor's Signature	Date
Residence 173 rue Saint Merry, 7730 Fontainebleau, France		Citizenship French
Post Office Address 173 rue Saint Merry, 7730 Fontainebleau, France		



DECLARATION

As a below-named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; I believe I am an original, first, and joint inventor of the subject matter, which is claimed and for which a patent is sought on the invention entitled: DNA SEQUENCE OF THE LTR REGION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) the specification of which was filed on September 19, 1994, as United States Application No. 08/308,219 and Confirmation No. 4832.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims. I acknowledge the duty to disclose information, which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate or § 365(a) of any PCT international application(s) designating at least one country other than the United States, listed below and have also identified below, any foreign application(s) for patent or inventor's certificate, or any PCT International application(s) having a filing date before that of the application(s) of which priority is claimed:

Country	Application Number	Date of Filing	Priority Claimed Under 35 U.S.C. 119
UNITED KINGDOM	84 29099	November 16, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
FRANCE	84 16013	October 18, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	84 23659	September 19, 1984	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
UNITED KINGDOM	83 24800	September 15, 1983	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional applications listed below:

Application Number	Date of Filing


I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) or § 365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application(s) in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application(s) and the national or PCT International filing date of this application:


Application Number	Date of Filing	Status (Patented, Pending, Abandoned)
06/771,248	August 30, 1985	Abandoned
07/999,410	December 31, 1992	Pending
07/499,210	March 19, 1990	Pending
06/771,230	August 30, 1985	Abandoned
06/706,562	February 28, 1985	Abandoned
06/558,109	December 5, 1983	Abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full Name of First Inventor: Robert C. Gallo	Inventor's Signature	Date
Residence 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		Citizenship United States
Post Office Address 9100 Aldershot Drive, Bethesda, Maryland 20817-1902		
Full Name of Second Inventor Mikulas Popovic	Inventor's Signature	Date
Residence 9917 Holmhurst Road, Bethesda, Maryland 20817		Citizenship United States
Post Office Address 9917 Holmhurst Road, Bethesda, Maryland 20817		
Full Name of Third Inventor: Mangalasseril G. Samgadharan	Inventor's Signature	Date
Residence 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		Citizenship United States
Post Office Address 8422 Holly Leaf Drive, McLean, Virginia 22102-2224		
Full Name of Fourth Inventor: Solange Chamaret	Inventor's Signature	Date
Residence 138 boulevard Voltaire, 750M Paris, France		Citizenship French
Post Office Address 138 boulevard Voltaire, 750M Paris, France		
Full Name of Fifth Inventor: Claudine Axler-Blin	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Sixth Inventor Francoise Rey	Inventor's Signature	Date
Residence 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		Citizenship French
Post Office Address 84 boulevard du Redon-Le Floucat-Allee des Pins, 13009 Marseille, France		
Full Name of Seventh Inventor: Marie-Therese Nugeyre	Inventor's Signature	Date
Residence 92130 Issy-les-Moulineaux, France		Citizenship French
Post Office Address 92130 Issy-les-Moulineaux, France		
Full Name of Eighth Inventor Jacqueline Gruet (Deceased) Jacques Gruet (Legal Successor)	Inventor's Signature	Date
Residence Grue du Gué, 94240 L'Hay les Roses, France		Citizenship French
Post Office Address Grue du Gué, 94240 L'Hay les Roses, France		

Full Name of Ninth Inventor: Charles Dauguet	Inventor's Signature	Date
Residence 137 rue Lecourbe, 75015 Paris, France		Citizenship French
Post Office Address 137 rue Lecourbe, 75015 Paris, France		
Full Name of Tenth Inventor Willy Rozenbaum	Inventor's Signature	Date
Residence 20 rue de Sucy, 94430 Chennnevières-sur-Mame, France		Citizenship French
Post Office Address 20 rue de Sucy, 94430 Chennnevières-sur-Mame, France		
Full Name of Eleventh Inventor: Christine Rouzioux	Inventor's Signature	Date
Residence 21 rue de Dantzig, 75015 Paris, France		Citizenship French
Post Office Address 21 rue de Dantzig, 75015 Paris, France		
Full Name of Twelfth Inventor Francois Brun-Vezinet	Inventor's Signature	Date
Residence 24 boulevard Saint Germain, 75005 Paris, France		Citizenship French
Post Office Address 24 boulevard Saint Germain, 75005 Paris, France		
Full Name of Thirteenth Inventor: Luc Montagnier	Inventor's Signature	Date
Residence 21 rue de Malabry, 92350 Le Plessis-Robinson, France		Citizenship French
Post Office Address 21 rue de Malabry, 92350 Le Plessis-Robinson, France		
Full Name of Fourteenth Inventor Jean-Claude Chermann	Inventor's Signature	Date
Residence Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		Citizenship French
Post Office Address Le Messuguet, 22 rue Cardalino, 13260 Cassis, France		
Full Name of Fifteenth Inventor: Francoise Barre-Sinoussi	Inventor's Signature	Date
Residence 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		Citizenship French
Post Office Address 104 de Capricorne, 50 rue d'Érevan, 92130 Issy les Moulineaux, Franch		
Full Name of Sixteenth Inventor Pierre Tiollais	Inventor's Signature	Date
Residence 16 rue de la Glaciere, 75013 Paris, France		Citizenship French
Post Office Address 16 rue de la Glaciere, 75013 Paris, France		

Full Name of Seventeenth Inventor: Marc Alizon	Inventor's Signature	Date
Residence 26 rue Censier, 75005 Paris, France		Citizenship French
Post Office Address 26 rue Censier, 75005 Paris, France		
Full Name of Eighteenth Inventor Pierre Sonigo	Inventor's Signature	Date
Residence 21 rue Gutenberg, 75015 Paris, France		Citizenship French
Post Office Address 21 rue Gutenberg, 75015 Paris, France		
Full Name of Nineteenth Inventor: Simon Wain-Hobson	Inventor's Signature	Date
Residence 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		Citizenship United Kingdom
Post Office Address 3 rue Jean de la Fontaine, 78180 Montigny le Bretonneux, France		
Full Name of Twentieth Inventor Stewart Cole	Inventor's Signature	Date
Residence 23 bis rue Cécile Dunant, 92140 Clahart, France		Citizenship United Kingdom
Post Office Address 23 bis rue Cécile Dunant, 92140 Clahart, France		
Full Name of Twenty-First Inventor: Oliver Danos	Inventor's Signature 	Date June 1 st , 2006
Residence 173 rue Saint Merry, 7730 Fontainebleau, France		Citizenship French
Post Office Address 173 rue Saint Merry, 7730 Fontainebleau, France		

**Application Data Sheet****U.S. Application No. 08/308,219****Filed: September 19, 1994****Attorney Docket No. 03495.0010-20000**

Application Information

Application No.: 08/308/219
Filing Date: 09/18/1994
Title Line One: DNA Sequence of the LTR Region of Human
Title Line Two: Immunodeficiency Virus Type 1 (HIV-1) (as amended)
Total Drawing Sheets: 26
Formal Drawings?: N/A
Application Type: Utility
Docket Number: 03495.0010-20000

Representative Information

Representative Customer Number: 22,852

Correspondence Information

Name Line One: Kenneth J. Meyers
Name Line Two: FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.
Correspondence Customer No.: 22,852
Telephone One: (202) 408-4033
Fax: (202) 408-4400
Electronic Mail: ken.meyers@finnegan.com

Assignment Information

Assignee Name: Institut Pasteur
Street Mailing Address: 28, rue du Docteur Roux
City of Mailing Address: Paris
State, Province, or Country: France
Postal or Zip Code: 75724

Assignee Name:: The United States of America as represented by the Secretary
of the Department of Health and Human Services
Street Mailing Address:: 900 Rockville Pike
City of Mailing Address:: Bethesda
State, Province or Country:: Maryland
Postal or Zip code:: 20892

Domestic Priority Information

Application:	Continuity Type:	Parent Application:	Parent Filing Date:
This application	Division of	07/158,652	02/22/88
07/158,652	Division of	06/771,248	08/30/85
This application	Continuation-in-part of	07/999,410	12/31/92
07/999,410	Continuation of	07/499,210	03/19/90
07/499,210	Continuation of	06/771,230	08/30/95
06/771,230	Continuation-in-part of	06/706,562	02/28/85
06/706,562	Continuation-in-part of	06/558,109	12/05/83

Foreign Priority Information

Country:	Application Number:	Filing Date:	Priority Claimed:
United Kingdom	84 29099	11/16/84	Yes
France	84 16013	10/18/84	Yes
United Kingdom	83 24800	09/15/83	Yes
United Kingdom	84 23659	09/19/84	Yes

Inventor Information

Inventor One Given Name:: Jean-Claude
Family Name:: CHERMANN
Postal Address Line One:: LeMessuguet, 22 rue Cardalino
City:: Cassis
State or Province:: France
Postal or Zip Code:: 13260
Citizenship Country:: French

Inventor Two Given Name:: Solange
Family Name:: CHAMARET
Postal Address Line One:: 138 boulevard Voltaire
City:: Paris
State or Province:: France
Postal or Zip Code:: 750M
Citizenship Country:: French

Inventor Three Given Name:: Claudine
 Family Name:: AXLER-BLIN
 Postal Address Line One:: 137 rue Lecourbe
 City:: Paris
 State or Province:: France
 Postal or Zip Code:: 75015
 Citizenship Country:: French

Inventor Four Given Name:: Francoise
 Family Name:: REY
 Postal Address Line One:: 84 boulevard du Redon-Le Floucat-Alee des Pins
 City:: Marseille
 State or Province:: France
 Postal or Zip Code:: 13009
 Citizenship Country:: French

Inventor Five Given Name:: Marie-Therese
 Family Name:: NUGEYRE
 Postal Address Line One:: 92130 Issy-les-Moulineaux
 City::
 State or Province:: France
 Postal or Zip Code::
 Citizenship Country:: French

Inventor Six Given Name:: Jacqueline
 Family Name:: GRUEST
 Postal Address Line One:: Grue du Gué
 City:: L'Hay les Roses
 State or Province:: France
 Postal or Zip Code:: 94240
 Citizenship Country:: French

Inventor Seven Given Name:: Charles
 Family Name:: DAUGUET
 Postal Address Line One:: 137 rue Lecourbe
 City:: Paris
 State or Province:: France
 Postal or Zip Code:: 75015
 Citizenship Country:: French

Inventor Eight Given Name:: Willy
 Family Name:: ROZENBAUM
 Postal Address Line One:: 20 rue de Sucy
 City:: Chennnevières-sur-Marne
 State or Province:: France

Postal or Zip Code:: 94430
 Citizenship Country:: French

Inventor Nine Given Name:: Christine
 Family Name:: ROUZIUX
 Postal Address Line One:: 21 rue de Dantzig
 City:: Paris
 State or Province:: France
 Postal or Zip Code:: 75015
 Citizenship Country:: French

Inventor Ten Given Name:: Francois
 Family Name:: BRUN-VEZINET
 Postal Address Line One:: 24 boulevard Saint Germain
 City:: Paris
 State or Province:: France
 Postal or Zip Code:: 75005
 Citizenship Country:: French

Inventor Eleven Given Name:: Luc
 Family Name:: MONTAGNIER
 Postal Address Line One:: 21 rue de Malabry
 City:: Le Plessis-Robinson
 State or Province:: France
 Postal or Zip Code:: 92350
 Citizenship Country:: French

Inventor Twelve Given Name:: Simon
 Family Name:: WAIN-HOBSON
 Postal Address Line One:: 3 rue Jean de la Fontaine
 City:: Montigny le Bretonneux
 State or Province:: France
 Postal or Zip Code:: 78180
 Citizenship Country:: United Kingdom

Inventor Thirteen Given Name:: Francoise
 Family Name:: BARRE-SINOUSI
 Postal Address Line One:: 104 de Capricorne, 50 rue d'Érevan
 City:: Issy les Moulineaux
 State or Province:: France
 Postal or Zip Code:: 92130
 Citizenship Country:: French

Inventor Fourteen Given Name:: Pierre
Family Name:: TIOLLAIS
Postal Address Line One:: 16 rue de la Glaciere
City:: Paris
State or Province:: France
Postal or Zip Code:: 75013
Citizenship Country:: French

Inventor Fifteen Given Name: Marc
Family Name:: ALIZON
Postal Address Line One:: 26 rue Censier
City:: Paris
State or Province:: France
Postal or Zip Code:: 75005
Citizenship Country:: French

Inventor Sixteen Given Name:: Pierre
Family Name:: SONIGO
Postal Address Line One:: 21 rue Gutenberg
City:: Paris
State or Province:: France
Postal or Zip Code:: 75015
Citizenship Country:: French

Inventor Seventeen Given Name: Stewart
Family Name:: COLE
Postal Address Line One:: 23 bis rue Cécile Dunant
City:: Clahart
State or Province:: France
Postal or Zip Code:: 92140
Citizenship Country:: United Kingdom

Inventor Eighteen Given Name: Oliver
Family Name:: DANOS
Postal Address Line One:: 173 rue Saint Merry
City:: Fontainebleau
State or Province:: France
Postal or Zip Code:: 7730
Citizenship Country:: French

Inventor Nineteen Given Name:: Robert C.
Family Name:: GALLO
Postal Address Line One:: 9100 Aldershot Drive
City:: Bethesda
State or Province:: Maryland
Postal or Zip Code:: 20817-1902
Citizenship Country:: United States

Inventor Twenty Given Name:: Mikulas
Family Name:: POPOVIC
Postal Address Line One:: 9917 Holmhurst Road
City:: Bethesda
State or Province:: Maryland
Postal or Zip Code:: 20817
Citizenship Country:: United States

Inventor Twenty-one Given Name:: Mangalasseril G.
Family Name:: SARNGADHARAN
Postal Address Line One:: 8422 Holly Leaf Drive
City:: McLean
State or Province:: Virginia
Postal or Zip Code:: 22101-2224
Citizenship Country:: United States

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
) Group Art Unit: 1637
Marc Alizon et al.)
) Examiner: Jeffrey N. Fredman
Application No.: 08/308,219)
) Confirmation No.: 4832
Filed: September 19, 1994)
)
For: DNA SEQUENCE OF THE LTR
REGION OF HUMAN
IMMUNODEFICIENCY VIRUS
TYPE 1 (HIV-1)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

POWER OF ATTORNEY

Applicants' Assignee hereby grants power of attorney to **FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.** Customer Number 22,852, to transact all business in the Patent and Trademark Office connected therewith, and to receive the Letters Patent. Please also send all future correspondence concerning this application to Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P., Customer Number 22,852

The undersigned is authorized to sign this Power of Attorney.

Respectfully submitted,

Dated: JUNE 6, 2006

By: Jack Spiegel
Name: JACK SPIEGEL (REG # 34,477)
Title: SENIOR ADVISOR FOR TECHNOLOGY TRANSFER OPERATIONS
Assignee: United States of America as
represented by the Secretary of
the Department of Health and
Human Services



PATENT
Customer No. 22,852
Attorney Docket No. 3495.0010-20

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Marc Alizon et al.

Application No.: 08/308,219

Filed: September 19, 1994

For: DNA SEQUENCE OF THE LTR
REGION OF HUMAN
IMMUNODEFICIENCY VIRUS
TYPE 1 (HIV-1)

)
) Group Art Unit: 1637
)
) Examiner: Jeffrey N. Fredman
)
) Confirmation No.: 4832
)
)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

STATEMENT OF CHRISTINE ROUZIUX
(Being Added As An Inventor)

I have read U.S. application Serial No. 08/308,219.

I am informed that I was not named as an inventor in application Serial No.
08/308,219 when the application was filed in the U.S. Patent and Trademark Office.

I have been informed that the claims in U.S. application Serial No. 08/308,219
have been amended by adding claims 17-22, 25, and 27-40 to the application.

I am informed that a copy of claims 17-22, 25, and 27-40 is attached hereto.


I have read claims 17-22, 25, and 27-40, which I am informed were added to
U.S. application Serial No. 08/308,219 to claim previously unclaimed subject matter.

I understand that I am being added as an inventor to U.S. application Serial No. 08/308,219.

I have been informed that my addition as an inventor to U.S. application Serial No. 08/308,219 is necessitated by the amendment of the claims by adding claims 17-22, 25, and 27-40 to the application.

The inventorship error resulting from the amendment of the claims by adding claims 17-22, 25, and 27-40 to U.S. application Serial No. 08/308,219 occurred without deceptive intention on my part.

I hereby declare that all statements made of my own knowledge and belief are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Christine Rozewsky
By: 
Date: 30.05.2006

U.S. Patent Application No. 08/308,219
Filed: September 19, 1994
Inventors: Marc ALIZON et al.
Div. of 07/158,652 (02/22/88);
Div. of 06/771,248 (08/30/85);
CIP of 07/999,410 (12/31/92);
Cont. of 07/499,210 (03/19/90);
Cont of 06/771,230 (08/30/85);
CIP of 06/706,562 (02/28/85);
CIP of 06/558,109 (12/5/83)
DI No.: 84-37
Our Reference: 03495.0010-20000

Pending Claims

17. A purified recombinant DNA of human immunodeficiency virus type 1 (HIV-1), wherein the DNA comprises the sequence:

8570	8580	8590	8600	8610
GGGGGACTGG	AAGGGCTAAT	TCACTCCCAA	CGAAGACAAG	ATATCCTTGA
8620	8630	8640	8650	8660
TCTGTGGATC	TACCACACAC	AAGGCTACTT	CCCTGATTGG	CAGAACTACA
8670	8680	8690	8700	8710
CACCAGGGCC	AGGGGTCAGA	TATCCACTGA	CCTTTGGATG	GTGCTACAAG
8720	8730	8740	8750	8760
CTAGTACCAG	TTGAGCCAGA	TAAGGTAGAA	GAGGCCAATA	AAGGAGAGAA
8770	8780	8790	8800	8810
CACCAGCTTG	TTACACCCTG	TGAGCCTGCA	TGGAATGGAT	GACCCTGAGA
8820	8830	8840	8850	8860
GAGAAGTGTT	AGAGTGGAGG	TTTGACAGCC	GCCTAGCATT	TCATCACGTG
8870	8880	8890	8900	8910
GCCCAGAGAGC	TGCATCCGGA	GTA CT TCAAG	AACTGCTGAC	ATCGAGCTTG
8920	8930	8940	8950	8960
CTACAAGGGA	CTTTCCGCTG	GGGACTTTCC	AGGGAGGCGT	GGCCTGGGCG
8970	8980	8990	9000	9010
GAACTGGGGA	GTGGCGAGCC	CTCAGATGCT	GCATATAAGC	AGCTGCTTTT

9020	9030	9040	9050	9060
TGCCTGTACT	GGGTCTCTCT	GGTTAGACCA	GATTTGAGCC	TGGGAGCTCT
9070	9080	9090	9097	10
CTGGCTAACT	AGGGAACCCA	CTGCTTAAGC	CTCAATA	AAGCTTGCCT
20	30	40	50	60
TGAGTGCTTC	AAGTAGTGTG	TGCCCCGTCTG	TTGTGTGACT	CTGGTAACTA
70	80	90	100	110
GAGATCCCTC	AGACCCTTTT	AGTCAGTGTG	GAAAATCTCT	AGCAGTGGCG
120	130	140	150	159
CCCGAACAGG	GACTTGAAAG	CGAAAGGGAA	ACCAGAGGAG	CTCTCTCGA

18. The purified recombinant DNA of claim 17, wherein said nucleic acid is labeled with a label selected from the group consisting of a radioisotope, an enzyme, a fluorescent label, and a chromophore label.

19. A method of using the purified recombinant DNA of claim 17 for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and
- (c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified recombinant DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

20. The method of claim 19, wherein the biological fluid is blood.

21. A method of using the purified recombinant DNA of claim 18 for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and

(c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified recombinant DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

22. The method of claim 21, wherein the biological fluid is blood.

25. A method for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and

(c) detecting the presence of HIV-1 RNA.

27. The method of claim 25, wherein the presence of HIV-1 RNA is detected by contacting the HIV-1 RNA with the DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

28. The method of claim 25, wherein the presence of HIV-1 RNA is detected by contacting the HIV-1 RNA with the DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

29. A method for preparing HIV-1 RNA for detecting the presence of

HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA.

30. The method of claim 29, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

31. The method of claim 29, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

32. A method for preparing HIV-1 RNA for detecting the presence of

HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) isolating HIV-1 virions from the cell-free supernatant; and

(c) disrupting the virions to release HIV-1 RNA.

33. The method of claim 32, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

34. The method of claim 32, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

35. A purified fragment of the recombinant DNA of claim 17, wherein said fragment comprises the sequence:

CTCAATAAAGCTTGCCTTG.

36. The purified fragment of claim 35, wherein said nucleic acid is labeled with a label selected from the group consisting of a radioisotope, an enzyme, a fluorescent label, and a chromophore label.

37. A method of using the purified fragment of claim 35 for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and

(c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified fragment of claim 35 and detecting hybridization between the HIV-1 RNA and the purified fragment.

38. The method of claim 37, wherein the biological fluid is blood.

39. A method of using the purified fragment of claim 36 for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and

(c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified fragment of claim 36 and detecting hybridization between the HIV-1 RNA and the purified fragment.

40. The method of claim 39, wherein the biological fluid is blood.



PATENT
Customer No. 22,852
Attorney Docket No. 3495.0010-20

UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
) Group Art Unit: 1637
Marc Alizon et al.)
) Examiner: Jeffrey N. Fredman
Application No.: 08/308,219)
) Confirmation No.: 4832
Filed: September 19,1994)
)
For: DNA SEQUENCE OF THE LTR
REGION OF HUMAN
IMMUNODEFICIENCY VIRUS
TYPE 1 (HIV-1)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

STATEMENT OF LUC MONTAGNIER
(Being Added As An Inventor)

I have read U.S. application Serial No. 08/308,219.

I am informed that I was not named as an inventor in application Serial No.
08/308,219 when the application was filed in the U.S. Patent and Trademark Office.

I have been informed that the claims in U.S. application Serial No. 08/308,219
have been amended by adding claims 17-22, 25, and 27-40 to the application.

I am informed that a copy of claims 17-22, 25, and 27-40 is attached hereto.

I have read claims 17-22, 25, and 27-40, which I am informed were added to
U.S. application Serial No. 08/308,219 to claim previously unclaimed subject matter.

I understand that I am being added as an inventor to U.S. application Serial No. 08/308,219.

I have been informed that my addition as an inventor to U.S. application Serial No. 08/308,219 is necessitated by the amendment of the claims by adding claims 17-22, 25, and 27-40 to the application.

The inventorship error resulting from the amendment of the claims by adding claims 17-22, 25, and 27-40 to U.S. application Serial No. 08/308,219 occurred without deceptive intention on my part.

I hereby declare that all statements made of my own knowledge and belief are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

By: 

Date: May 24 2006

U.S. Patent Application No. 08/308,219

Filed: September 19, 1994

Inventors: Marc ALIZON et al.

Div. of 07/158,652 (02/22/88);

Div. of 06/771,248 (08/30/85);

CIP of 07/999,410 (12/31/92);

Cont. of 07/499,210 (03/19/90);

Cont of 06/771,230 (08/30/85);

CIP of 06/706,562 (02/28/85)'

CIP of 06/558,109 (12/5/83)

DI No.: 84-37

Our Reference: 03495.0010-20000

Pending Claims

17. A purified recombinant DNA of human immunodeficiency virus type 1 (HIV-1), wherein the DNA comprises the sequence:

8570	8580	8590	8600	8610
GGGGGACTGG	AAGGGCTAAT	TCACTCCCAA	CGAAGACAAG	ATATCCTTGA
8620	8630	8640	8650	8660
TCTGTGGATC	TACCACACAC	AAGGCTACTT	CCCTGATTGG	CAGAACTACA
8670	8680	8690	8700	8710
CACCAGGGCC	AGGGGTCAGA	TATCCACTGA	CCTTTGGATG	GTGCTACAAG
8720	8730	8740	8750	8760
CTAGTACCAG	TTGAGCCAGA	TAAGGTAGAA	GAGGCCAATA	AAGGAGAGAA
8770	8780	8790	8800	8810
CACCAGCTTG	TTACACCCTG	TGAGCCTGCA	TGGAATGGAT	GACCCTGAGA
8820	8830	8840	8850	8860
GAGAAGTGTT	AGAGTGGAGG	TTTGACAGCC	GCCTAGCATT	TCATCACGTG
8870	8880	8890	8900	8910
GCCCGAGAGC	TGCATCCGGA	GTA CTTC AAG	AACTGCTGAC	ATCGAGCTTG
8920	8930	8940	8950	8960
CTACAAGGGA	CTTTCCGCTG	GGGACTTTCC	AGGGAGGCGT	GGCCTGGGCG
8970	8980	8990	9000	9010
GAAGTGGGGA	GTGGCGAGCC	CTCAGATGCT	GCATATAAGC	AGCTGCTTTT

9020	9030	9040	9050	9060
TGCCTGTACT	GGGTCTCTCT	GGTTAGACCA	GATTTGAGCC	TGGGAGCTCT
9070	9080	9090	9097	10
CTGGCTAACT	AGGGAACCCA	CTGCTTAAGC	CTCAATA	AAGCTTGCCT
20	30	40	50	60
TGAGTGCTTC	AAGTAGTGTG	TGCCCCGTCTG	TTGTGTGACT	CTGGTAACTA
70	80	90	100	110
GAGATCCCTC	AGACCCTTTT	AGTCAGTGTG	GAAAATCTCT	AGCAGTGGCG
120	130	140	150	159
CCCGAACAGG	GACTTGAAAG	CGAAAGGGAA	ACCAGAGGAG	CTCTCTCGA

18. The purified recombinant DNA of claim 17, wherein said nucleic acid is labeled with a label selected from the group consisting of a radioisotope, an enzyme, a fluorescent label, and a chromophore label.

19. A method of using the purified recombinant DNA of claim 17 for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and
- (c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified recombinant DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

20. The method of claim 19, wherein the biological fluid is blood.

21. A method of using the purified recombinant DNA of claim 18 for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and
- (c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified recombinant DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

22. The method of claim 21, wherein the biological fluid is blood.

25. A method for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and
- (c) detecting the presence of HIV-1 RNA.

27. The method of claim 25, wherein the presence of HIV-1 RNA is detected by contacting the HIV-1 RNA with the DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

28. The method of claim 25, wherein the presence of HIV-1 RNA is detected by contacting the HIV-1 RNA with the DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

29. A method for preparing HIV-1 RNA for detecting the presence of

HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA.

30. The method of claim 29, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

31. The method of claim 29, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

32. A method for preparing HIV-1 RNA for detecting the presence of

HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) isolating HIV-1 virions from the cell-free supernatant; and

(c) disrupting the virions to release HIV-1 RNA.

33. The method of claim 32, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

34. The method of claim 32, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

35. A purified fragment of the recombinant DNA of claim 17, wherein said fragment comprises the sequence:
CTCAATAAAGCTTGCCTTG.

36. The purified fragment of claim 35, wherein said nucleic acid is labeled with a label selected from the group consisting of a radioisotope, an enzyme, a fluorescent label, and a chromophore label.

37. A method of using the purified fragment of claim 35 for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and

(c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified fragment of claim 35 and detecting hybridization between the HIV-1 RNA and the purified fragment.

38. The method of claim 37, wherein the biological fluid is blood.

39. A method of using the purified fragment of claim 36 for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and

(c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified fragment of claim 36 and detecting hybridization between the HIV-1 RNA and the purified fragment.

40. The method of claim 39, wherein the biological fluid is blood.



PATENT
Customer No. 22,852
Attorney Docket No. 3495.0010-20

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Marc Alizon et al.) Group Art Unit: 1637
Application No.: 08/308,219) Examiner: Jeffrey N. Fredman
Filed: September 19, 1994) Confirmation No.: 4832
For: DNA SEQUENCE OF THE LTR)
REGION OF HUMAN)
IMMUNODEFICIENCY VIRUS)
TYPE 1 (HIV-1))

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

STATEMENT OF JEAN-CLAUDE CHERMANN
(Being Added As An Inventor)

I have read U.S. application Serial No. 08/308,219.

I am informed that I was not named as an inventor in application Serial No. 08/308,219 when the application was filed in the U.S. Patent and Trademark Office.

I have been informed that the claims in U.S. application Serial No. 08/308,219 have been amended by adding claims 17-22, 25, and 27-40 to the application.

I am informed that a copy of claims 17-22, 25, and 27-40 is attached hereto.

I have read claims 17-22, 25, and 27-40, which I am informed were added to U.S. application Serial No. 08/308,219 to claim previously unclaimed subject matter.

I understand that I am being added as an inventor to U.S. application Serial No. 08/308,219.

I have been informed that my addition as an inventor to U.S. application Serial No. 08/308,219 is necessitated by the amendment of the claims by adding claims 17-22, 25, and 27-40 to the application.

The inventorship error resulting from the amendment of the claims by adding claims 17-22, 25, and 27-40 to U.S. application Serial No. 08/308,219 occurred without deceptive intention on my part.

I hereby declare that all statements made of my own knowledge and belief are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

By: Jean. Claude Chermusany

Date: May 26 . 06

U.S. Patent Application No. 08/308,219
Filed: September 19, 1994
Inventors: Marc ALIZON et al.
Div. of 07/158,652 (02/22/88);
Div. of 06/771,248 (08/30/85);
CIP of 07/999,410 (12/31/92);
Cont. of 07/499,210 (03/19/90);
Cont of 06/771,230 (08/30/85);
CIP of 06/706,562 (02/28/85)'
CIP of 06/558,109 (12/5/83)
DI No.: 84-37
Our Reference: 03495.0010-20000

Pending Claims

17. A purified recombinant DNA of human immunodeficiency virus type 1 (HIV-1), wherein the DNA comprises the sequence:

8570	8580	8590	8600	8610
GGGGGACTGG	AAGGGCTAAT	TCACTCCCAA	CGAAGACAAG	ATATCCTTGA
8620	8630	8640	8650	8660
TCTGTGGATC	TACCACACAC	AAGGCTACTT	CCCTGATTGG	CAGAACTACA
8670	8680	8690	8700	8710
CACCAGGGCC	AGGGGTCAGA	TATCCACTGA	CCTTTGGATG	GTGCTACAAG
8720	8730	8740	8750	8760
CTAGTACCAG	TTGAGCCAGA	TAAGGTAGAA	GAGGCCAATA	AAGGAGAGAA
8770	8780	8790	8800	8810
CACCAGCTTG	TTACACCCTG	TGAGCCTGCA	TGGAATGGAT	GACCCTGAGA
8820	8830	8840	8850	8860
GAGAAGTGTT	AGAGTGGAGG	TTTGACAGCC	GCCTAGCATT	TCATCACGTG
8870	8880	8890	8900	8910
GCCCCGAGAGC	TGCATCCGGA	GTACTTCAAG	AACTGCTGAC	ATCGAGCTTG
8920	8930	8940	8950	8960
CTACAAGGGA	CTTTCCGCTG	GGGACTTTCC	AGGGAGGCGT	GGCCTGGGCG
8970	8980	8990	9000	9010
GAACTGGGGA	GTGGCGAGCC	CTCAGATGCT	GCATATAAGC	AGCTGCTTTT

9020	9030	9040	9050	9060
TGCCTGTACT	GGGTCTCTCT	GGTTAGACCA	GATTTGAGCC	TGGGAGCTCT
9070	9080	9090	9097	10
CTGGCTAACT	AGGGAACCCA	CTGCTTAAGC	CTCAATA	AAGCTTGCCT
20	30	40	50	60
TGAGTGCTTC	AAGTAGTGTG	TGCCCCGTCTG	TTGTGTGACT	CTGGTAACTA
70	80	90	100	110
GAGATCCCTC	AGACCCTTTT	AGTCAGTGTG	GAAAATCTCT	AGCAGTGGCG
120	130	140	150	159
CCCGAACAGG	GACTTGAAAG	CGAAAGGGAA	ACCAGAGGAG	CTCTCTCGA

18. The purified recombinant DNA of claim 17, wherein said nucleic acid is labeled with a label selected from the group consisting of a radioisotope, an enzyme, a fluorescent label, and a chromophore label.

19. A method of using the purified recombinant DNA of claim 17 for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and
- (c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified recombinant DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

20. The method of claim 19, wherein the biological fluid is blood.

21. A method of using the purified recombinant DNA of claim 18 for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and

(c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified recombinant DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

22. The method of claim 21, wherein the biological fluid is blood.

25. A method for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and

(c) detecting the presence of HIV-1 RNA.

27. The method of claim 25, wherein the presence of HIV-1 RNA is detected by contacting the HIV-1 RNA with the DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

28. The method of claim 25, wherein the presence of HIV-1 RNA is detected by contacting the HIV-1 RNA with the DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

29. A method for preparing HIV-1 RNA for detecting the presence of

HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA.

30. The method of claim 29, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

31. The method of claim 29, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

32. A method for preparing HIV-1 RNA for detecting the presence of

HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) isolating HIV-1 virions from the cell-free supernatant; and

(c) disrupting the virions to release HIV-1 RNA.

33. The method of claim 32, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

34. The method of claim 32, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

35. A purified fragment of the recombinant DNA of claim 17, wherein said fragment comprises the sequence:
CTCAATAAAGCTTGCCTTG.

36. The purified fragment of claim 35, wherein said nucleic acid is labeled with a label selected from the group consisting of a radioisotope, an enzyme, a fluorescent label, and a chromophore label.

37. A method of using the purified fragment of claim 35 for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and

(c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified fragment of claim 35 and detecting hybridization between the HIV-1 RNA and the purified fragment.

38. The method of claim 37, wherein the biological fluid is blood.

39. A method of using the purified fragment of claim 36 for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and

(c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified fragment of claim 36 and detecting hybridization between the HIV-1 RNA and the purified fragment.

40. The method of claim 39, wherein the biological fluid is blood.



PATENT
Customer No. 22,852
Attorney Docket No. 3495.0010-20

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
) Group Art Unit: 1637
Marc Alizon et al.)
) Examiner: Jeffrey N. Fredman
Application No.: 08/308,219)
) Confirmation No.: 4832
Filed: September 19, 1994)
)
For: DNA SEQUENCE OF THE LTR
REGION OF HUMAN
IMMUNODEFICIENCY VIRUS
TYPE 1 (HIV-1)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

STATEMENT OF FRANÇOISE BARRE-SINOUSS
(Being Added As An Inventor)

I have read U.S. application Serial No. 08/308,219.

I am informed that I was not named as an inventor in application Serial No.
08/308,219 when the application was filed in the U.S. Patent and Trademark Office.

I have been informed that the claims in U.S. application Serial No. 08/308,219
have been amended by adding claims 17-22, 25, and 27-40 to the application.

I am informed that a copy of claims 17-22, 25, and 27-40 is attached hereto.

I have read claims 17-22, 25, and 27-40, which I am informed were added to
U.S. application Serial No. 08/308,219 to claim previously unclaimed subject matter.

I understand that I am being added as an inventor to U.S. application Serial No. 08/308,219.

I have been informed that my addition as an inventor to U.S. application Serial No. 08/308,219 is necessitated by the amendment of the claims by adding claims 17-22, 25, and 27-40 to the application.

The inventorship error resulting from the amendment of the claims by adding claims 17-22, 25, and 27-40 to U.S. application Serial No. 08/308,219 occurred without deceptive intention on my part.

I hereby declare that all statements made of my own knowledge and belief are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

By:  _____

Date: 05.24.2006

U.S. Patent Application No. 08/308,219

Filed: September 19, 1994

Inventors: Marc ALIZON et al.

Div. of 07/158,652 (02/22/88);

Div. of 06/771,248 (08/30/85);

CIP of 07/999,410 (12/31/92);

Cont. of 07/499,210 (03/19/90);

Cont of 06/771,230 (08/30/85);

CIP of 06/706,562 (02/28/85)'

CIP of 06/558,109 (12/5/83)

DI No.: 84-37

Our Reference: 03495.0010-20000

Pending Claims

17. A purified recombinant DNA of human immunodeficiency virus type 1 (HIV-1), wherein the DNA comprises the sequence:

8570	8580	8590	8600	8610
GGGGGACTGG	AAGGGCTAAT	TCACTCCCAA	CGAAGACAAG	ATATCCTTGA
8620	8630	8640	8650	8660
TCTGTGGATC	TACCACACAC	AAGGCTACTT	CCCTGATTGG	CAGAACTACA
8670	8680	8690	8700	8710
CACCAGGGCC	AGGGGTCAGA	TATCCACTGA	CCTTTGGATG	GTGCTACAAG
8720	8730	8740	8750	8760
CTAGTACCAG	TTGAGCCAGA	TAAGGTAGAA	GAGGCCAATA	AAGGAGAGAA
8770	8780	8790	8800	8810
CACCAGCTTG	TTACACCCTG	TGAGCCTGCA	TGGAATGGAT	GACCCCTGAGA
8820	8830	8840	8850	8860
GAGAAGTGTT	AGAGTGGAGG	TTTGACAGCC	GCCTAGCATT	TCATCACGTG
8870	8880	8890	8900	8910
GCCCGAGAGC	TGCATCCGGA	GTA CTTCAAG	AACTGCTGAC	ATCGAGCTTG
8920	8930	8940	8950	8960
CTACAAGGGA	CTTTCCGCTG	GGGACTTTCC	AGGGAGGCGT	GGCCTGGGCG
8970	8980	8990	9000	9010
GAACTGGGGA	GTGGCGAGCC	CTCAGATGCT	GCATATAAGC	AGCTGCTTTT

9020	9030	9040	9050	9060
TGCCTGTACT	GGGTCTCTCT	GGTTAGACCA	GATTTGAGCC	TGGGAGCTCT
9070	9080	9090	9097	10
CTGGCTAACT	AGGGAACCCA	CTGCTTAAGC	CTCAATA	AAGCTTGCCT
20	30	40	50	60
TGAGTGCTTC	AAGTAGTGTG	TGCCCCGTCTG	TTGTGTGACT	CTGGTAACTA
70	80	90	100	110
GAGATCCCTC	AGACCCTTTT	AGTCAGTGTG	GAAAATCTCT	AGCAGTGGCG
120	130	140	150	159
CCCGAACAGG	GACTTGAAAG	CGAAAGGGAA	ACCAGAGGAG	CTCTCTCGA

18. The purified recombinant DNA of claim 17, wherein said nucleic acid is labeled with a label selected from the group consisting of a radioisotope, an enzyme, a fluorescent label, and a chromophore label.

19. A method of using the purified recombinant DNA of claim 17 for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and
- (c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified recombinant DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

20. The method of claim 19, wherein the biological fluid is blood.

28. The method of claim 25, wherein the presence of HIV-1 RNA is detected by contacting the HIV-1 RNA with the DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

29. A method for preparing HIV-1 RNA for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA.

30. The method of claim 29, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

31. The method of claim 29, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

32. A method for preparing HIV-1 RNA for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

21. A method of using the purified recombinant DNA of claim 18 for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and
- (c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified recombinant DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

22. The method of claim 21, wherein the biological fluid is blood.

25. A method for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and
- (c) detecting the presence of HIV-1 RNA.

27. The method of claim 25, wherein the presence of HIV-1 RNA is detected by contacting the HIV-1 RNA with the DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

(b) isolating HIV-1 virions from the cell-free supernatant; and

(c) disrupting the virions to release HIV-1 RNA.

33. The method of claim 32, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

34. The method of claim 32, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

35. A purified fragment of the recombinant DNA of claim 17, wherein said fragment comprises the sequence:
CTCAATAAAGCTTGCCTTG.

36. The purified fragment of claim 35, wherein said nucleic acid is labeled with a label selected from the group consisting of a radioisotope, an enzyme, a fluorescent label, and a chromophore label.

37. A method of using the purified fragment of claim 35 for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and

(c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified fragment of claim 35 and detecting hybridization between the HIV-1 RNA and the purified fragment.

38. The method of claim 37, wherein the biological fluid is blood.

39. A method of using the purified fragment of claim 36 for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and

(c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified fragment of claim 36 and detecting hybridization between the HIV-1 RNA and the purified fragment.

40. The method of claim 39, wherein the biological fluid is blood.



PATENT
Customer No. 22,852
Attorney Docket No. 3495.0010-20

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
) Group Art Unit: 1637
Marc Alizon et al.)
) Examiner: Jeffrey N. Fredman
Application No.: 08/308,219)
) Confirmation No.: 4832
Filed: September 19, 1994)
)
For: DNA SEQUENCE OF THE LTR
REGION OF HUMAN
IMMUNODEFICIENCY VIRUS
TYPE 1 (HIV-1)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

STATEMENT OF PIERRE TIOLLAIS
(Being Added As An Inventor)

I have read U.S. application Serial No. 08/308,219.

I am informed that I was not named as an inventor in application Serial No.
08/308,219 when the application was filed in the U.S. Patent and Trademark Office.

I have been informed that the claims in U.S. application Serial No. 08/308,219
have been amended by adding claims 17-22, 25, and 27-40 to the application.

I am informed that a copy of claims 17-22, 25, and 27-40 is attached hereto.

I have read claims 17-22, 25, and 27-40, which I am informed were added to
U.S. application Serial No. 08/308,219 to claim previously unclaimed subject matter.

I understand that I am being added as an inventor to U.S. application Serial No. 08/308,219.

I have been informed that my addition as an inventor to U.S. application Serial No. 08/308,219 is necessitated by the amendment of the claims by adding claims 17-22, 25, and 27-40 to the application.

The inventorship error resulting from the amendment of the claims by adding claims 17-22, 25, and 27-40 to U.S. application Serial No. 08/308,219 occurred without deceptive intention on my part.

I hereby declare that all statements made of my own knowledge and belief are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

By: 

Date: 24 mai 06

U.S. Patent Application No. 08/308,219

Filed: September 19, 1994

Inventors: Marc ALIZON et al.

Div. of 07/158,652 (02/22/88);

Div. of 06/771,248 (08/30/85);

CIP of 07/999,410 (12/31/92);

Cont. of 07/499,210 (03/19/90);

Cont of 06/771,230 (08/30/85);

CIP of 06/706,562 (02/28/85)'

CIP of 06/558,109 (12/5/83)

DI No.: 84-37

Our Reference: 03495.0010-20000

Pending Claims

17. A purified recombinant DNA of human immunodeficiency virus type 1 (HIV-1), wherein the DNA comprises the sequence:

8570	8580	8590	8600	8610
GGGGGACTGG	AAGGGCTAAT	TCACTCCCAA	CGAAGACAAG	ATATCCTTGA
8620	8630	8640	8650	8660
TCTGTGGATC	TACCACACAC	AAGGCTACTT	CCCTGATTGG	CAGAACTACA
8670	8680	8690	8700	8710
CACCAGGGCC	AGGGGTCAGA	TATCCACTGA	CCTTTGGATG	GTGCTACAAG
8720	8730	8740	8750	8760
CTAGTACCAG	TTGAGCCAGA	TAAGGTAGAA	GAGGCCAATA	AAGGAGAGAA
8770	8780	8790	8800	8810
CACCAGCTTG	TTACACCCTG	TGAGCCTGCA	TGGAATGGAT	GACCCTGAGA
8820	8830	8840	8850	8860
GAGAAGTGTT	AGAGTGGAGG	TTTGACAGCC	GCCTAGCATT	TCATCACGTG
8870	8880	8890	8900	8910
GCCCGAGAGC	TGCATCCGGA	GTACTTCAAG	AACTGCTGAC	ATCGAGCTTG
8920	8930	8940	8950	8960
CTACAAGGGA	CTTTCCGCTG	GGGACTTTCC	AGGGAGGCGT	GGCCTGGGCG
8970	8980	8990	9000	9010
GAACTGGGGA	GTGGCGAGCC	CTCAGATGCT	GCATATAAGC	AGCTGCTTTT

9020	9030	9040	9050	9060
TGCCTGTACT	GGGTCTCTCT	GGTTAGACCA	GATTTGAGCC	TGGGAGCTCT
9070	9080	9090	9097	10
CTGGCTAACT	AGGGAACCCA	CTGCTTAAGC	CTCAATA	AAGCTTGCCCT
20	30	40	50	60
TGAGTGCTTC	AAGTAGTGTG	TGCCCCGTCTG	TTGTGTGACT	CTGGTAACTA
70	80	90	100	110
GAGATCCCTC	AGACCCTTTT	AGTCAGTGTG	GAAAATCTCT	AGCAGTGGCG
120	130	140	150	159
CCCGAACAGG	GACTTGAAAG	CGAAAGGGAA	ACCAGAGGAG	CTCTCTCGA

18. The purified recombinant DNA of claim 17, wherein said nucleic acid is labeled with a label selected from the group consisting of a radioisotope, an enzyme, a fluorescent label, and a chromophore label.

19. A method of using the purified recombinant DNA of claim 17 for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and
- (c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified recombinant DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

20. The method of claim 19, wherein the biological fluid is blood.

21. A method of using the purified recombinant DNA of claim 18 for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and
- (c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified recombinant DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

22. The method of claim 21, wherein the biological fluid is blood.

25. A method for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and
- (c) detecting the presence of HIV-1 RNA.

27. The method of claim 25, wherein the presence of HIV-1 RNA is detected by contacting the HIV-1 RNA with the DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

28. The method of claim 25, wherein the presence of HIV-1 RNA is detected by contacting the HIV-1 RNA with the DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

29. A method for preparing HIV-1 RNA for detecting the presence of

HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA.

30. The method of claim 29, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

31. The method of claim 29, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

32. A method for preparing HIV-1 RNA for detecting the presence of

HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) isolating HIV-1 virions from the cell-free supernatant; and

(c) disrupting the virions to release HIV-1 RNA.

33. The method of claim 32, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

34. The method of claim 32, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

35. A purified fragment of the recombinant DNA of claim 17, wherein said fragment comprises the sequence:
CTCAATAAAGCTTGCCTTG.

36. The purified fragment of claim 35, wherein said nucleic acid is labeled with a label selected from the group consisting of a radioisotope, an enzyme, a fluorescent label, and a chromophore label.

37. A method of using the purified fragment of claim 35 for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and

(c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified fragment of claim 35 and detecting hybridization between the HIV-1 RNA and the purified fragment.

38. The method of claim 37, wherein the biological fluid is blood.

39. A method of using the purified fragment of claim 36 for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and

(c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified fragment of claim 36 and detecting hybridization between the HIV-1 RNA and the purified fragment.

40. The method of claim 39, wherein the biological fluid is blood.



PATENT
Customer No. 22,852
Attorney Docket No. 3495.0010-20

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Marc Alizon et al.

Application No.: 08/308,219

Filed: September 19, 1994

For: DNA SEQUENCE OF THE LTR
REGION OF HUMAN
IMMUNODEFICIENCY VIRUS
TYPE 1 (HIV-1)

)
) Group Art Unit: 1637
)
) Examiner: Jeffrey N. Fredman
)
) Confirmation No.: 4832
)
)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

STATEMENT OF ROBERT C. GALLO
(Being Added As An Inventor)

I have read U.S. application Serial No. 08/308,219.

I am informed that I was not named as an inventor in application Serial No. 08/308,219 when the application was filed in the U.S. Patent and Trademark Office.

I have been informed that the claims in U.S. application Serial No. 08/308,219 have been amended by adding claims 25, 29, and 32 to the application.

I am informed that a copy of claims 25, 29, and 32 is attached hereto.

I have read claims 25, 29, and 32, which I am informed were added to U.S. application Serial No. 08/308,219 to claim previously unclaimed subject matter.

I understand that I am being added as an inventor to U.S. application Serial No. 08/308,219.

I have been informed that my addition as an inventor to U.S. application Serial No. 08/308,219 is necessitated by the amendment of the claims by adding 25, 29, and 32 to the application.

The inventorship error resulting from the amendment of the claims by adding claims 25, 29, and 32 to U.S. application Serial No. 08/308,219 occurred without deceptive intention on my part.

I hereby declare that all statements made of my own knowledge and belief are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

By: Robert C. Gallo

Date: May 31, 06

U.S. Patent Application No. 08/308,219
Filed: September 19, 1994
Inventors: Marc ALIZON et al.
Div. of 07/158,652 (02/22/88);
Div. of 06/771,248 (08/30/85);
CIP of 07/999,410 (12/31/92);
Cont. of 07/499,210 (03/19/90);
Cont of 06/771,230 (08/30/85);
CIP of 06/706,562 (02/28/85)'
CIP of 06/558,109 (12/5/83)
DI No.: 84-37
Our Reference: 03495.0010-20000

25. A method for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and
- (c) detecting the presence of HIV-1 RNA.

29. A method for preparing HIV-1 RNA for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA.

32. A method for preparing HIV-1 RNA for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) isolating HIV-1 virions from the cell-free supernatant; and

(c) disrupting the virions to release HIV-1 RNA.



PATENT
Customer No. 22,852
Attorney Docket No. 3495.0010-20

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
) Group Art Unit: 1637
Marc Alizon et al.)
) Examiner: Jeffrey N. Fredman
Application No.: 08/308,219)
) Confirmation No.: 4832
Filed: September 19, 1994)
)
For: DNA SEQUENCE OF THE LTR
REGION OF HUMAN
IMMUNODEFICIENCY VIRUS
TYPE 1 (HIV-1)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

STATEMENT OF MIKULAS POPOVIC
(Being Added As An Inventor)

I have read U.S. application Serial No. 08/308,219.

I am informed that I was not named as an inventor in application Serial No.
08/308,219 when the application was filed in the U.S. Patent and Trademark Office.

I have been informed that the claims in U.S. application Serial No. 08/308,219
have been amended by adding claims 25, 29, and 32 to the application.

I am informed that a copy of claims 25, 29, and 32 is attached hereto.


I have read claims 25, 29, and 32, which I am informed were added to U.S.
application Serial No. 08/308,219 to claim previously unclaimed subject matter.

I understand that I am being added as an inventor to U.S. application Serial No. 08/308,219.

I have been informed that my addition as an inventor to U.S. application Serial No. 08/308,219 is necessitated by the amendment of the claims by adding 25, 29, and 32 to the application.

The inventorship error resulting from the amendment of the claims by adding claims 25, 29, and 32 to U.S. application Serial No. 08/308,219 occurred without deceptive intention on my part.

I hereby declare that all statements made of my own knowledge and belief are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

By: 

Date: June 1, 2006

U.S. Patent Application No. 08/308,219
Filed: September 19, 1994
Inventors: Marc ALIZON et al.
Div. of 07/158,652 (02/22/88);
Div. of 06/771,248 (08/30/85);
CIP of 07/999,410 (12/31/92);
Cont. of 07/499,210 (03/19/90);
Cont of 06/771,230 (08/30/85);
CIP of 06/706,562 (02/28/85);
CIP of 06/558,109 (12/5/83)
DI No.: 84-37
Our Reference: 03495.0010-20000

25. A method for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and
- (c) detecting the presence of HIV-1 RNA.

29. A method for preparing HIV-1 RNA for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA.

32. A method for preparing HIV-1 RNA for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) isolating HIV-1 virions from the cell-free supernatant; and

(c) disrupting the virions to release HIV-1 RNA.



PATENT
Customer No. 22,852
Attorney Docket No. 3495.0010-20

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Marc Alizon et al.) Group Art Unit: 1637
Application No.: 08/308,219) Examiner: Jeffrey N. Fredman
Filed: September 19, 1994) Confirmation No.: 4832
For: DNA SEQUENCE OF THE LTR)
REGION OF HUMAN)
IMMUNODEFICIENCY VIRUS)
TYPE 1 (HIV-1)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

STATEMENT OF MANGALASSERIL G. SARNGADHARAN
(Being Added As An Inventor)

I have read U.S. application Serial No. 08/308,219.

I am informed that I was not named as an inventor in application Serial No. 08/308,219 when the application was filed in the U.S. Patent and Trademark Office.

I have been informed that the claims in U.S. application Serial No. 08/308,219 have been amended by adding claims 25, 29, and 32 to the application.

I am informed that a copy of claims 25, 29, and 32 is attached hereto.

I have read claims 25, 29, and 32, which I am informed were added to U.S. application Serial No. 08/308,219 to claim previously unclaimed subject matter.

I understand that I am being added as an inventor to U.S. application Serial No. 08/308,219.

I have been informed that my addition as an inventor to U.S. application Serial No. 08/308,219 is necessitated by the amendment of the claims by adding 25, 29, and 32 to the application.

The inventorship error resulting from the amendment of the claims by adding claims 25, 29, and 32 to U.S. application Serial No. 08/308,219 occurred without deceptive intention on my part.

I hereby declare that all statements made of my own knowledge and belief are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

By: Mangalasseri G. Sarnadharan

Date: June 4, 2006

U.S. Patent Application No. 08/308,219
Filed: September 19, 1994
Inventors: Marc ALIZON et al.
Div. of 07/158,652 (02/22/88);
Div. of 06/771,248 (08/30/85);
CIP of 07/999,410 (12/31/92);
Cont. of 07/499,210 (03/19/90);
Cont of 06/771,230 (08/30/85);
CIP of 06/706,562 (02/28/85)'
CIP of 06/558,109 (12/5/83)
DI No.: 84-37
Our Reference: 03495.0010-20000

25. A method for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and
- (c) detecting the presence of HIV-1 RNA.

29. A method for preparing HIV-1 RNA for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA.

32. A method for preparing HIV-1 RNA for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) isolating HIV-1 virions from the cell-free supernatant; and

(c) disrupting the virions to release HIV-1 RNA.



PATENT
Customer No. 22,852
Attorney Docket No. 3495.0010-20

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Marc Alizon et al.

Application No.: 08/308,219

Filed: September 19, 1994

For: DNA SEQUENCE OF THE LTR
REGION OF HUMAN
IMMUNODEFICIENCY VIRUS
TYPE 1 (HIV-1)

)
) Group Art Unit: 1637
)
) Examiner: Jeffrey N. Fredman
)
) Confirmation No.: 4832
)
)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

**CONSENT OF ASSIGNEE THE UNITED STATES OF AMERICA
TO AMENDMENT OF INVENTORSHIP**

The United States of America as represented by the Secretary of the Department of Health and Human Services, having its principal place of business at 900 Rockville Pike, Bethesda, Maryland 20892, as an Assignee of the above-identified application, does hereby consent to amendment of inventorship from the inventive entity:

Marc Alizon
Pierre Sonigo
Simon Wain-Hobson
Stewart Cole
Oliver Danos


to the inventive entity:

Robert C. Gallo
Mikulas Popovic
Mangalasseril G. Sarngadharan
Solange Chamaret
Claudine Axler-Blin
Françoise Rey
Marie-Therese Nugeyre
Jacqueline Gruet
Charles Dauguet
Willy Rozenbaum
Christine Rouzioux
François Brun-Vezinet
Luc Montagnier
Jean-Claude Chermann
Françoise Barre-Sinoussi
Pierre Tiollais
Marc Alizon
Pierre Sonigo
Simon Wain-Hobson
Stewart Cole
Oliver Danos

The undersigned is authorized to act on behalf of the Assignee, the United States of America as represented by the Secretary of the Department of Health and Human Services.

I hereby declare that all statements made of my own knowledge and belief are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Respectfully submitted,

By: 
Name: JACK SPIEGEL (REG# 34,477)
Title: SENIOR ADVISOR FOR TECHNOLOGY TRANSFER OPERATIONS
For Assignee: The United States of America
as represented by the
Secretary of the Department of
Health and Human Services.

Dated: JUNE 5, 2006

1110249

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Marc Alizon et al.) Group Art Unit: 1637
Application No.: 08/308,219) Examiner: Jeffrey N. Fredman
Filed: September 19, 1994) Confirmation No.: 4832
For: DNA SEQUENCE OF THE LTR)
REGION OF HUMAN)
IMMUNODEFICIENCY VIRUS)
TYPE 1 (HIV-1))

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

**CONSENT OF ASSIGNEE INSTITUT PASTEUR
TO AMENDMENT OF INVENTORSHIP**

Institut Pasteur, duly organized under the laws of France and having its principal place of business at 28, rue du Docteur Roux, 75724 Paris Cedex 15, France, as an Assignee of the above-identified application, does hereby consent to amendment of inventorship from the inventive entity:

Marc Alizon
Pierre Sonigo
Simon Wain-Hobson
Stewart Cole
Oliver Danos

to the inventive entity:

Solange Chamaret
Claudine Axler-Blin
Françoise Rey
Marie-Therese Nugeyre
Jacqueline Gruet
Charles Dauguet
Willy Rozenbaum
Christine Rouzioux
François Brun-Vezinet
Luc Montagnier
Jean-Claude Chermann
Françoise Barre-Sinoussi
Pierre Tiollais
Marc Alizon
Pierre Sonigo
Simon Wain-Hobson
Stewart Cole
Oliver Danos
Robert C. Gallo
Mikulas Popovic
Mangalasseril G. Sarngadharan

The undersigned is authorized to act on behalf of the Assignee, Institut Pasteur.

I hereby declare that all statements made of my own knowledge and belief are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Respectfully submitted,

A. Dautry

By: _____
Name: Alice Dautry
Title: President
For Assignee: Institut Pasteur

Dated: _____

June 1st, 2006



PATENT
Customer No. 22,852
Attorney Docket No. 3495.0010-20

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
) Group Art Unit: 1637
Marc Alizon et al.)
) Examiner: Jeffrey N. Fredman
Application No.: 08/308,219)
) Confirmation No.: 4832
Filed: September 19,1994)
)
For: DNA SEQUENCE OF THE LTR
REGION OF HUMAN
IMMUNODEFICIENCY VIRUS
TYPE 1 (HIV-1)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

STATEMENT OF SOLANGE CHAMARET
(Being Added As An Inventor)

I have read U.S. application Serial No. 08/308,219.

I am informed that I was not named as an inventor in application Serial No.
08/308,219 when the application was filed in the U.S. Patent and Trademark Office.

I have been informed that the claims in U.S. application Serial No. 08/308,219
have been amended by adding claims 17-22, 25, and 27-40 to the application.

I am informed that a copy of claims 17-22, 25, and 27-40 is attached hereto.

I have read claims 17-22, 25, and 27-40, which I am informed were added to
U.S. application Serial No. 08/308,219 to claim previously unclaimed subject matter.

I understand that I am being added as an inventor to U.S. application Serial No. 08/308,219.

I have been informed that my addition as an inventor to U.S. application Serial No. 08/308,219 is necessitated by the amendment of the claims by adding claims 17-22, 25, and 27-40 to the application.

The inventorship error resulting from the amendment of the claims by adding claims 17-22, 25, and 27-40 to U.S. application Serial No. 08/308,219 occurred without deceptive intention on my part.

I hereby declare that all statements made of my own knowledge and belief are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

By: S. Hamare

Date: 24-05-2008

U.S. Patent Application No. 08/308,219

Filed: September 19, 1994

Inventors: Marc ALIZON et al.

Div. of 07/158,652 (02/22/88);

Div. of 06/771,248 (08/30/85);

CIP of 07/999,410 (12/31/92);

Cont. of 07/499,210 (03/19/90);

Cont of 06/771,230 (08/30/85);

CIP of 06/706,562 (02/28/85)'

CIP of 06/558,109 (12/5/83)

DI No.: 84-37

Our Reference: 03495.0010-20000

Pending Claims

17. A purified recombinant DNA of human immunodeficiency virus type 1 (HIV-1), wherein the DNA comprises the sequence:

8570	8580	8590	8600	8610
GGGGGACTGG	AAGGGCTAAT	TCACTCCCAA	CGAAGACAAG	ATATCCTTGA
8620	8630	8640	8650	8660
TCTGTGGATC	TACCACACAC	AAGGCTACTT	CCCTGATTGG	CAGAACTACA
8670	8680	8690	8700	8710
CACCAGGGCC	AGGGGTCAGA	TATCCACTGA	CCTTTGGATG	GTGCTACAAG
8720	8730	8740	8750	8760
CTAGTACCAG	TTGAGCCAGA	TAAGGTAGAA	GAGGCCAATA	AAGGAGAGAA
8770	8780	8790	8800	8810
CACCAGCTTG	TTACACCCTG	TGAGCCTGCA	TGGAATGGAT	GACCCTGAGA
8820	8830	8840	8850	8860
GAGAAGTGTT	AGAGTGGAGG	TTTGACAGCC	GCCTAGCATT	TCATCACGTG
8870	8880	8890	8900	8910
GCCCGAGAGC	TGCATCCGGA	GTA CTTCAAG	AACTGCTGAC	ATCGAGCTTG
8920	8930	8940	8950	8960
CTACAAGGGA	CTTTCCGCTG	GGGACTTTCC	AGGGAGGCGT	GGCCTGGGCG
8970	8980	8990	9000	9010
GAAGTGGGGA	GTGGCGAGCC	CTCAGATGCT	GCA TATAAGC	AGCTGCTTTT

9020	9030	9040	9050	9060
TGCCTGTACT	GGGTCTCTCT	GGTTAGACCA	GATTTGAGCC	TGGGAGCTCT
9070	9080	9090	9097	10
CTGGCTAACT	AGGGAACCCA	CTGCTTAAGC	CTCAATA	AAGCTTGCCT
20	30	40	50	60
TGAGTGCTTC	AAGTAGTGTG	TGCCCCGTCTG	TTGTGTGACT	CTGGTAACTA
70	80	90	100	110
GAGATCCCTC	AGACCCTTTT	AGTCAGTGTG	GAAAATCTCT	AGCAGTGGCG
120	130	140	150	159
CCCGAACAGG	GACTTGAAAG	CGAAAGGGAA	ACCAGAGGAG	CTCTCTCGA

18. The purified recombinant DNA of claim 17, wherein said nucleic acid is labeled with a label selected from the group consisting of a radioisotope, an enzyme, a fluorescent label, and a chromophore label.

19. A method of using the purified recombinant DNA of claim 17 for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and
- (c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified recombinant DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

20. The method of claim 19, wherein the biological fluid is blood.

21. A method of using the purified recombinant DNA of claim 18 for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and
- (c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified recombinant DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

22. The method of claim 21, wherein the biological fluid is blood.

25. A method for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and
- (c) detecting the presence of HIV-1 RNA.

27. The method of claim 25, wherein the presence of HIV-1 RNA is detected by contacting the HIV-1 RNA with the DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

28. The method of claim 25, wherein the presence of HIV-1 RNA is detected by contacting the HIV-1 RNA with the DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

29. A method for preparing HIV-1 RNA for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA.

30. The method of claim 29, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

31. The method of claim 29, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

32. A method for preparing HIV-1 RNA for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) isolating HIV-1 virions from the cell-free supernatant; and

(c) disrupting the virions to release HIV-1 RNA.

33. The method of claim 32, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

34. The method of claim 32, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

35. A purified fragment of the recombinant DNA of claim 17, wherein said fragment comprises the sequence:
CTCAATAAAGCTTGCCTTG.

36. The purified fragment of claim 35, wherein said nucleic acid is labeled with a label selected from the group consisting of a radioisotope, an enzyme, a fluorescent label, and a chromophore label.

37. A method of using the purified fragment of claim 35 for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and

(c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified fragment of claim 35 and detecting hybridization between the HIV-1 RNA and the purified fragment.

38. The method of claim 37, wherein the biological fluid is blood.

39. A method of using the purified fragment of claim 36 for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and

(c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified fragment of claim 36 and detecting hybridization between the HIV-1 RNA and the purified fragment.

40. The method of claim 39, wherein the biological fluid is blood.



PATENT
Customer No. 22,852
Attorney Docket No. 3495.0010-20

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Marc Alizon et al.) Group Art Unit: 1637
Application No.: 08/308,219) Examiner: Jeffrey N. Fredman
Filed: September 19, 1994) Confirmation No.: 4832
For: DNA SEQUENCE OF THE LTR)
REGION OF HUMAN)
IMMUNODEFICIENCY VIRUS)
TYPE 1 (HIV-1))

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

STATEMENT OF CLAUDINE AXLER-BLIN
(Being Added As An Inventor)

I have read U.S. application Serial No. 08/308,219.

I am informed that I was not named as an inventor in application Serial No. 08/308,219 when the application was filed in the U.S. Patent and Trademark Office.

I have been informed that the claims in U.S. application Serial No. 08/308,219 have been amended by adding claims 17-22, 25, and 27-40 to the application.

I am informed that a copy of claims 17-22, 25, and 27-40 is attached hereto.

I have read claims 17-22, 25, and 27-40, which I am informed were added to U.S. application Serial No. 08/308,219 to claim previously unclaimed subject matter.

I understand that I am being added as an inventor to U.S. application Serial No. 08/308,219.

I have been informed that my addition as an inventor to U.S. application Serial No. 08/308,219 is necessitated by the amendment of the claims by adding claims 17-22, 25, and 27-40 to the application.

The inventorship error resulting from the amendment of the claims by adding claims 17-22, 25, and 27-40 to U.S. application Serial No. 08/308,219 occurred without deceptive intention on my part.

I hereby declare that all statements made of my own knowledge and belief are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

By: Claudine Axler-Blin

Date: 26 May 2006

U.S. Patent Application No. 08/308,219

Filed: September 19, 1994

Inventors: Marc ALIZON et al.

Div. of 07/158,652 (02/22/88);

Div. of 06/771,248 (08/30/85);

CIP of 07/999,410 (12/31/92);

Cont. of 07/499,210 (03/19/90);

Cont of 06/771,230 (08/30/85);

CIP of 06/706,562 (02/28/85)'

CIP of 06/558,109 (12/5/83)

DI No.: 84-37

Our Reference: 03495.0010-20000

Pending Claims

17. A purified recombinant DNA of human immunodeficiency virus type 1 (HIV-1), wherein the DNA comprises the sequence:

8570	8580	8590	8600	8610
GGGGGACTGG	AAGGGCTAAT	TCACTCCCAA	CGAAGACAAG	ATATCCTTGA
8620	8630	8640	8650	8660
TCTGTGGATC	TACCACACAC	AAGGCTACTT	CCCTGATTGG	CAGAACTACA
8670	8680	8690	8700	8710
CACCAGGGCC	AGGGGTCAGA	TATCCACTGA	CCTTTGGATG	GTGCTACAAG
8720	8730	8740	8750	8760
CTAGTACCAG	TTGAGCCAGA	TAAGGTAGAA	GAGGCCAATA	AAGGAGAGAA
8770	8780	8790	8800	8810
CACCAGCTTG	TTACACCCTG	TGAGCCTGCA	TGGAATGGAT	GACCCTGAGA
8820	8830	8840	8850	8860
GAGAAGTGTT	AGAGTGGAGG	TTTGACAGCC	GCCTAGCATT	TCATCACGTG
8870	8880	8890	8900	8910
GCCCGAGAGC	TGCATCCGGA	GTA CT TCAAG	AACTGCTGAC	ATCGAGCTTG
8920	8930	8940	8950	8960
CTACAAGGGA	CTTTCCGCTG	GGGACTTTCC	AGGGAGGCGT	GGCCTGGGCG
8970	8980	8990	9000	9010
GAAGTGGGGA	GTGGCGAGCC	CTCAGATGCT	GCATATAAGC	AGCTGCTTTT

9020	9030	9040	9050	9060
TGCTGTACT	GGGTCTCTCT	GGTTAGACCA	GATTTGAGCC	TGGGAGCTCT
9070	9080	9090	9097	10
CTGGCTAACT	AGGGAACCCA	CTGCTTAAGC	CTCAATA	AAGCTTGCCT
20	30	40	50	60
TGAGTGCTTC	AAGTAGTGTG	TGCCCCGTCTG	TTGTGTGACT	CTGGTAACTA
70	80	90	100	110
GAGATCCCTC	AGACCCTTTT	AGTCAGTGTG	GAAAATCTCT	AGCAGTGGCG
120	130	140	150	159
CCCGAACAGG	GACTTGAAAG	CGAAAGGGAA	ACCAGAGGAG	CTCTCTCGA

18. The purified recombinant DNA of claim 17, wherein said nucleic acid is labeled with a label selected from the group consisting of a radioisotope, an enzyme, a fluorescent label, and a chromophore label.

19. A method of using the purified recombinant DNA of claim 17 for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and
- (c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified recombinant DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

20. The method of claim 19, wherein the biological fluid is blood.

21. A method of using the purified recombinant DNA of claim 18 for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and
- (c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified recombinant DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

22. The method of claim 21, wherein the biological fluid is blood.

25. A method for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and
- (c) detecting the presence of HIV-1 RNA.

27. The method of claim 25, wherein the presence of HIV-1 RNA is detected by contacting the HIV-1 RNA with the DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

28. The method of claim 25, wherein the presence of HIV-1 RNA is detected by contacting the HIV-1 RNA with the DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

29. A method for preparing HIV-1 RNA for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA.

30. The method of claim 29, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

31. The method of claim 29, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

32. A method for preparing HIV-1 RNA for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) isolating HIV-1 virions from the cell-free supernatant; and

(c) disrupting the virions to release HIV-1 RNA.

33. The method of claim 32, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

34. The method of claim 32, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

35. A purified fragment of the recombinant DNA of claim 17, wherein said fragment comprises the sequence:
CTCAATAAAGCTTGCCTTG.

36. The purified fragment of claim 35, wherein said nucleic acid is labeled with a label selected from the group consisting of a radioisotope, an enzyme, a fluorescent label, and a chromophore label.

37. A method of using the purified fragment of claim 35 for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and

(c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified fragment of claim 35 and detecting hybridization between the HIV-1 RNA and the purified fragment.

38. The method of claim 37, wherein the biological fluid is blood.

39. A method of using the purified fragment of claim 36 for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and

(c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified fragment of claim 36 and detecting hybridization between the HIV-1 RNA and the purified fragment.

40. The method of claim 39, wherein the biological fluid is blood.



PATENT
Customer No. 22,852
Attorney Docket No. 3495.0010-20

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Marc Alizon et al.) Group Art Unit: 1637
Application No.: 08/308,219) Examiner: Jeffrey N. Fredman
Filed: September 19, 1994) Confirmation No.: 4832
For: DNA SEQUENCE OF THE LTR)
REGION OF HUMAN)
IMMUNODEFICIENCY VIRUS)
TYPE 1 (HIV-1)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

STATEMENT OF FRANÇOISE REY
(Being Added As An Inventor)

I have read U.S. application Serial No. 08/308,219.

I am informed that I was not named as an inventor in application Serial No. 08/308,219 when the application was filed in the U.S. Patent and Trademark Office.

I have been informed that the claims in U.S. application Serial No. 08/308,219 have been amended by adding claims 17-22, 25, and 27-40 to the application.

I am informed that a copy of claims 17-22, 25, and 27-40 is attached hereto.


I have read claims 17-22, 25, and 27-40, which I am informed were added to U.S. application Serial No. 08/308,219 to claim previously unclaimed subject matter.

I understand that I am being added as an inventor to U.S. application Serial No. 08/308,219.

I have been informed that my addition as an inventor to U.S. application Serial No. 08/308,219 is necessitated by the amendment of the claims by adding claims 17-22, 25, and 27-40 to the application.

The inventorship error resulting from the amendment of the claims by adding claims 17-22, 25, and 27-40 to U.S. application Serial No. 08/308,219 occurred without deceptive intention on my part.

I hereby declare that all statements made of my own knowledge and belief are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

By:  _____

Date: 29 March 2006

U.S. Patent Application No. 08/308,219

Filed: September 19, 1994

Inventors: Marc ALIZON et al.

Div. of 07/158,652 (02/22/88);

Div. of 06/771,248 (08/30/85);

CIP of 07/999,410 (12/31/92);

Cont. of 07/499,210 (03/19/90);

Cont of 06/771,230 (08/30/85);

CIP of 06/706,562 (02/28/85);

CIP of 06/558,109 (12/5/83)

DI No.: 84-37

Our Reference: 03495.0010-20000

Pending Claims

17. A purified recombinant DNA of human immunodeficiency virus type 1 (HIV-1), wherein the DNA comprises the sequence:

8570	8580	8590	8600	8610
GGGGGACTGG	AAGGGCTAAT	TCACTCCCAA	CGAAGACAAG	ATATCCTTGA
8620	8630	8640	8650	8660
TCTGTGGATC	TACCACACAC	AAGGCTACTT	CCCTGATTGG	CAGAACTACA
8670	8680	8690	8700	8710
CACCAGGGCC	AGGGGTCAGA	TATCCACTGA	CCTTTGGATG	GTGCTACAAG
8720	8730	8740	8750	8760
CTAGTACCAG	TTGAGCCAGA	TAAGGTAGAA	GAGGCCAATA	AAGGAGAGAA
8770	8780	8790	8800	8810
CACCAGCTTG	TTACACCCTG	TGAGCCTGCA	TGGAATGGAT	GACCCTGAGA
8820	8830	8840	8850	8860
GAGAAGTGTT	AGAGTGGAGG	TTTGACAGCC	GCCTAGCATT	TCATCACGTG
8870	8880	8890	8900	8910
GCCCGAGAGC	TGCATCCGGA	GTACTTCAAG	AACTGCTGAC	ATCGAGCTTG
8920	8930	8940	8950	8960
CTACAAGGGA	CTTTCCGCTG	GGGACTTTCC	AGGGAGGCGT	GGCCTGGGCG
8970	8980	8990	9000	9010
GAAGTGGGGA	GTGGCGAGCC	CTCAGATGCT	GCATATAAGC	AGCTGCTTTT

9020	9030	9040	9050	9060
TGCCTGTACT	GGGTCTCTCT	GGTTAGACCA	GATTTGAGCC	TGGGAGCTCT
9070	9080	9090	9097	10
CTGGCTAACT	AGGGAACCCA	CTGCTTAAGC	CTCAATA	AAGCTTGCCT
20	30	40	50	60
TGAGTGCTTC	AAGTAGTGTG	TGCCCCGTCTG	TTGTGTGACT	CTGGTAACTA
70	80	90	100	110
GAGATCCCTC	AGACCCTTTT	AGTCAGTGTG	GAAAATCTCT	AGCAGTGGCG
120	130	140	150	159
CCCGAACAGG	GACTTGAAAG	CGAAAGGGAA	ACCAGAGGAG	CTCTCTCGA

18. The purified recombinant DNA of claim 17, wherein said nucleic acid is labeled with a label selected from the group consisting of a radioisotope, an enzyme, a fluorescent label, and a chromophore label.

19. A method of using the purified recombinant DNA of claim 17 for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and
- (c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified recombinant DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

20. The method of claim 19, wherein the biological fluid is blood.

21. A method of using the purified recombinant DNA of claim 18 for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and
- (c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified recombinant DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

22. The method of claim 21, wherein the biological fluid is blood.

25. A method for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and
- (c) detecting the presence of HIV-1 RNA.

27. The method of claim 25, wherein the presence of HIV-1 RNA is detected by contacting the HIV-1 RNA with the DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

28. The method of claim 25, wherein the presence of HIV-1 RNA is detected by contacting the HIV-1 RNA with the DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

29. A method for preparing HIV-1 RNA for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA.

30. The method of claim 29, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

31. The method of claim 29, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

32. A method for preparing HIV-1 RNA for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) isolating HIV-1 virions from the cell-free supernatant; and

(c) disrupting the virions to release HIV-1 RNA.

33. The method of claim 32, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

34. The method of claim 32, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

35. A purified fragment of the recombinant DNA of claim 17, wherein said fragment comprises the sequence:
CTCAATAAAGCTTGCCTTG.

36. The purified fragment of claim 35, wherein said nucleic acid is labeled with a label selected from the group consisting of a radioisotope, an enzyme, a fluorescent label, and a chromophore label.

37. A method of using the purified fragment of claim 35 for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and

(c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified fragment of claim 35 and detecting hybridization between the HIV-1 RNA and the purified fragment.

38. The method of claim 37, wherein the biological fluid is blood.


39. A method of using the purified fragment of claim 36 for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and

(c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified fragment of claim 36 and detecting hybridization between the HIV-1 RNA and the purified fragment.

40. The method of claim 39, wherein the biological fluid is blood.



PATENT
Customer No. 22,852
Attorney Docket No. 3495.0010-20

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Marc Alizon et al.) Group Art Unit: 1637
Application No.: 08/308,219) Examiner: Jeffrey N. Fredman
Filed: September 19, 1994) Confirmation No.: 4832
For: DNA SEQUENCE OF THE LTR)
REGION OF HUMAN)
IMMUNODEFICIENCY VIRUS)
TYPE 1 (HIV-1))

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

STATEMENT OF MARIE-THERESE NUGEYRE
(Being Added As An Inventor)

I have read U.S. application Serial No. 08/308,219.

I am informed that I was not named as an inventor in application Serial No. 08/308,219 when the application was filed in the U.S. Patent and Trademark Office.

I have been informed that the claims in U.S. application Serial No. 08/308,219 have been amended by adding claims 17-22, 25, and 27-40 to the application.

I am informed that a copy of claims 17-22, 25, and 27-40 is attached hereto.


I have read claims 17-22, 25, and 27-40, which I am informed were added to U.S. application Serial No. 08/308,219 to claim previously unclaimed subject matter.

I understand that I am being added as an inventor to U.S. application Serial No. 08/308,219.

I have been informed that my addition as an inventor to U.S. application Serial No. 08/308,219 is necessitated by the amendment of the claims by adding claims 17-22, 25, and 27-40 to the application.

The inventorship error resulting from the amendment of the claims by adding claims 17-22, 25, and 27-40 to U.S. application Serial No. 08/308,219 occurred without deceptive intention on my part.

I hereby declare that all statements made of my own knowledge and belief are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

By: 

Date: May 29 2006

U.S. Patent Application No. 08/308,219

Filed: September 19, 1994

Inventors: Marc ALIZON et al.

Div. of 07/158,652 (02/22/88);

Div. of 06/771,248 (08/30/85);

CIP of 07/999,410 (12/31/92);

Cont. of 07/499,210 (03/19/90);

Cont of 06/771,230 (08/30/85);

CIP of 06/706,562 (02/28/85)'

CIP of 06/558,109 (12/5/83)

DI No.: 84-37

Our Reference: 03495.0010-20000

Pending Claims

17. A purified recombinant DNA of human immunodeficiency virus type 1 (HIV-1), wherein the DNA comprises the sequence:

8570	8580	8590	8600	8610
GGGGGACTGG	AAGGGCTAAT	TCACTCCCAA	CGAAGACAAG	ATATCCTTGA
8620	8630	8640	8650	8660
TCTGTGGATC	TACCACACAC	AAGGCTACTT	CCCTGATTGG	CAGAACTACA
8670	8680	8690	8700	8710
CACCAGGGCC	AGGGGTCAGA	TATCCACTGA	CCTTTGGATG	GTGCTACAAG
8720	8730	8740	8750	8760
CTAGTACCAG	TTGAGCCAGA	TAAGGTAGAA	GAGGCCAATA	AAGGAGAGAA
8770	8780	8790	8800	8810
CACCAGCTTG	TTACACCCTG	TGAGCCTGCA	TGGAATGGAT	GACCCTGAGA
8820	8830	8840	8850	8860
GAGAAGTGTT	AGAGTGGAGG	TTTGACAGCC	GCCTAGCATT	TCATCACGTG
8870	8880	8890	8900	8910
GCCCGAGAGC	TGCATCCGGA	GTA CTTC AAG	AACTGCTGAC	ATCGAGCTTG
8920	8930	8940	8950	8960
CTACAAGGGA	CTTTCCGCTG	GGGACTTTCC	AGGGAGGCGT	GGCCTGGGCG
8970	8980	8990	9000	9010
GAACTGGGGA	GTGGCGAGCC	CTCAGATGCT	GCATATAAGC	AGCTGCTTTT

9020	9030	9040	9050	9060
TGCCTGTACT	GGGTCTCTCT	GGTTAGACCA	GATTTGAGCC	TGGGAGCTCT
9070	9080	9090	9097	10
CTGGCTAACT	AGGGAACCCA	CTGCTTAAGC	CTCAATA	AAGCTTGCCT
20	30	40	50	60
TGAGTGCTTC	AAGTAGTGTG	TGCCCCGTCTG	TTGTGTGACT	CTGGTAACTA
70	80	90	100	110
GAGATCCCTC	AGACCCTTTT	AGTCAGTGTG	GAAAATCTCT	AGCAGTGGCG
120	130	140	150	159
CCCGAACAGG	GACTTGAAAG	CGAAAGGGAA	ACCAGAGGAG	CTCTCTCGA

18. The purified recombinant DNA of claim 17, wherein said nucleic acid is labeled with a label selected from the group consisting of a radioisotope, an enzyme, a fluorescent label, and a chromophore label.

19. A method of using the purified recombinant DNA of claim 17 for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and
- (c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified recombinant DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

20. The method of claim 19, wherein the biological fluid is blood.

21. A method of using the purified recombinant DNA of claim 18 for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and
- (c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified recombinant DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

22. The method of claim 21, wherein the biological fluid is blood.

25. A method for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and
- (c) detecting the presence of HIV-1 RNA.

27. The method of claim 25, wherein the presence of HIV-1 RNA is detected by contacting the HIV-1 RNA with the DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

28. The method of claim 25, wherein the presence of HIV-1 RNA is detected by contacting the HIV-1 RNA with the DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

29. A method for preparing HIV-1 RNA for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA.

30. The method of claim 29, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

31. The method of claim 29, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

32. A method for preparing HIV-1 RNA for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) isolating HIV-1 virions from the cell-free supernatant; and

(c) disrupting the virions to release HIV-1 RNA.

33. The method of claim 32, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

34. The method of claim 32, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

35. A purified fragment of the recombinant DNA of claim 17, wherein said fragment comprises the sequence:
CTCAATAAAGCTTGCCTTG.

36. The purified fragment of claim 35, wherein said nucleic acid is labeled with a label selected from the group consisting of a radioisotope, an enzyme, a fluorescent label, and a chromophore label.

37. A method of using the purified fragment of claim 35 for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and

(c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified fragment of claim 35 and detecting hybridization between the HIV-1 RNA and the purified fragment.

38. The method of claim 37, wherein the biological fluid is blood.

39. A method of using the purified fragment of claim 36 for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and

(c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified fragment of claim 36 and detecting hybridization between the HIV-1 RNA and the purified fragment.

40. The method of claim 39, wherein the biological fluid is blood.



PATENT
Customer No. 22,852
Attorney Docket No. 3495.0010-20

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Marc Alizon et al.

Application No.: 08/308,219

Filed: September 19, 1994

For: DNA SEQUENCE OF THE LTR
REGION OF HUMAN
IMMUNODEFICIENCY VIRUS
TYPE 1 (HIV-1)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

STATEMENT ON BEHALF OF JACQUELINE GRUEST
(Being Added As An Inventor)

I, JACQUES GRUEST, am the heir of the estate of JACQUELINE GRUEST, who is deceased.

I have been informed that Jacqueline Gruest was not named as an inventor in application Serial No. 08/308,219 when the application was filed in the U.S. Patent and Trademark Office.

I have been informed that the claims in U.S. application Serial No. 08/308,219 have been amended by adding claims 17-22, 25, and 27-40 to the application.

I have been informed that a copy of claims 17-22, 25, and 27-40 is attached hereto.


I have been informed that claims 17-22, 25, and 27-40 were added to U.S. application Serial No. 08/308,219 to claim previously unclaimed subject matter.

I have been informed that Jacqueline Gruet is being added as an inventor to U.S. application Serial No. 08/308,219.

I have been informed that the addition of Jacqueline Gruet as an inventor to U.S. application Serial No. 08/308,219 is necessitated by the amendment of the claims by adding claims 17-22, 25, and 27-40 to the application.

On information and belief, the inventorship error resulting from the amendment of the claims by adding claims 17-22, 25, and 27-40 to U.S. application Serial No. 08/308,219 occurred without deceptive intention on the part of Jacqueline Gruet.

I hereby declare that all statements made of my own knowledge and belief are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

By: 
JACQUES GRUEST
Heir of the Estate of Jacqueline Gruet

Date: 25.05.2006

U.S. Patent Application No. 08/308,219

Filed: September 19, 1994

Inventors: Marc ALIZON et al.

Div. of 07/158,652 (02/22/88);

Div. of 06/771,248 (08/30/85);

CIP of 07/999,410 (12/31/92);

Cont. of 07/499,210 (03/19/90);

Cont of 06/771,230 (08/30/85);

CIP of 06/706,562 (02/28/85)'

CIP of 06/558,109 (12/5/83)

DI No.: 84-37

Our Reference: 03495.0010-20000

Pending Claims

17. A purified recombinant DNA of human immunodeficiency virus type 1 (HIV-1), wherein the DNA comprises the sequence:

8570	8580	8590	8600	8610
GGGGGACTGG	AAGGGCTAAT	TCACTCCCAA	CGAAGACAAG	ATATCCTTGA
8620	8630	8640	8650	8660
TCTGTGGATC	TACCACACAC	AAGGCTACTT	CCCTGATTGG	CAGAACTACA
8670	8680	8690	8700	8710
CACCAGGGCC	AGGGGTCAGA	TATCCACTGA	CCTTTGGATG	GTGCTACAAG
8720	8730	8740	8750	8760
CTAGTACCAG	TTGAGCCAGA	TAAGGTAGAA	GAGGCCAATA	AAGGAGAGAA
8770	8780	8790	8800	8810
CACCAGCTTG	TTACACCCTG	TGAGCCTGCA	TGGAATGGAT	GACCCTGAGA
8820	8830	8840	8850	8860
GAGAAGTGTT	AGAGTGGAGG	TTTGACAGCC	GCCTAGCATT	TCATCACGTG
8870	8880	8890	8900	8910
GCCCGAGAGC	TGCATCCGGA	GTA CTTCAAG	AACTGCTGAC	ATCGAGCTTG
8920	8930	8940	8950	8960
CTACAAGGGA	CTTTCCGCTG	GGGACTTTCC	AGGGAGGCGT	GGCCTGGGCG
8970	8980	8990	9000	9010
GAAGTGGGGA	GTGGCGAGCC	CTCAGATGCT	GCATATAAGC	AGCTGCTTTT

9020	9030	9040	9050	9060
TGCCTGTACT	GGGTCTCTCT	GGTTAGACCA	GATTTGAGCC	TGGGAGCTCT
9070	9080	9090	9097	10
CTGGCTAACT	AGGGAACCCA	CTGCTTAAGC	CTCAATA	AAGCTTGCCT
20	30	40	50	60
TGAGTGCTTC	AAGTAGTGTG	TGCCCCGTCTG	TTGTGTGACT	CTGGTAACTA
70	80	90	100	110
GAGATCCCTC	AGACCCTTTT	AGTCAGTGTG	GAAAATCTCT	AGCAGTGGCG
120	130	140	150	159
CCCGAACAGG	GACTTGAAAG	CGAAAGGGAA	ACCAGAGGAG	CTCTCTCGA

18. The purified recombinant DNA of claim 17, wherein said nucleic acid is labeled with a label selected from the group consisting of a radioisotope, an enzyme, a fluorescent label, and a chromophore label.

19. A method of using the purified recombinant DNA of claim 17 for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and
- (c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified recombinant DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

20. The method of claim 19, wherein the biological fluid is blood.

21. A method of using the purified recombinant DNA of claim 18 for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and

(c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified recombinant DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

22. The method of claim 21, wherein the biological fluid is blood.

25. A method for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and

(c) detecting the presence of HIV-1 RNA.

27. The method of claim 25, wherein the presence of HIV-1 RNA is detected by contacting the HIV-1 RNA with the DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

28. The method of claim 25, wherein the presence of HIV-1 RNA is detected by contacting the HIV-1 RNA with the DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

29. A method for preparing HIV-1 RNA for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA.

30. The method of claim 29, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

31. The method of claim 29, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

32. A method for preparing HIV-1 RNA for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) isolating HIV-1 virions from the cell-free supernatant; and

(c) disrupting the virions to release HIV-1 RNA.

33. The method of claim 32, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

34. The method of claim 32, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

35. A purified fragment of the recombinant DNA of claim 17, wherein said fragment comprises the sequence:
CTCAATAAAGCTTGCCTTG.

36. The purified fragment of claim 35, wherein said nucleic acid is labeled with a label selected from the group consisting of a radioisotope, an enzyme, a fluorescent label, and a chromophore label.

37. A method of using the purified fragment of claim 35 for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and

(c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified fragment of claim 35 and detecting hybridization between the HIV-1 RNA and the purified fragment.

38. The method of claim 37, wherein the biological fluid is blood.

39. A method of using the purified fragment of claim 36 for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and

(c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified fragment of claim 36 and detecting hybridization between the HIV-1 RNA and the purified fragment.

40. The method of claim 39, wherein the biological fluid is blood.



PATENT
Customer No. 22,852
Attorney Docket No. 3495.0010-20

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Marc Alizon et al.

Application No.: 08/308,219

Filed: September 19, 1994

For: DNA SEQUENCE OF THE LTR
REGION OF HUMAN
IMMUNODEFICIENCY VIRUS
TYPE 1 (HIV-1)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

STATEMENT OF CHARLES DAUGUET
(Being Added As An Inventor)

I have read U.S. application Serial No. 08/308,219.

I am informed that I was not named as an inventor in application Serial No.
08/308,219 when the application was filed in the U.S. Patent and Trademark Office.

I have been informed that the claims in U.S. application Serial No. 08/308,219
have been amended by adding claims 17-22, 25, and 27-40 to the application.

I am informed that a copy of claims 17-22, 25, and 27-40 is attached hereto.

I have read claims 17-22, 25, and 27-40, which I am informed were added to
U.S. application Serial No. 08/308,219 to claim previously unclaimed subject matter.

I understand that I am being added as an inventor to U.S. application Serial No. 08/308,219.

I have been informed that my addition as an inventor to U.S. application Serial No. 08/308,219 is necessitated by the amendment of the claims by adding claims 17-22, 25, and 27-40 to the application.

The inventorship error resulting from the amendment of the claims by adding claims 17-22, 25, and 27-40 to U.S. application Serial No. 08/308,219 occurred without deceptive intention on my part.

I hereby declare that all statements made of my own knowledge and belief are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

By: Charles D. Dargatzis

Date: 26 Mar 2006

U.S. Patent Application No. 08/308,219

Filed: September 19, 1994

Inventors: Marc ALIZON et al.

Div. of 07/158,652 (02/22/88);

Div. of 06/771,248 (08/30/85);

CIP of 07/999,410 (12/31/92);

Cont. of 07/499,210 (03/19/90);

Cont of 06/771,230 (08/30/85);

CIP of 06/706,562 (02/28/85)'

CIP of 06/558,109 (12/5/83)

DI No.: 84-37

Our Reference: 03495.0010-20000

Pending Claims

17. A purified recombinant DNA of human immunodeficiency virus type 1 (HIV-1), wherein the DNA comprises the sequence:

8570	8580	8590	8600	8610
GGGGGACTGG	AAGGGCTAAT	TCACTCCCAA	CGAAGACAAG	ATATCCTTGA
8620	8630	8640	8650	8660
TCTGTGGATC	TACCACACAC	AAGGCTACTT	CCCTGATTGG	CAGAACTACA
8670	8680	8690	8700	8710
CACCAGGGCC	AGGGGTCAGA	TATCCACTGA	CCTTTGGATG	GTGCTACAAG
8720	8730	8740	8750	8760
CTAGTACCAG	TTGAGCCAGA	TAAGGTAGAA	GAGGCCAATA	AAGGAGAGAA
8770	8780	8790	8800	8810
CACCAGCTTG	TTACACCCTG	TGAGCCTGCA	TGGAATGGAT	GACCCTGAGA
8820	8830	8840	8850	8860
GAGAAGTGTT	AGAGTGGAGG	TTTGACAGCC	GCCTAGCATT	TCATCACGTG
8870	8880	8890	8900	8910
GCCCGAGAGC	TGCATCCGGA	GTACTTCAAG	AACTGCTGAC	ATCGAGCTTG
8920	8930	8940	8950	8960
CTACAAGGGA	CTTTCCGCTG	GGGACTTTCC	AGGGAGGCGT	GGCCTGGGCG
8970	8980	8990	9000	9010
GAACTGGGGA	GTGGCGAGCC	CTCAGATGCT	GCATATAAGC	AGCTGCTTTT

9020	9030	9040	9050	9060
TGCCTGTACT	GGGTCTCTCT	GGTTAGACCA	GATTTGAGCC	TGGGAGCTCT
9070	9080	9090	9097	10
CTGGCTAACT	AGGGAACCCA	CTGCTTAAGC	CTCAATA	AAGCTTGCCT
20	30	40	50	60
TGAGTGCTTC	AAGTAGTGTG	TGCCCCGTCTG	TTGTGTGACT	CTGGTAACTA
70	80	90	100	110
GAGATCCCTC	AGACCCTTTT	AGTCAGTGTG	GAAAATCTCT	AGCAGTGGCG
120	130	140	150	159
CCCGAACAGG	GACTTGAAAG	CGAAAGGGAA	ACCAGAGGAG	CTCTCTCGA

18. The purified recombinant DNA of claim 17, wherein said nucleic acid is labeled with a label selected from the group consisting of a radioisotope, an enzyme, a fluorescent label, and a chromophore label.

19. A method of using the purified recombinant DNA of claim 17 for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and
- (c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified recombinant DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

20. The method of claim 19, wherein the biological fluid is blood.

21. A method of using the purified recombinant DNA of claim 18 for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and
- (c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified recombinant DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

22. The method of claim 21, wherein the biological fluid is blood.

25. A method for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and
- (c) detecting the presence of HIV-1 RNA.

27. The method of claim 25, wherein the presence of HIV-1 RNA is detected by contacting the HIV-1 RNA with the DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

28. The method of claim 25, wherein the presence of HIV-1 RNA is detected by contacting the HIV-1 RNA with the DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

29. A method for preparing HIV-1 RNA for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA.

30. The method of claim 29, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

31. The method of claim 29, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

32. A method for preparing HIV-1 RNA for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) isolating HIV-1 virions from the cell-free supernatant; and

(c) disrupting the virions to release HIV-1 RNA.

33. The method of claim 32, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

34. The method of claim 32, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

35. A purified fragment of the recombinant DNA of claim 17, wherein said fragment comprises the sequence:
CTCAATAAAGCTTGCCTTG.

36. The purified fragment of claim 35, wherein said nucleic acid is labeled with a label selected from the group consisting of a radioisotope, an enzyme, a fluorescent label, and a chromophore label.

37. A method of using the purified fragment of claim 35 for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and

(c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified fragment of claim 35 and detecting hybridization between the HIV-1 RNA and the purified fragment.

38. The method of claim 37, wherein the biological fluid is blood.

39. A method of using the purified fragment of claim 36 for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and

(c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified fragment of claim 36 and detecting hybridization between the HIV-1 RNA and the purified fragment.

40. The method of claim 39, wherein the biological fluid is blood.



PATENT
Customer No. 22,852
Attorney Docket No. 3495.0010-20

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
) Group Art Unit: 1637
Marc Alizon et al.)
) Examiner: Jeffrey N. Fredman
Application No.: 08/308,219)
) Confirmation No.: 4832
Filed: September 19,1994)
)
For: DNA SEQUENCE OF THE LTR
REGION OF HUMAN
IMMUNODEFICIENCY VIRUS
TYPE 1 (HIV-1)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

STATEMENT OF WILLY ROZENBAUM
(Being Added As An Inventor)

I have read U.S. application Serial No. 08/308,219.

I am informed that I was not named as an inventor in application Serial No.
08/308,219 when the application was filed in the U.S. Patent and Trademark Office.

I have been informed that the claims in U.S. application Serial No. 08/308,219
have been amended by adding claims 17-22, 25, and 27-40 to the application.

I am informed that a copy of claims 17-22, 25, and 27-40 is attached hereto.


I have read claims 17-22, 25, and 27-40, which I am informed were added to
U.S. application Serial No. 08/308,219 to claim previously unclaimed subject matter.

I understand that I am being added as an inventor to U.S. application Serial No. 08/308,219.

I have been informed that my addition as an inventor to U.S. application Serial No. 08/308,219 is necessitated by the amendment of the claims by adding claims 17-22, 25, and 27-40 to the application.

The inventorship error resulting from the amendment of the claims by adding claims 17-22, 25, and 27-40 to U.S. application Serial No. 08/308,219 occurred without deceptive intention on my part.

I hereby declare that all statements made of my own knowledge and belief are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

By: 
Willy RORENBAUM.
Date: 25 May 2006

U.S. Patent Application No. 08/308,219

Filed: September 19, 1994

Inventors: Marc ALIZON et al.

Div. of 07/158,652 (02/22/88);

Div. of 06/771,248 (08/30/85);

CIP of 07/999,410 (12/31/92);

Cont. of 07/499,210 (03/19/90);

Cont of 06/771,230 (08/30/85);

CIP of 06/706,562 (02/28/85)'

CIP of 06/558,109 (12/5/83)

DI No.: 84-37

Our Reference: 03495.0010-20000

Pending Claims

17. A purified recombinant DNA of human immunodeficiency virus type 1 (HIV-1), wherein the DNA comprises the sequence:

8570	8580	8590	8600	8610
GGGGGACTGG	AAGGGCTAAT	TCACTCCCAA	CGAAGACAAG	ATATCCTTGA
8620	8630	8640	8650	8660
TCTGTGGATC	TACCACACAC	AAGGCTACTT	CCCTGATTGG	CAGAACTACA
8670	8680	8690	8700	8710
CACCAGGGCC	AGGGGTCAGA	TATCCACTGA	CCTTTGGATG	GTGCTACAAG
8720	8730	8740	8750	8760
CTAGTACCAG	TTGAGCCAGA	TAAGGTAGAA	GAGGCCAATA	AAGGAGAGAA
8770	8780	8790	8800	8810
CACCAGCTTG	TTACACCCTG	TGAGCCTGCA	TGGAATGGAT	GACCCTGAGA
8820	8830	8840	8850	8860
GAGAAGTGTT	AGAGTGGAGG	TTTGACAGCC	GCCTAGCATT	TCATCACGTG
8870	8880	8890	8900	8910
GCCCGAGAGC	TGCATCCGGA	GTA CTTCAAG	AACTGCTGAC	ATCGAGCTTG
8920	8930	8940	8950	8960
CTACAAGGGA	CTTTCCGCTG	GGGACTTTCC	AGGGAGGCGT	GGCCTGGGCG
8970	8980	8990	9000	9010
GAAGTGGGGA	GTGGCGAGCC	CTCAGATGCT	GCATATAAGC	AGCTGCTTTT

9020	9030	9040	9050	9060
TGCCTGTACT	GGGTCTCTCT	GGTTAGACCA	GATTTGAGCC	TGGGAGCTCT
9070	9080	9090	9097	10
CTGGCTAACT	AGGGAACCCA	CTGCTTAAGC	CTCAATA	AAGCTTGCCT
20	30	40	50	60
TGAGTGCTTC	AAGTAGTGTG	TGCCCCGTCTG	TTGTGTGACT	CTGGTAACTA
70	80	90	100	110
GAGATCCCTC	AGACCCTTTT	AGTCAGTGTG	GAAAATCTCT	AGCAGTGGCG
120	130	140	150	159
CCCGAACAGG	GACTTGAAAG	CGAAAGGGAA	ACCAGAGGAG	CTCTCTCGA

18. The purified recombinant DNA of claim 17, wherein said nucleic acid is labeled with a label selected from the group consisting of a radioisotope, an enzyme, a fluorescent label, and a chromophore label.

19. A method of using the purified recombinant DNA of claim 17 for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and
- (c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified recombinant DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

20. The method of claim 19, wherein the biological fluid is blood.

21. A method of using the purified recombinant DNA of claim 18 for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and
- (c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified recombinant DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

22. The method of claim 21, wherein the biological fluid is blood.

25. A method for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and
- (c) detecting the presence of HIV-1 RNA.

27. The method of claim 25, wherein the presence of HIV-1 RNA is detected by contacting the HIV-1 RNA with the DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

28. The method of claim 25, wherein the presence of HIV-1 RNA is detected by contacting the HIV-1 RNA with the DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

29. A method for preparing HIV-1 RNA for detecting the presence of

HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA.

30. The method of claim 29, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

31. The method of claim 29, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

32. A method for preparing HIV-1 RNA for detecting the presence of

HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) isolating HIV-1 virions from the cell-free supernatant; and

(c) disrupting the virions to release HIV-1 RNA.

33. The method of claim 32, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

34. The method of claim 32, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

35. A purified fragment of the recombinant DNA of claim 17, wherein said fragment comprises the sequence:
CTCAATAAAGCTTGCCTTG.

36. The purified fragment of claim 35, wherein said nucleic acid is labeled with a label selected from the group consisting of a radioisotope, an enzyme, a fluorescent label, and a chromophore label.

37. A method of using the purified fragment of claim 35 for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and

(c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified fragment of claim 35 and detecting hybridization between the HIV-1 RNA and the purified fragment.

38. The method of claim 37, wherein the biological fluid is blood.

39. A method of using the purified fragment of claim 36 for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and

(c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified fragment of claim 36 and detecting hybridization between the HIV-1 RNA and the purified fragment.

40. The method of claim 39, wherein the biological fluid is blood.



PATENT
Customer No. 22,852
Attorney Docket No. 3495.0010-20

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Marc Alizon et al.) Group Art Unit: 1637
Application No.: 08/308,219) Examiner: Jeffrey N. Fredman
Filed: September 19, 1994) Confirmation No.: 4832
For: DNA SEQUENCE OF THE LTR)
REGION OF HUMAN)
IMMUNODEFICIENCY VIRUS)
TYPE 1 (HIV-1))

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

STATEMENT OF FRANÇOISE BRON-VEZINET
(Being Added As An Inventor)

I have read U.S. application Serial No. 08/308,219.

I am informed that I was not named as an inventor in application Serial No. 08/308,219 when the application was filed in the U.S. Patent and Trademark Office.

I have been informed that the claims in U.S. application Serial No. 08/308,219 have been amended by adding claims 17-22, 25, and 27-40 to the application.

I am informed that a copy of claims 17-22, 25, and 27-40 is attached hereto.

I have read claims 17-22, 25, and 27-40, which I am informed were added to U.S. application Serial No. 08/308,219 to claim previously unclaimed subject matter.


I understand that I am being added as an inventor to U.S. application Serial No. 08/308,219.

I have been informed that my addition as an inventor to U.S. application Serial No. 08/308,219 is necessitated by the amendment of the claims by adding claims 17-22, 25, and 27-40 to the application.

The inventorship error resulting from the amendment of the claims by adding claims 17-22, 25, and 27-40 to U.S. application Serial No. 08/308,219 occurred without deceptive intention on my part.

I hereby declare that all statements made of my own knowledge and belief are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

By:

FRANÇOISE BRUN-JEANNE


Date:

30/05/06..

U.S. Patent Application No. 08/308,219

Filed: September 19, 1994

Inventors: Marc ALIZON et al.

Div. of 07/158,652 (02/22/88);

Div. of 06/771,248 (08/30/85);

CIP of 07/999,410 (12/31/92);

Cont. of 07/499,210 (03/19/90);

Cont of 06/771,230 (08/30/85);

CIP of 06/706,562 (02/28/85)'

CIP of 06/558,109 (12/5/83)

DI No.: 84-37

Our Reference: 03495.0010-20000

Pending Claims

17. A purified recombinant DNA of human immunodeficiency virus type 1 (HIV-1), wherein the DNA comprises the sequence:

8570	8580	8590	8600	8610
GGGGGACTGG	AAGGGCTAAT	TCACTCCCAA	CGAAGACAAG	ATATCCTTGA
8620	8630	8640	8650	8660
TCTGTGGATC	TACCACACAC	AAGGCTACTT	CCCTGATTGG	CAGAACTACA
8670	8680	8690	8700	8710
CACCAGGGCC	AGGGGTCAGA	TATCCACTGA	CCTTTGGATG	GTGCTACAAG
8720	8730	8740	8750	8760
CTAGTACCAG	TTGAGCCAGA	TAAGGTAGAA	GAGGCCAATA	AAGGAGAGAA
8770	8780	8790	8800	8810
CACCAGCTTG	TTACACCCTG	TGAGCCTGCA	TGGAATGGAT	GACCCTGAGA
8820	8830	8840	8850	8860
GAGAAGTGTT	AGAGTGGAGG	TTTGACAGCC	GCCTAGCATT	TCATCACGTG
8870	8880	8890	8900	8910
GCCCCGAGAGC	TGCATCCGGA	GTACTTCAAG	AACTGCTGAC	ATCGAGCTTG
8920	8930	8940	8950	8960
CTACAAGGGA	CTTTCCGCTG	GGGACTTTCC	AGGGAGGCGT	GGCCTGGGCG
8970	8980	8990	9000	9010
GAACTGGGGA	GTGGCGAGCC	CTCAGATGCT	GCATATAAGC	AGCTGCTTTT

9020	9030	9040	9050	9060
TGCCTGTACT	GGGTCTCTCT	GGTTAGACCA	GATTTGAGCC	TGGGAGCTCT
9070	9080	9090	9097	10
CTGGCTAACT	AGGGAACCCA	CTGCTTAAGC	CTCAATA	AAGCTTGCCT
20	30	40	50	60
TGAGTGCTTC	AAGTAGTGTG	TGCCCCGTCTG	TTGTGTGACT	CTGGTAACTA
70	80	90	100	110
GAGATCCCTC	AGACCCTTTT	AGTCAGTGTG	GAAAATCTCT	AGCAGTGGCG
120	130	140	150	159
CCCGAACAGG	GACTTGAAAG	CGAAAGGGAA	ACCAGAGGAG	CTCTCTCGA

18. The purified recombinant DNA of claim 17, wherein said nucleic acid is labeled with a label selected from the group consisting of a radioisotope, an enzyme, a fluorescent label, and a chromophore label.

19. A method of using the purified recombinant DNA of claim 17 for detecting the presence of HIV-1 RNA comprising:

- (a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;
- (b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and
- (c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified recombinant DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

20. The method of claim 19, wherein the biological fluid is blood.

28. The method of claim 25, wherein the presence of HIV-1 RNA is detected by contacting the HIV-1 RNA with the DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

29. A method for preparing HIV-1 RNA for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA.

30. The method of claim 29, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

31. The method of claim 29, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

32. A method for preparing HIV-1 RNA for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

21. A method of using the purified recombinant DNA of claim 18 for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and

(c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified recombinant DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

22. The method of claim 21, wherein the biological fluid is blood.

25. A method for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and

(c) detecting the presence of HIV-1 RNA.

27. The method of claim 25, wherein the presence of HIV-1 RNA is detected by contacting the HIV-1 RNA with the DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

(b) isolating HIV-1 virions from the cell-free supernatant; and

(c) disrupting the virions to release HIV-1 RNA.

33. The method of claim 32, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 17 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

34. The method of claim 32, further comprising detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the DNA of claim 18 and detecting hybridization between the HIV-1 RNA and the purified recombinant DNA.

35. A purified fragment of the recombinant DNA of claim 17, wherein said fragment comprises the sequence:
CTCAATAAAGCTTGCCTTG.

36. The purified fragment of claim 35, wherein said nucleic acid is labeled with a label selected from the group consisting of a radioisotope, an enzyme, a fluorescent label, and a chromophore label.

37. A method of using the purified fragment of claim 35 for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and

(c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified fragment of claim 35 and detecting hybridization between the HIV-1 RNA and the purified fragment.

38. The method of claim 37, wherein the biological fluid is blood.


39. A method of using the purified fragment of claim 36 for detecting the presence of HIV-1 RNA comprising:

(a) providing a cell-free supernatant of a biological fluid comprising cells infected with HIV-1;

(b) disrupting HIV-1 virions in the cell-free supernatant to release HIV-1 RNA; and

(c) detecting the presence of HIV-1 RNA by contacting the HIV-1 RNA with the purified fragment of claim 36 and detecting hybridization between the HIV-1 RNA and the purified fragment.

40. The method of claim 39, wherein the biological fluid is blood.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of:

Marc Alizon et al.

Application No.: 08/308,219

Filed: September 19, 1994

For: DNA SEQUENCE OF THE LTR
REGION OF HUMAN
IMMUNODEFICIENCY VIRUS
TYPE 1 (HIV-1)

)
) Group Art Unit: 1637
)
) Examiner: Jeffrey N. Fredman
)
) Confirmation No.: 4832
)
)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUBMISSION UNDER 37 C.F.R. § 3.73(b)

Institut Pasteur, duly organized under the laws of France and having its principal place of business at 28, rue du Docteur Roux, 75724 Paris Cedex 15, France, submits that it, together with the United States of America as represented by the Secretary of the Department of Health and Human Services, are the Assignees and owners of 100% of the right, title, and interest in the patent application identified above. Institut Pasteur's ownership interest is evidenced by:

An Assignment from the inventors to Institut Pasteur and Centre Nationale de la Recherche Scientifique, jointly, which was recorded in the Patent and Trademark Office at Reel 016769, Frame 0280, on July 14, 2005; copies of the recorded Assignment and the Notice of Recordation are attached hereto as Exhibit A; and

An Assignment from Centre Nationale de la Recherche Scientifique, having its principal place of business at 3, Rue Michel-Ange, 75794 Paris, Cedex 16, France, to Institut Pasteur, a copy of which is attached hereto as Exhibit B; and

Assignments from Solange Chamaret, Claudine Axler-Blin, Françoise Rey, Marie Therese Nugeyre, Jacqueline Gruet, Charles Dauguet, Willy Rozenbaum, Christine Rouzioux, Françoise Brun-Vezinet, Luc Montagnier, Jean-Claude Chermann, Françoise Barre-Sinoussi, and Pierre Tiollais, who are being added as inventors to the patent application identified above, to Institut Pasteur; copies of these Assignments are included in Exhibit C attached hereto.

The undersigned is authorized to act on behalf of the assignee, Institut Pasteur.

I hereby declare that all statements made of my own knowledge and belief are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Respectfully submitted,

A. Dautry

By: _____
Name: Alice Dautry
Title: President
Assignee: Institut Pasteur

Dated: _____

June 1st, 2006

7-1425

To the Director of the U.S. Patent and Trademark Office Please record the attached original copy		U.S. Department of Commerce Patent and Trademark Office Atty. Docket No. 3495.0010-15 Attorney Customer Number: 22,850 Mail Stop Assignment Recordation Services	
1. Name of conveying party(ies): 1. Marc ALIZON 2. Pierre SONIGO 3. Cole STEWART 4. Oliver DANOS 5. Simon WAIN-HOBSON		2. Name and address of receiving party(ies): 1. Institut Pasteur 25-28, rue du Doctor Roux 75724 Paris Cedex 15, France 2. Centre Nationale de la Recherche Scientifique 15, Quai Anatole France 75007 Paris, France	
Additional name(s) of conveying party(ies) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No			
3. Nature of conveyance: <input checked="" type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input type="checkbox"/> Change of Name <input type="checkbox"/> Other: [Describe]			
Execution Date: February 7, 1986		Additional name(s) & Address(es) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
4. Application number(s) or patent number(s): If this document is being filed together with a new application, the execution date of the application: A. Patent Application Number(s): 1. Appin. No. 06/771,248 (08/30/1985) Additional numbers attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		B. Patent Number(s): 1. US No. 5,980,900 (11/09/1999) <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	
5. Name and address of party to whom correspondence concerning document should be mailed: Name: Salvatore J. Arrigo, Reg. No. 48,063 Internal Address: FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P. Street Address: 901 New York Avenue, N.W. City: Washington, D.C. State: Zip: 20001-4413		6. Total number of applications and registrations involved: 14 7. Total fee (37 CFR 1.21(h) and 3.41): \$560 (\$40 x 14) <input checked="" type="checkbox"/> Enclosed (Please charge deficiency to deposit account 06-0916) <input type="checkbox"/> Authorized to be charged to deposit account 8. Deposit Account No.: 06-0916	
9. Statement and signature To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document. 07/18/2005 18YRNE 00000140 5980900 01 FC 8021 560.00 DP Salvatore J. Arrigo Signature: <i>[Signature]</i> Date: 7/14/05 Total number of pages including cover sheet, attachments and documents: 3			

PATENT
REEL: 016769 FRAME: 0280

4. Application/Patent Numbers (Continued)

Patent Applications

2. Appln. No. 07/158,652 (02/22/1998)
3. Appln. No. 08/026,736 (03/04/1993)
4. Appln. No. 08/051,226 (04/23/1993)
5. Appln. No. 08/156,930 (11/24/1993)
6. Appln. No. 08/308,218 (09/19/1994)
7. Appln. No. 08/308,219 (09/19/1994)
8. Appln. No. 08/475,822 (06/07/1995)

Issued Patents

2. US No. 5,705,612 (01/06/1998)
3. US No. 6,894,152 (02/25/1994)
4. US No. 6,555,112 (04/29/2003)
5. US No. 6,261,564 (07/17/2001)
6. US No. 6,706,268 (03/16/2004)

ASSIGNMENT
FOR UNFILED APPLICATION FOR UNITED STATES PATENT
(Sole or Joint Inventors)

ALL NAME(S) AND
OFFICE ADDRESS(ES)
OF INVENTOR(S)
(including country)

WHEREAS:

- ALIZON Marc, 71, rue du Cardinal Lemoine 75005 PARIS (France)
- SONIGO Pierre 23, rue Gutenberg 75015 PARIS (France)
- STEWART Cole
4Bis Villa Denise 92320 CHATILLON (France)
- DANOS Oliver 1, Place Rollet 75015 PARIS (France)
- WAIN-HOBSON Simon 3, rue Jean de la Fontaine
78180 MONTIGNY LES BRETONNEUX (France)

FILE OF
VENTION

(hereinafter referred to as ASSIGNOR), have invented and own a certain invention entitled:

**CLONED DNA SEQUENCES RELATED TO THE GENOMIC RNA OF
LYMPHADENOPATHY-ASSOCIATED VIRUS(LAV) AND... RNA**

for which application for Letters Patent of the United States has been executed on ~~XXXXXX~~
~~XXXXXX~~, August 30, 1985,

ALL NAME AND
ADDRESS (including
country) OF
SIGNEE

INSTITUT PASTEUR
25-28, rue du Dr. Roux
WHEREAS: 75724 PARIS CEDEX 15 (France) and

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
15, Quai Anatole France
75007 PARIS (France)

(hereinafter referred to as ASSIGNEE), is desirous of acquiring the entire interest in, to and under said invention and the United States Letters Patent to be obtained therefor;

NOW, THEREFORE, TO ALL WHOM IT MAY CONCERN: Be it known that in consideration of the payment by ASSIGNEE to ASSIGNOR of the sum of One Dollar (\$1.00), the receipt of which is hereby acknowledged, and for other good and valuable consideration, ASSIGNOR hereby sells, assigns and transfers to ASSIGNEE the full and exclusive right, title and interest to said invention and all Letters Patent of the United States to be obtained therefor on said application or any continuation, division, renewal, substitute or reissue thereof for the full term or terms for which the same may be granted.

ASSIGNOR hereby covenants that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment and sale;

ASSIGNOR further covenants that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said application, said invention and said Letters Patent as may be known and accessible to ASSIGNOR and will testify as to the same in any interference or litigation relating thereto and will promptly execute and deliver to ASSIGNEE or its legal representative any and all papers, instruments or affidavits required to apply for, obtain, maintain and enforce said application, said invention and said Letters Patent which may be necessary or desirable to carry out the purposes hereof.

DATE OF SIGNING:
to appear in the space
the date of signing
the date of signing
and one of the parties or
sign application.

IN WITNESS WHEREOF, I/We have hereunto set hand and seal this 7-2-1986
(Date of Signing)

SIGNATURE(S)
of assignor(s) must
correspond with the
name(s) of the
inventor(s) above.

Stewart Cole

Pierre SONIGO

Marc ALIZON

11/1/86 - Simon Wain-Hobson

11/1/86 - Marc ALIZON

Simon Wain-Hobson

NOTE: No witnessing, notarization or legalization is necessary, but can be included if desired as a crime.

RECORDED: 07/14/2005

PATENT
REEL: 016769 FRAME: 0282

ASSIGNMENT

WHEREAS, by virtue of an Assignment recorded in the United States Patent and Trademark Office on Reel 016769, Frames 0280-282, on July 14, 2005, Centre Nationale de la Recherche Scientifique (hereinafter referred to as ASSIGNOR), is the owner of rights, title, and interest in United States Patent Application Serial No. 08/308,219, filed September 19, 1994, (Attorney Docket No. 3495.0010-20), in the name of Marc Allzon, Pierre Sonigo, Cole Stewart, Oliver Danos, and Simon Wain-Hobson and entitled DNA SEQUENCE OF THE LTR REGION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1).

WHEREAS, Institut Pasteur (hereinafter referred to as ASSIGNEE), is desirous of acquiring from ASSIGNOR the ASSIGNOR's rights, title, and interest in, to and under the aforesaid patent application and the invention therein in the United States of America and its territories and possessions.

NOW THEREFORE, in consideration of good and valuable consideration, receipt of which from ASSIGNEE is acknowledged by ASSIGNOR, ASSIGNOR hereby sells, assigns, and transfers to the ASSIGNEE, its lawful successors and assigns, all of ASSIGNOR's rights to said invention in the United States, its territories and possessions, and all of ASSIGNOR's rights, title, and interest in and to said United States patent application Serial No. 08/308,219, filed September 19, 1994, and in and to any Letters Patent, which may be granted therefor in the United States, its territories and possessions, and in and to reissues, reexaminations, and extensions thereof.

5,352-1212

ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States to issue any and all of said Letters Patent, when granted, to said ASSIGNEE, its lawful successors and assigns as the assignee of the entire right, title, and interest in and to the same, for the sole use and enjoyment of said ASSIGNEE, its lawful successors and assigns.

Furthermore, ASSIGNOR agrees that it will communicate to said ASSIGNEE, or its representatives, any facts known to ASSIGNOR respecting said invention, and, at ASSIGNEE's expense, testify in any legal proceedings, sign all lawful papers, execute all reissue, reexamination and extension applications, execute all necessary assignment papers to cause any and all of said Letters Patent to be issued to said ASSIGNEE, its lawful successors and assigns, to obtain and enforce proper protection for said invention in the United States, its territories and possessions.

IN WITNESS WHEREOF, ASSIGNOR has hereunto set its hand this 31st day of May, 2006.

Centre Nationale de la Recherche
Scientifique

By: _____

Title: _____

Marc J. LEDOUX

*Chargé de
Mission.*

Responsable du Pilotage
de la Valorisation

TITLE: _____

Frédéric FOUBERT



JOINT INVENTION
Attorney Docket No. 03495.0010-20

ASSIGNMENT

WHEREAS I, the below named inventor, [hereinafter referred to as Assignor], have made an invention entitled:

**DNA SEQUENCE OF THE LTR REGION OF HUMAN
IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1)**

for which an application for United States Letters Patent was filed on September 19, 1994 (Application No. 08/308,219); and

WHEREAS, Institut Pasteur, whose post office address is 28, rue du Docteur Roux, 75724 Paris Cedex 15, France (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in the United States, and in and to the application for United States Letters Patent on this invention and the Letters Patent to be issued upon this application;

NOW THEREFORE, be it known that for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, I, as Assignor, have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, my entire right, title, and interest in and to this invention, and this application, and all divisions, and continuations thereof, and all Letters Patent of the United States, which may be granted thereon, and all reissues thereof, and I hereby authorize and request the Commissioner of Patents and Trademarks of the United States, whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, I HEREBY covenant that I have the full right to convey the interest assigned by this Assignment, and I have not executed and will not execute any agreement in conflict with this Assignment;

AND, I HEREBY further covenant and agree that I will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to me respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

IN TESTIMONY WHEREOF, I have hereunto set my hand.



Solange Chamaret

24-05-06
Date

JOINT INVENTION
Attorney Docket No. 03495.0010-20

ASSIGNMENT

WHEREAS I, the below named inventor, [hereinafter referred to as Assignor], have made an invention entitled:

**DNA SEQUENCE OF THE LTR REGION OF HUMAN
IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1)**

for which an application for United States Letters Patent was filed on September 19, 1994 (Application No. 08/308,219); and

WHEREAS, Institut Pasteur, whose post office address is 28, rue du Docteur Roux, 75724 Paris Cedex 15, France (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in the United States, and in and to the application for United States Letters Patent on this invention and the Letters Patent to be issued upon this application;

NOW THEREFORE, be it known that for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, I, as Assignor, have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, my entire right, title, and interest in and to this invention, and this application, and all divisions, and continuations thereof, and all Letters Patent of the United States, which may be granted thereon, and all reissues thereof, and I hereby authorize and request the Commissioner of Patents and Trademarks of the United States, whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, I HEREBY covenant that I have the full right to convey the interest assigned by this Assignment, and I have not executed and will not execute any agreement in conflict with this Assignment;

AND, I HEREBY further covenant and agree that I will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to me respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

IN TESTIMONY WHEREOF, I have hereunto set my hand.

C-Axler-Blin
Claudine Axler-Blin

26 Mar 2006
Date

JOINT INVENTION
Attorney Docket No. 03495.0010-20

ASSIGNMENT

WHEREAS I, the below named inventor, [hereinafter referred to as Assignor], have made an invention entitled:

**DNA SEQUENCE OF THE LTR REGION OF HUMAN
IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1)**

for which an application for United States Letters Patent was filed on September 19, 1994 (Application No. 08/308,219); and

WHEREAS, Institut Pasteur, whose post office address is 28, rue du Docteur Roux, 75724 Paris Cedex 15, France (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in the United States, and in and to the application for United States Letters Patent on this invention and the Letters Patent to be issued upon this application;

NOW THEREFORE, be it known that for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, I, as Assignor, have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, my entire right, title, and interest in and to this invention, and this application, and all divisions, and continuations thereof, and all Letters Patent of the United States, which may be granted thereon, and all reissues thereof, and I hereby authorize and request the Commissioner of Patents and Trademarks of the United States, whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, I HEREBY covenant that I have the full right to convey the interest assigned by this Assignment, and I have not executed and will not execute any agreement in conflict with this Assignment;

AND, I HEREBY further covenant and agree that I will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to me respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

IN TESTIMONY WHEREOF, I have hereunto set my hand.



Françoise Rey



Date

JOINT INVENTION
Attorney Docket No. 03495.0010-20

ASSIGNMENT

WHEREAS I, the below named inventor, [hereinafter referred to as Assignor], have made an invention entitled:

**DNA SEQUENCE OF THE LTR REGION OF HUMAN
IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1)**

for which an application for United States Letters Patent was filed on September 19, 1994 (Application No. 08/308,219); and

WHEREAS, Institut Pasteur, whose post office address is 28, rue du Docteur Roux, 75724 Paris Cedex 15, France (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in the United States, and in and to the application for United States Letters Patent on this invention and the Letters Patent to be issued upon this application;

NOW THEREFORE, be it known that for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, I, as Assignor, have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, my entire right, title, and interest in and to this invention, and this application, and all divisions, and continuations thereof, and all Letters Patent of the United States, which may be granted thereon, and all reissues thereof, and I hereby authorize and request the Commissioner of Patents and Trademarks of the United States, whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, I HEREBY covenant that I have the full right to convey the interest assigned by this Assignment, and I have not executed and will not execute any agreement in conflict with this Assignment;

AND, I HEREBY further covenant and agree that I will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to me respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

IN TESTIMONY WHEREOF, I have hereunto set my hand.



Marie-Therese Nugeyre

May 29 2006

Date

JOINT INVENTION
Attorney Docket No. 03495.0010-20

ASSIGNMENT

WHEREAS, JACQUELINE GRUEST, [hereinafter referred to as Assignor], made an invention entitled:

**DNA SEQUENCE OF THE LTR REGION OF HUMAN
IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1)**

for which an application for United States Letters Patent was filed on September 19, 1994 (Application No. 08/308,219); and


WHEREAS, Institut Pasteur, whose post office address is 28, rue du Docteur Roux, 75724 Paris Cedex 15, France (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in the United States, and in and to the application for United States Letters Patent on this invention and the Letters Patent to be issued upon this application;

NOW THEREFORE, be it known that for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, I, as Assignor, have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, my entire right, title, and interest in and to this invention, and this application, and all divisions, and continuations thereof, and all Letters Patent of the United States, which may be granted thereon, and all reissues thereof, and I hereby authorize and request the Commissioner of Patents and Trademarks of the United States, whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, I HEREBY covenant that I have the full right to convey the interest assigned by this Assignment, and I have not executed and will not execute any agreement in conflict with this Assignment;

AND, I HEREBY further covenant and agree that I will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to me respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

IN TESTIMONY WHEREOF, I have hereunto set my hand.



Jacqueline Gruest

By: Jacques Gruest, Heir to the Estate of
Jacqueline Gruest, Deceased

25.05.2006

Date

JOINT INVENTION
Attorney Docket No. 03495.0010-20

ASSIGNMENT

WHEREAS I, the below named inventor, [hereinafter referred to as Assignor], have made an invention entitled:

**DNA SEQUENCE OF THE LTR REGION OF HUMAN
IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1)**

for which an application for United States Letters Patent was filed on September 19, 1994 (Application No. 08/308,219); and

WHEREAS, Institut Pasteur, whose post office address is 28, rue du Docteur Roux, 75724 Paris Cedex 15, France (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in the United States, and in and to the application for United States Letters Patent on this invention and the Letters Patent to be issued upon this application;

NOW THEREFORE, be it known that for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, I, as Assignor, have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, my entire right, title, and interest in and to this invention, and this application, and all divisions, and continuations thereof, and all Letters Patent of the United States, which may be granted thereon, and all reissues thereof, and I hereby authorize and request the Commissioner of Patents and Trademarks of the United States, whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, I HEREBY covenant that I have the full right to convey the interest assigned by this Assignment, and I have not executed and will not execute any agreement in conflict with this Assignment;

AND, I HEREBY further covenant and agree that I will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to me respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

IN TESTIMONY WHEREOF, I have hereunto set my hand.

Charles Dauguet
Charles Dauguet

2006.6.26/mai
Date

JOINT INVENTION
Attorney Docket No. 03495.0010-20

ASSIGNMENT

WHEREAS I, the below named inventor, [hereinafter referred to as Assignor], have made an invention entitled:

**DNA SEQUENCE OF THE LTR REGION OF HUMAN
IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1)**

for which an application for United States Letters Patent was filed on September 19, 1994 (Application No. 08/308,219); and

WHEREAS, Institut Pasteur, whose post office address is 28, rue du Docteur Roux, 75724 Paris Cedex 15, France (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in the United States, and in and to the application for United States Letters Patent on this invention and the Letters Patent to be issued upon this application;

NOW THEREFORE, be it known that for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, I, as Assignor, have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, my entire right, title, and interest in and to this invention, and this application, and all divisions, and continuations thereof, and all Letters Patent of the United States, which may be granted thereon, and all reissues thereof, and I hereby authorize and request the Commissioner of Patents and Trademarks of the United States, whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, I HEREBY covenant that I have the full right to convey the interest assigned by this Assignment, and I have not executed and will not execute any agreement in conflict with this Assignment;

AND, I HEREBY further covenant and agree that I will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to me respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

IN TESTIMONY WHEREOF, I have hereunto set my hand.



Willy Rozenbaum

25 May 2006
Date

JOINT INVENTION
Attorney Docket No. 03495.0010-20

ASSIGNMENT

WHEREAS I, the below named inventor, [hereinafter referred to as Assignor], have made an invention entitled:

**DNA SEQUENCE OF THE LTR REGION OF HUMAN
IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1)**

for which an application for United States Letters Patent was filed on September 19, 1994 (Application No. 08/308,219); and

WHEREAS, Institut Pasteur, whose post office address is 28, rue du Docteur Roux, 75724 Paris Cedex 15, France (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in the United States, and in and to the application for United States Letters Patent on this invention and the Letters Patent to be issued upon this application;

NOW THEREFORE, be it known that for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, I, as Assignor, have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, my entire right, title, and interest in and to this invention, and this application, and all divisions, and continuations thereof, and all Letters Patent of the United States, which may be granted thereon, and all reissues thereof, and I hereby authorize and request the Commissioner of Patents and Trademarks of the United States, whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, I HEREBY covenant that I have the full right to convey the interest assigned by this Assignment, and I have not executed and will not execute any agreement in conflict with this Assignment;

AND, I HEREBY further covenant and agree that I will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to me respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

IN TESTIMONY WHEREOF, I have hereunto set my hand.

Christine Rouzioux

30 05 2006
Date

JOINT INVENTION
Attorney Docket No. 03495.0010-20

ASSIGNMENT

WHEREAS I, the below named Inventor, [hereinafter referred to as Assignor], have made an invention entitled:

DNA SEQUENCE OF THE LTR REGION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1)

for which an application for United States Letters Patent was filed on September 19, 1994 (Application No. 08/308,219); and

WHEREAS, Institut Pasteur, whose post office address is 28, rue du Docteur Roux, 75724 Paris Cedex 15, France (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in the United States, and in and to the application for United States Letters Patent on this invention and the Letters Patent to be issued upon this application;

NOW THEREFORE, be it known that for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, I, as Assignor, have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, my entire right, title, and interest in and to this invention, and this application, and all divisions, and continuations thereof, and all Letters Patent of the United States, which may be granted thereon, and all reissues thereof, and I hereby authorize and request the Commissioner of Patents and Trademarks of the United States, whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;


AND, I HEREBY covenant that I have the full right to convey the interest assigned by this Assignment, and I have not executed and will not execute any agreement in conflict with this Assignment;

AND, I HEREBY further covenant and agree that I will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to me respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

IN TESTIMONY WHEREOF, I have hereunto set my hand.

FRANÇOIS BRUN-VEZINET
François Brun-Vezinet

30/05/06
Date



JOINT INVENTION
Attorney Docket No. 03495.0010-20

ASSIGNMENT

WHEREAS I, the below named inventor, [hereinafter referred to as Assignor], have made an invention entitled:

**DNA SEQUENCE OF THE LTR REGION OF HUMAN
IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1)**

for which an application for United States Letters Patent was filed on September 19, 1994 (Application No. 08/308,219); and

WHEREAS, Institut Pasteur, whose post office address is 28, rue du Docteur Roux, 75724 Paris Cedex 15, France (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in the United States, and in and to the application for United States Letters Patent on this invention and the Letters Patent to be issued upon this application;

NOW THEREFORE, be it known that for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, I, as Assignor, have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, my entire right, title, and interest in and to this invention, and this application, and all divisions, and continuations thereof, and all Letters Patent of the United States, which may be granted thereon, and all reissues thereof, and I hereby authorize and request the Commissioner of Patents and Trademarks of the United States, whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, I HEREBY covenant that I have the full right to convey the interest assigned by this Assignment, and I have not executed and will not execute any agreement in conflict with this Assignment;

AND, I HEREBY further covenant and agree that I will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to me respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

IN TESTIMONY WHEREOF, I have hereunto set my hand.



Luc Montagnier

May 24 2006
Date

JOINT INVENTION
Attorney Docket No. 03495.0010-20

ASSIGNMENT

WHEREAS I, the below named inventor, [hereinafter referred to as Assignor], have made an invention entitled:

DNA SEQUENCE OF THE LTR REGION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1)

for which an application for United States Letters Patent was filed on September 19, 1994 (Application No. 08/308,219); and


WHEREAS, Institut Pasteur, whose post office address is 28, rue du Docteur Roux, 75724 Paris Cedex 15, France (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in the United States, and in and to the application for United States Letters Patent on this invention and the Letters Patent to be issued upon this application;

NOW THEREFORE, be it known that for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, I, as Assignor, have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, my entire right, title, and interest in and to this invention, and this application, and all divisions, and continuations thereof, and all Letters Patent of the United States, which may be granted thereon, and all reissues thereof, and I hereby authorize and request the Commissioner of Patents and Trademarks of the United States, whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;


AND, I HEREBY covenant that I have the full right to convey the interest assigned by this Assignment, and I have not executed and will not execute any agreement in conflict with this Assignment;

AND, I HEREBY further covenant and agree that I will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to me respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

IN TESTIMONY WHEREOF, I have hereunto set my hand.



Jean-Claude Chermann



Date

JOINT INVENTION
Attorney Docket No. 03495.0010-20

ASSIGNMENT

WHEREAS I, the below named inventor, [hereinafter referred to as Assignor], have made an invention entitled:

**DNA SEQUENCE OF THE LTR REGION OF HUMAN
IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1)**

for which an application for United States Letters Patent was filed on September 19, 1994 (Application No. 08/308,219); and


WHEREAS, Institut Pasteur, whose post office address is 28, rue du Docteur Roux, 75724 Paris Cedex 15, France (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in the United States, and in and to the application for United States Letters Patent on this invention and the Letters Patent to be issued upon this application;

NOW THEREFORE, be it known that for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, I, as Assignor, have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, my entire right, title, and interest in and to this invention, and this application, and all divisions, and continuations thereof, and all Letters Patent of the United States, which may be granted thereon, and all reissues thereof, and I hereby authorize and request the Commissioner of Patents and Trademarks of the United States, whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, I HEREBY covenant that I have the full right to convey the interest assigned by this Assignment, and I have not executed and will not execute any agreement in conflict with this Assignment;

AND, I HEREBY further covenant and agree that I will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to me respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

IN TESTIMONY WHEREOF, I have hereunto set my hand.



Françoise Barre-Sinoussi

05.24.2006
Date

JOINT INVENTION
Attorney Docket No. 03495.0010-20

ASSIGNMENT

WHEREAS I, the below named inventor, [hereinafter referred to as Assignor], have made an invention entitled:

**DNA SEQUENCE OF THE LTR REGION OF HUMAN
IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1)**

for which an application for United States Letters Patent was filed on September 19, 1994 (Application No. 08/308,219); and

WHEREAS, Institut Pasteur, whose post office address is 28, rue du Docteur Roux, 75724 Paris Cedex 15, France (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in the United States, and in and to the application for United States Letters Patent on this invention and the Letters Patent to be issued upon this application;

NOW THEREFORE, be it known that for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, I, as Assignor, have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, my entire right, title, and interest in and to this invention, and this application, and all divisions, and continuations thereof, and all Letters Patent of the United States, which may be granted thereon, and all reissues thereof, and I hereby authorize and request the Commissioner of Patents and Trademarks of the United States, whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, I HEREBY covenant that I have the full right to convey the interest assigned by this Assignment, and I have not executed and will not execute any agreement in conflict with this Assignment;

AND, I HEREBY further covenant and agree that I will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to me respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

IN TESTIMONY WHEREOF, I have hereunto set my hand.



Pierre Tiollais

24 mai 06
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
) Group Art Unit: 1637
Marc Alizon et al.)
) Examiner: Jeffrey N. Fredman
Application No.: 08/308,219)
) Confirmation No.: 4832
Filed: September 19, 1994)
)
For: DNA SEQUENCE OF THE LTR
REGION OF HUMAN
IMMUNODEFICIENCY VIRUS
TYPE 1 (HIV-1)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUBMISSION UNDER 37 C.F.R. § 3.73(b)


The United States of America as represented by the Secretary of the Department of Health and Human Services, having its principal place of business at 900 Rockville Pike, Bethesda, Maryland 20892, submits that it, together with Institut Pasteur of Paris, France, are the Assignees and owners of 100% of the right, title, and interest in the patent application identified above. The United States of America as represented by the Secretary of the Department of Health and Human Services' ownership interest is evidenced by:

Assignments from Robert C. Gallo, Mikulas Popovic, and Mangalasseril G. Sarngadharan, who are being added as inventors to the patent application identified above; copies of these Assignments are included in Exhibit A attached hereto.

The undersigned is authorized to act on behalf of the assignee, The United States of America as represented by the Secretary of the Department of Health and Human Services.

I hereby declare that all statements made of my own knowledge and belief are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Respectfully submitted,

By: 
Name: JACK SPIEGEL (REG# 34,477)
Title: SENIOR ADVISOR FOR TECHNOLOGY TRANSFER OPERATIONS
Assignee: The United States of America
as represented by the
Secretary of the Department of
Health and Human Services.

Dated: JUNE 5, 2006

1111556

ASSIGNMENT

WHEREAS I, the below named inventor, [hereinafter referred to as Assignor], have made an invention entitled:

DNA SEQUENCE OF THE LTR REGION OF HUMAN
IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1)

for which an application for United States Letters Patent was filed on September 19, 1994 (Application No. 08/308,219); and


WHEREAS, The United States of America as represented by the Secretary of the Department of Health and Human Services, whose post office address is 900 Rockville Pike, Bethesda, Maryland 20892 (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in the United States, and in and to the application for United States Letters Patent on this invention and the Letters Patent to be issued upon this application;


NOW THEREFORE, be it known that for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, I, as Assignor, have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, my entire right, title, and interest in and to this invention, and this application, and all divisions, and continuations thereof, and all Letters Patent of the United States, which may be granted thereon, and all reissues thereof, and I hereby authorize and request the Commissioner of Patents and Trademarks of the United States, whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, I HEREBY covenant that I have the full right to convey the interest assigned by this Assignment, and I have not executed and will not execute any agreement in conflict with this Assignment;

AND, I HEREBY further covenant and agree that I will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to me respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

IN TESTIMONY WHEREOF, I have hereunto set my hand.


Robert C. Gallo


Date

ASSIGNMENT

WHEREAS I, the below named inventor, [hereinafter referred to as Assignor], have made an invention entitled:

DNA SEQUENCE OF THE LTR REGION OF HUMAN
IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1)

for which an application for United States Letters Patent was filed on September 19, 1994 (Application No. 08/308,219); and


WHEREAS, The United States of America as represented by the Secretary of the Department of Health and Human Services, whose post office address is 900 Rockville Pike, Bethesda, Maryland 20892 (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in the United States, and in and to the application for United States Letters Patent on this invention and the Letters Patent to be issued upon this application;

NOW THEREFORE, be it known that for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, I, as Assignor, have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, my entire right, title, and interest in and to this invention, and this application, and all divisions, and continuations thereof, and all Letters Patent of the United States, which may be granted thereon, and all reissues thereof, and I hereby authorize and request the Commissioner of Patents and Trademarks of the United States, whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;


AND, I HEREBY covenant that I have the full right to convey the interest assigned by this Assignment, and I have not executed and will not execute any agreement in conflict with this Assignment;

AND, I HEREBY further covenant and agree that I will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to me respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

IN TESTIMONY WHEREOF, I have hereunto set my hand.



Mikulas Popovic


Date

ASSIGNMENT

WHEREAS I, the below named inventor, [hereinafter referred to as Assignor], have made an invention entitled:

DNA SEQUENCE OF THE LTR REGION OF HUMAN
IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1)

for which an application for United States Letters Patent was filed on September 19, 1994 (Application No. 08/308,219); and

WHEREAS, The United States of America as represented by the Secretary of the Department of Health and Human Services, whose post office address is 900 Rockville Pike, Bethesda, Maryland 20892 (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in the United States, and in and to the application for United States Letters Patent on this invention and the Letters Patent to be issued upon this application;

NOW THEREFORE, be it known that for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, I, as Assignor, have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, my entire right, title, and interest in and to this invention, and this application, and all divisions, and continuations thereof, and all Letters Patent of the United States, which may be granted thereon, and all reissues thereof, and I hereby authorize and request the Commissioner of Patents and Trademarks of the United States, whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, I HEREBY covenant that I have the full right to convey the interest assigned by this Assignment, and I have not executed and will not execute any agreement in conflict with this Assignment;

AND, I HEREBY further covenant and agree that I will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to me respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

IN TESTIMONY WHEREOF, I have hereunto set my hand.

Mangalasseril G. Sarngadharan

Mangalasseril G. Sarngadharan

June 4, 2006

Date



300-101-
90-102-
480-103-
104-

Cloned DNA sequences related to the genomic RNA of lymphadenopathy-associated-virus (LAV) and proteins encoded by said LAV genomic RNA

5 The invention relates to cloned DNA sequences indistinguishable from genomic RNA and DNA of lymphadenopathy-associated virus (LAV), a process for their preparation and their uses. It relates more particularly to stable probes including a DNA sequence which can be used for the detection of the LAV virus or related viruses
10 or DNA proviruses in any medium, particularly biological samples containing any of them. The invention also relates to polypeptides, whether glycosylated or not, encoded by said DNA sequences.

15 Lymphadenopathy-associated virus (LAV) is a human retrovirus first isolated from the lymph node of a homosexual patient with lymphadenopathy syndrome, frequently a prodrome or a benign form of acquired immune deficiency syndrome (AIDS). Subsequently other LAV isolates have been recovered from patients with AIDS or pre-AIDS. All available
20 data are consistent with the virus being the causative agent of AIDS.

A method for cloning such DNA sequences has already been disclosed in British Patent Application Nr. 84 23659 filed on September 19, 1984. Reference is hereafter made to that application as concerns subject matter
25 in common with the further improvements to the invention disclosed herein.

The present invention aims at providing additional new means which should not only also be useful for the
30 detection of LAV or related viruses (hereafter more generally referred to as "LAV viruses"), but also have more versatility, particularly in detecting specific parts of the genomic DNA of said viruses whose expression products are not always directly detectable by immunological
35 methods.

The present invention further aims at providing		
09/05/85 771248	2 101	300.00 CK
09/05/85 771248	2 102	90.00 CK
09/05/85 771248	2 103	40.00 CK
09/05/85 771248	2 104	100.00 CK

polypeptides containing sequences in common with polypeptides encoded by the LAV genomic RNA. It relates even more particularly to polypeptides comprising antigenic determinants included in the proteins encoded and expressed by the LAV genome occurring in nature. An additional object of the invention is to further provide means for the detection of proteins related to LAV virus, particularly for the diagnosis of AIDS or pre-AIDS or, to the contrary, for the detection of antibodies against the LAV virus or proteins related therewith, particularly in patients afflicted with AIDS or pre-AIDS or more generally in asymptomatic carriers and in blood-related products. Finally the invention also aims at providing immunogenic polypeptides, and more particularly protective polypeptides for use in the preparation of vaccine compositions against AIDS or related syndroms.

The present invention relates to additional DNA fragments, hybridizable with the genomic RNA of LAV as they will be disclosed hereafter, as well as with additional cDNA variants corresponding to the whole genomes of LAV viruses. It further relates to DNA recombinants containing said DNAs or cDNA fragments.

The invention relates more particularly to a cDNA variant corresponding to the whole of LAV retroviral genomes, which is characterized by a series of restriction sites in the order hereafter (from the 5' end to the 3' end).

The coordinates of the successive sites of the whole LAV genome (restriction map) are indicated hereafter too, with respect to the Hind III site (selected as of coordinate 1) which is located in the R region. The coordinates are estimated with an accuracy of ± 200 bp :

	Hind III	0
	Sac I	50
35	Hind III	520
	Pst I	800
	Hind III	1 100

	Bgl II	1 500
	Kpn I	3 500
	Kpn I	3 900
	Eco RI	4 100
5	Eco RI	5 300
	Sal I	5 500
	Kpn I	6 100
	Bgl II	6 500
	Bgl II	7 800
10	Hind III	7 850
	Bam HI	8 150
	Xho I	8 600
	Kpn I	8 700
	Bgl II	8 750
15	Bgl II	9 150
	Sac I	9 200
	Hind III	9 250

Another DNA variant according to this invention optionally contains an additional Hind III approximately at the 5 550 coordinate.

Reference is further made to fig. 1 which shows a more detailed restriction map of said whole-DNA (AJ19).

An even more detailed nucleotide sequence of a preferred DNA according to the invention is shown in fig. 4-12 hereafter.

The invention further relates to other preferred DNA fragments which will be referred to hereafter.

Additional features of the invention will appear in the course of the non-limitative disclosure of additional features of preferred DNAs of the invention, as well as of preferred polypeptides according to the invention. Reference will further be had to the drawings in which :

- fig. 1 is the restriction map of a complete LAV genome (clone AJ19) ;

- figs. 2 and 3 show diagrammatically parts of the three

possible reading phases of LAV genomic RNA, including the open reading frames (ORF) apparent in each of said reading phases :

- figs. 4-12 show the successive nucleotidic sequences of a complete LAV genome. The possible peptide sequences in relation to the three possible reading phases related to the nucleotide sequences shown are also indicated ;
- figs. 13-18 reiterate the sequence of part of the LAV genome containing the genes coding for the envelope proteins, with particular boxed peptidic sequences which corresponds to groups which normally carry glycosyl groups.

The sequencing and determination of sites of particular interest was carried out on a phage recombinant corresponding to AJ19 disclosed in the abovesaid British Patent application Nr. 84 23659. A method for preparing it is disclosed in that application.

The whole recombinant phage DNA of clone AJ19 (disclosed in the earlier application) was sonicated according to the protocol of DEININGER (1983), Analytical Biochem. 129, 216. the DNA was repaired by a Klenow reaction for 12 hours at 16°C. The DNA was electrophoresed through 0.8 % agarose gel and DNA in the size range of 300-600 bp was cut out and electroeluted and precipitated. Resuspended DNA (in 10 mM Tris, pH 8 ; 0.1 mM EDTA) was ligated into M13mp8 RF DNA (cut by the restriction enzyme SmaI and subsequently alkaline phosphated), using T4 DNA- and RNA-ligases (Maniatis T et al (1982) - Molecular cloning - Cold Spring Harbor Laboratory). An *E. coli* strain designated as TGI was used for further study. This strain has the following genotype :


Δ lac pro, supE, thi.F' traD36, proAB, lacI^q, ZAM15, r⁻

This *E. coli* TGI strain has the peculiarity of enabling recombinants to be recognized easily. The blue colour of the cells transfected with plasmids which did

not recombine with a fragment of LAV DNA is not modified. To the contrary cells transfected by a recombinant plasmid containing a LAV DNA fragment yield white colonies. The technique which was used is disclosed in Gene (1983), 28, 101.

This strain was transformed with the ligation mix using the Hanahan method (Hanahan D (1983) J. Mol. Biol. 166, 557). Cells were plated out on tryptone-agarose plate with IPTG and X-gal in soft agarose. White plaques were either picked and screened or screened directly in situ using nitrocellulose filters. Their DNAs were hybridized with nick-translated DNA inserts of pUC18 Hind III subclones of λ J19. this permitted the isolation of the plasmids or subclones of λ which are identified in the table hereafter. In relation to this table it should also be noted that the designation of each plasmid is followed by the deposition number of a cell culture of E. coli TGI containing the corresponding plasmid at the "Collection Nationale des Cultures de Micro-organismes" (C.N.C.M.) of the Pasteur Institute in Paris, France. A non-transformed TGI cell line was also deposited at the C.N.C.M. under Nr. I-364. All these deposits took place on November 15, 1984. The sizes of the corresponding inserts derived from the LAV genome have also been indicated.

25



TABLE

Essential features of the recombinant plasmids

5	- pJ19 - 1 plasmid	(I-365)	0.5 kb
	Hind III - Sac I - Hind III		
10	- pJ19 - 17 plasmid	(I-367)	0.6 kb
	Hind III - Pst I - Hind III		
	- pJ19 - 6 plasmid	(I-366)	1.5 kb
15	Hind III (5')		
	Bam HI		
	Xho I		
	Kpn I		
	Bgl II		
20	Sac I (3')		
	Hind III		
	- pJ19-13 plasmid	(I-368)	6.7 kb
25	Hind III (5')		
	Bgl II		
	Kpn I		
	Kpn I		
	Eco RI		
30	Eco RI		
	Sal I		
	Kpn I		
	Bgl II		
	Bgl II		
35	Hind III (3')		

Positively hybridizing M13 phage plates were grown up for 5 hours and the single-stranded DNAs were extracted.

M13mp8 subclones of λ J19 DNAs were sequenced according to the dideoxy method and technology devised by Sanger et al (Sanger et al (1977), Proc. Natl. Acad. Sci. USA, 74, 5463 and M13 cloning and sequencing handbook, AMERSHAM (1983). the 17-mer oligonucleotide primer α -³⁵SdATP (400Ci/mmol, AMERSHAM), and 0.5X-5X buffer gradient gels (Biggen M.O. et al (1983, Proc. Natl. Acad. Sci. USA, 50, 3963) were used. Gels were read and put into the computer under the programs of Staden (Staden R. (1982), Nucl. Acids Res. 10, 4731). All the appropriate references and methods can be found in the AMERSHAM M13 cloning and sequencing handbook.

The complete sequence of λ J19 was deduced from the experiments as further disclosed hereafter.

Figs. 4-12 provide the DNA nucleotide sequence of the complete genome of LAV. The numbering of the nucleotides starts from a left most Hind III restriction site (5'AAG...) of the restriction map. The numbering occurs in tens whereby the last zero number of each of the numbers occurring on the drawings is located just below the nucleotide corresponding to the nucleotides designated. I.e. the nucleotide at position 10 is T, the nucleotide at position 20 is C, etc..

Above each of the lines of the successive nucleotide sequences there are provided three lines of single letters corresponding to the aminoacid sequence deduced from the DNA sequence (using the genetic code) for each at the three reading phases, whereby said single letters have the following meanings.

A : alanine
R : arginine
K : lysine
H : histidine
C : cysteine

M : méthionine
 W : tryptophan
 F : phenylalanine
 Y : tyrosine
 5 L : leucine
 V : valine
 I : isoleucine
 G : glycine
 T : thréonine
 10 S : serine
 E : glutamic acid
 D : Aspartic acid
 N : asparagine
 Q : glutamine
 15 P : proline.

The asterik signs "*" correspond to stop codons (i.e. TAA, TAG and TGA).

20 Starting above the first line of the DNA nucleotidic sequence of fig. 4 the three reading phases are respectively marked "1", "2", "3", on the left handside of the drawing. The same relative presentation of the three theoritical reading phases is then used all over the successives lines of the LAV nucleotidic sequence.

25 Figs. 2 and 3 provide a diagrammatized representation of the lengths of the successive open reading frames corresponding to the successive reading phases (also referred to by numbers "1", "2" and "3" appearing in the left handside part of fig. 2). The relative positions of these open reading frames (ORF) with respect to the
 30 nucleotidic structure of the LAV genome is referred to by the scale of numbers representative of the respective positions of the corresponding nucleotides in the DNA sequence. The vertical bars correspond to the positions of the corresponding stop codons.

35 1) The "gag gene" (or ORF-gag)

The "gag gene" codes for core proteins.

Particularly it appears that a genomic fragment (ORF-gag) thought to code for the core antigens including the p25, p18 and p13 proteins is located between nucleotidic position 238 (starting with 5' CTA GCG GAG 3') and nucleotidic position 1759 (ending by CTCG TCA CAA 3'). The structure of the peptides or proteins encoded by parts of said ORF is deemed to be that corresponding to phase 2.

The methionine aminoacid "M" coded by the ATG at position 260-262 is the probable initiation methionine of the gag protein precursor. The end of ORF-gag and accordingly of gag protein appears to be located at position 1759.

The beginning of p25 protein, thought to start by a P-I-V-Q-N-I-Q-G-Q-M-V-H aminoacid sequence is thought to be coded for by the nucleotidic sequence CCTATA.... starting at position 656.

Hydrophilic peptides in the gag open reading frame are identified hereafter. They are defined starting from aminoacid 1 = Met (M) coded by the ATG starting from 260-2 in the LAV DNA sequence.

	Those hydrophilic peptides are
	12-32 aminoacids inclusive
	37-46 - -
	49-79 - -
25	88-153 - -
	158-165 - -
	178-188 - -
	200-220 - -
	226-234 - -
30	239-264 - -
	288-331 - -
	352-361 - -
	377-390 - -
	399-432 - -
35	437-484 - -
	492-498 - -

The invention also relates to any combination of these peptides.

2) The "pol gene" (or ORF-pol)

Figs. 4-12 also show that the DNA fragments
 5 extending from nucleotidic position 1555 (starting with
 5' TTT TTT 3' to nucleotidic position 5086 is thought
 to correspond to the pol gene. The polypeptidic structure
 of the corresponding polypeptides is deemed to be that
 corresponding to phase 1. It stops at position 4563 (end
 10 by 5' G GAT GAG GAT 3').

These genes are thought to code for the virus
 polymerase or reverse transcriptase.

3) The envelope gene (or ORF-env)

The DNA sequence thought to code for envelope
 15 proteins is thought to extend from nucleotidic position
 5670 (starting with 5' AAA GAG GAG A.... 3') up to nucleo-
 tidic position 8132 (ending by A ACT AAA GAA 3').
 Polypeptidic structures of sequences of the envelope
 protein correspond to those read according to the "phase
 20 3" reading phase.

The start of env transcription is thought to be at
 the level of the ATG codon at positions 5691-5693.

Additional feature of the envelope protein coded
 by the env genes appear on figs. 13-18. These are to be
 25 considered as paired figs. 13 and 14 ; 15 and 16 ; 17 and
 18 respectively.

It is to be mentioned that because of format
 difficulties.

Fig. 14 overlaps to some extent with fig. 13.

30 Fig. 16 overlaps to some extent with fig. 15.

Fig. 18 overlaps to some extent with fig. 17.

Thus for instance figs. 13 and 14 must be con-
 sidered together. Particularly the sequence shown on the
 first line on the top of fig. 13 overlaps with the
 35 sequence shown on the first line on the top of fig. 14. In
 other words the starting of the reading of the successive

sequences of the env gene as represented in figs. 13-18 involves first reading the first line at the top of fig. 13 then proceeding further with the first line of fig. 14. One then returns to the beginning of the second line of fig. 13, then again further proceed with the reading of the second line of page 14, etc... The same observations then apply to the reading of the paired figs. 15 and 16, and paired figs. 17 and 18, respectively.

The locations of neutralizing epitopes are further apparent in figs. 13-18. reference is more particularly made to the boxed groups of three letters included in the aminoacid sequences of the envelope proteins (reading phase 3) which can be designated generally by the formula N-X-S or N-X-T, wherein X is any other possible aminoacid. Thus the initial protein product of the env gene in a glycoprotein of molecular weight in excess of 91,000. These groups are deemed to generally carry glycosylated groups. These N-X-S and N-X-T groups with attached glycosylated groups form together hydrophylic regions of the protein and are deemed to be located at the periphery of and to be exposed outwardly with respect to the normal conformation of the proteins. Consequently they are considered as being epitopes which can efficiently be brought into play in vaccine compositions.

The invention thus concerns with more particularly peptide sequences included in the env-proteins and excizable therefrom (or having the same aminoacid structure), having sizes not exceeding 200 aminoacids.

Preferred peptides of this invention (referred to hereafter as a, b, c, d, e, f) are deemed to correspond to those encoded by the nucleotide sequences which extend respectively between the following positions :

- a) from about 6095 to about 6200
- b) " " 6260 " " 6310
- 35 c) " " 6390 " " 6440
- d) " " 6485 " " 6620

e) - " 6860 " " 6930
 f) - " 7535 " " 7630

Other hydrophilic peptides in the env open reading frame are identified hereafter. they are defined starting
 5 from

aminoacid 1 = lysine (K) coded by the AAA at position 5670-2 in the LAV DNA sequence.

These hydrophilic peptides are
 8-23 aminoacids inclusive

10	63-78	"	"
	82-90	"	"
	97-123	"	"
	127-183	"	"
	197-201	"	"
15	239-294	"	"
	300-327	"	"
	334-381	"	"
	397-424	"	"
	466-500	"	"
20	510-523	"	"
	551-577	"	"
	594-603	"	"
	621-630	"	"
	657-679	"	"
25	719-758	"	"
	780-803	"	"

The invention also relates to any combination of these peptides.

4) The other ORF

30 The invention further concerns DNA sequences which provide open reading frames defined as ORF-Q, ORF-R and as "1", "2", "3", "4", "5", the relative position of which appears more particularly in figs. 2 and 3.

These ORFs have the following locations :

35	ORF-Q	phase 1	start 4478	stop 5086
	ORF-R	" 2	" 8249	" 8896

ORF-1	"	1	"	5029	"	5316
ORF-2	"	2	"	5273	"	5515
ORF-3	"	1	"	5383	"	5616
ORF-4	"	2	"	5519	"	5773
5 ORF-5	"	1	"	7966	"	8279

The LTR (long terminal repeats) can be defined as lying between position 8560 and position 160 (and extending over position 9097/1). As a matter of fact the end of the genome is at 9097 and, because of the LTR structure of the retrovirus, links up with the beginning of the sequence :

Hind III
CTCAATAAAAGCTTGCCTTG
 ↑↑
 9097 1

The invention concerns more particularly all the DNA fragments which have been more specifically referred to hereabove and which correspond to open reading frames. It will be understood that the man skilled in the art will be able to obtain them all, for instance by cleaving an entire DNA corresponding to the complete genome of a LAV species, such as by cleavage by a partial or complete digestion thereof with a suitable restriction enzyme and by the subsequent recovery of the relevant fragments. The different DNAs disclosed in the earlier mentioned British Application can be resorted to also as a source of suitable fragments. The techniques disclosed hereabove for the isolation of the fragments which were then included in the plasmids referred to hereabove and which were then used for the DNA sequencing can be used.

Of course other methods can be used. Some of them have been exemplified in the earlier British Application. reference is for instance made to the following methods.

a) DNA can be transfected into mammalian cells with appropriate selection markers by a variety of techniques, calcium phosphate precipitation, polyethylene

glycol, protoplast-fusion, etc..

b) DNA fragments corresponding to genes can be cloned into expression vectors for E. coli, yeast- or mammalian cells and the resultant proteins purified.

5 c) The proviral DNA can be "shot-gunned" (fragmented) into procaryotic expression vectors to generate fusion polypeptides. Recombinant producing antigenically competent fusion proteins can be identified by simply screening the recombinants with antibodies against LAV
10 antigens.

The invention also relates more specifically to cloned probes which can be made starting from any DNA fragment according to this invention, thus to recombinant DNAs containing such fragments, particularly any plasmids
15 amplifiable in procaryotic or eucaryotic cells and carrying said fragments.

Using the cloned DNA fragments as a molecular hybridization probe - either by marking with radionucleotides or with fluorescent reagents - LAV virion RNA may be
20 detected directly in the blood, body fluids and blood products (e.g. of the antihemophylic factors such as Factor VIII concentrates) and vaccines, i.e. hepatitis B vaccine. It has already been shown that whole virus can be detected in culture supernatants of LAV producing cells. A
25 suitable method for achieving that detection comprises immobilizing virus onto said a support e.g. nitrocellulose filters, etc., disrupting the virion and hybridizing with labelled (radiolabelled or "cold" fluorescent- or enzyme-labelled) probes. Such an approach has already been
30 developed for Hepatitis B virus in peripheral blood (according to SCOTTO J. et al. Hepatology (1983), 3, 379-384).

Probes according to the invention can also be used for rapid screening of genomic DNA derived from the tissue
35 of patients with LAV related symptoms, to see if the proviral DNA or RNA is present in host tissue and other

tissues.

A method which can be used for such screening comprise the following steps : extraction of DNA from tissue, restriction enzyme cleavage of said DNA, electrophoresis of the fragments and Southern blotting of genomic DNA from tissues, subsequent hybridization with labelled cloned LAV proviral DNA. Hybridization in situ can also be used.

Lymphatic fluids and tissues and other non-lymphatic tissues of humans, primates and other mammalian species can also be screened to see if other evolutionary related retrovirus exist. The methods referred to hereabove can be used, although hybridization and washings would be done under non stringent conditions.

The DNA according to the invention can be used also for achieving the expression of LAV viral antigens for diagnostic purposes.

The invention also relates to the polypeptides themselves which can be expressed by the different DNAs of the inventions, particularly by the ORFs or fragments thereof, in appropriate hosts, particularly procaryotic or eucaryotic hosts, after transformation thereof with a suitable vector previously modified by the corresponding DNAs.

These polypeptides can be used as diagnostic tools, particularly for the detection of antibodies in biological media, particularly in sera or tissues of persons afflicted with pre-AIDS or AIDS, or simply carrying antibodies in the absence of any apparent disorders. Conversely the different peptides according to this invention can be used themselves for the production of antibodies, preferably monoclonal antibodies specific of the different peptides respectively. For the production of hybridomas secreting said monoclonal antibodies conventional production and screening methods are used. These monoclonal antibodies, which themselves are part of

the invention than provide very useful tools for the identification and even determination of relative proportions of the different polypeptides or proteins in biological samples, particularly human samples containing
5 LAV or related viruses.

Thus all of the above peptides can be used in diagnostics as sources of immunogens or antigens free of viral particles, produced using non-permissive systems, and thus of little or no biohazard risk.

10 The invention further relates to the hosts (procar-
yotic or eucaryotic cells) which are transformed by the above mentioned recombinants and which are capable of expressing said DNA fragments.

Finally it also relates to vaccine compositions
15 whose active principle is to be constituted by any of the expressed antigens, i.e. whole antigens, fusion polypep-
tides or oligopeptides in association with a suitable pharmaceutical or physiologically acceptable carrier.


Preferably the active principles to be considered
20 in that field consist of the peptides containing less than 250 aminoacid units, preferably less than 150 as deducible for the complete genomes of LAV, and even more preferably those peptides which contain one or more groups selected from N-X-S and N-X-T as defined above. Preferred peptides
25 for use in the production of vaccinating principles are peptides (a) to (f) as defined above. By way of example having no limitative character, there may be mentioned that suitable dosages of the vaccine compositions are those which enable administration to the host,
30 particularly human host ranging from 10 to 500 micrograms per kg, for instance 50 to 100 micrograms per kg.

For the purpose of clarity figs. 19 to 26 are added. reference may be made thereto in case of difficul-
ties of reading blurred parts of figs. 4 to 12.

Needless to say that figs. 19-26 are merely a reiteration of the whole DNA sequence of the LAV genoma.

Finally the invention also concerns vectors for the transformation of eucaryotic cells of human origin, particularly lymphocytes, the polymerases of which are capable of recognizing the LTRs of LAV. Particularly said vectors are characterized by the presence of a LAV LTR therein, said LTR being then active as a promoter enabling the efficient transcription and translation in a suitable host of the above defined, of a DNA insert coding for a determined protein placed under its controls.

Needless to say that the invention extends to all variants of genomes and corresponding DNA fragments (ORFs) having substantially equivalent properties, all of said genomes belonging to retroviruses which can be considered as equivalents of LAV.



CLAIMS

1. A DNA fragment of LAV extending from nucleotide position 238 to nucleotide position 1759.
2. A DNA fragment of LAV extending from nucleotide position 1555 to nucleotide position 5086.
3. A DNA fragment of LAV extending from nucleotide position 5670 to nucleotide position 8132.
4. A vector containing a DNA fragment according to any of claims 1 to 3.
5. Peptide corresponding to any of those encoded by the nucleotide sequences which extend respectively between the following positions :
 - a) from about 6095 to about 6200
 - b) " " 6260 " " 6310
 - c) " " 6390 " " 6440
 - d) " " 6485 " " 6620
 - e) " " 6860 " " 6930
 - f) " " 7535 " " 7630
6. Peptide characterized by a sequence of amino-acids deducible from LAV DNA the terminal aminoacids of which extend between the following positions with respect to the lysine (position 1) coded by the AAA at position 5670-5672 in the LAV DNA.

	8-23 aminoacids inclusive
25	63-78 " "
	82-90 " "
	97-123 " "
	127-183 " "
	197-201 " "
30	239-294 " "
	300-327 " "
	334-381 " "
	397-424 " "
	466-500 " "
35	510-523 " "
	551-577 " "

	594-603	-	-
	621-630	-	-
	657-679	-	-
	719-758	-	-
5	780-803	-	-

or any combination of these peptides.

7. Peptide corresponding to the aminoacid sequences deducible from LAV DNA and the terminal aminoacids of which are positioned at the positions hereafter counted from the Met at position 1 coded by the ATG sequence at nucleotide positions 260-2 :

	12-32 aminoacids inclusive
	37-46 " "
	49-79 " "
15	88-153 " "
	158-165 " "
	178-188 " "
	200-220 " "
	226-234 " "
20	239-264 " "
	288-331 " "
	352-361 " "
	377-390 " "
	399-432 " "
25	437-484 " "
	492-498 " "

and combination of said peptides.

8. Diagnostic means containing any of the DNA fragments of any of claims 1 to 3.

9. Diagnostic means containing any of the peptides of any of claims 4 to 6.


10. Vaccine compositions containing any of the peptides according to any of claims 4 to 6 in association with a pharmaceutical vehicle.

ABSTRACT

This invention is in the field of lymphadenopathy virus. This invention relates to a diagnostic means and method to detect the presence of DNA, RNA or antibodies of the lymphadenopathy retrovirus associated with the acquired immune deficiency syndrome or of the lymphadenopathy syndrome by the use of DNA fragments or the peptides encoded by said DNA fragments. The invention further relates to the DNA fragments, vectors comprising them and the proteins expressed.

7/1240

FIG.1.



23

111278




Fig. 2

111248




Fig. 3

1
 2
 3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525
 526
 527
 528
 529
 530
 531
 532
 533
 534
 535
 536
 537
 538
 539
 540
 541
 542
 543
 544
 545
 546
 547
 548
 549
 550
 551
 552
 553
 554
 555
 556
 557
 558
 559
 560
 561
 562
 563
 564
 565
 566
 567
 568
 569
 570
 571
 572
 573
 574
 575
 576
 577
 578
 579
 580
 581
 582
 583
 584
 585
 586
 587
 588
 589
 590
 591
 592
 593
 594
 595
 596
 597
 598
 599
 600
 601
 602
 603
 604
 605
 606
 607
 608
 609
 610
 611
 612
 613
 614
 615
 616
 617
 618
 619
 620
 621
 622
 623
 624
 625
 626
 627
 628
 629
 630
 631
 632
 633
 634
 635
 636
 637
 638
 639
 640
 641
 642
 643
 644
 645
 646
 647
 648
 649
 650
 651
 652
 653
 654
 655
 656
 657
 658
 659
 660
 661
 662
 663
 664
 665
 666
 667
 668
 669
 670
 671
 672
 673
 674
 675
 676
 677
 678
 679
 680
 681
 682
 683
 684
 685
 686
 687
 688
 689
 690
 691
 692
 693
 694
 695
 696
 697
 698
 699
 700
 701
 702
 703
 704
 705
 706
 707
 708
 709
 710
 711
 712
 713
 714
 715
 716
 717
 718
 719
 720
 721
 722
 723
 724
 725
 726
 727
 728
 729
 730
 731
 732
 733
 734
 735
 736
 737
 738
 739
 740
 741
 742
 743
 744
 745
 746
 747
 748
 749
 750
 751
 752
 753
 754
 755
 756
 757
 758
 759
 760
 761
 762
 763
 764
 765
 766
 767
 768
 769
 770
 771
 772
 773
 774
 775
 776
 777
 778
 779
 780
 781
 782
 783
 784
 785
 786
 787
 788
 789
 790
 791
 792
 793
 794
 795
 796
 797
 798
 799
 800
 801
 802
 803
 804
 805
 806
 807
 808
 809
 810
 811
 812
 813
 814
 815
 816
 817
 818
 819
 820
 821
 822
 823
 824
 825
 826
 827
 828
 829
 830
 831
 832
 833
 834
 835
 836
 837
 838
 839
 840
 841
 842
 843
 844
 845
 846
 847
 848
 849
 850
 851
 852
 853
 854
 855
 856
 857
 858
 859
 860
 861
 862
 863
 864
 865
 866
 867
 868
 869
 870
 871
 872
 873
 874
 875
 876
 877
 878
 879
 880
 881
 882
 883
 884
 885
 886
 887
 888
 889
 890
 891
 892
 893
 894
 895
 896
 897
 898
 899
 900
 901
 902
 903
 904
 905
 906
 907
 908
 909
 910
 911
 912
 913
 914
 915
 916
 917
 918
 919
 920
 921
 922
 923
 924
 925
 926
 927
 928
 929
 930
 931
 932
 933
 934
 935
 936
 937
 938
 939
 940
 941
 942
 943
 944
 945
 946
 947
 948
 949
 950
 951
 952
 953
 954
 955
 956
 957
 958
 959
 960
 961
 962
 963
 964
 965
 966
 967
 968
 969
 970
 971
 972
 973
 974
 975
 976
 977
 978
 979
 980
 981
 982
 983
 984
 985
 986
 987
 988
 989
 990
 991
 992
 993
 994
 995
 996
 997
 998
 999
 1000
 1001
 1002
 1003
 1004
 1005
 1006
 1007
 1008
 1009
 1010
 1011
 1012
 1013
 1014
 1015
 1016
 1017
 1018
 1019
 1020
 1021
 1022
 1023
 1024
 1025
 1026
 1027
 1028
 1029
 1030
 1031
 1032
 1033
 1034
 1035
 1036
 1037
 1038
 1039
 1040
 1041
 1042
 1043
 1044
 1045
 1046
 1047
 1048
 1049
 1050
 1051
 1052
 1053
 1054
 1055
 1056
 1057
 1058
 1059
 1060
 1061
 1062
 1063
 1064
 1065
 1066
 1067
 1068
 1069
 1070
 1071
 1072
 1073
 1074
 1075
 1076
 1077
 1078
 1079
 1080
 1081
 1082
 1083
 1084
 1085
 1086
 1087
 1088
 1089
 1090
 1091
 1092
 1093
 1094
 1095
 1096
 1097
 1098
 1099
 1100
 1101
 1102
 1103
 1104
 1105
 1106
 1107
 1108
 1109
 1110
 1111
 1112
 1113
 1114
 1115
 1116
 1117
 1118
 1119
 1120
 1121
 1122
 1123
 1124
 1125
 1126
 1127
 1128
 1129
 1130
 1131
 1132
 1133
 1134
 1135
 1136
 1137
 1138
 1139
 1140
 1141
 1142
 1143
 1144
 1145
 1146
 1147
 1148
 1149
 1150
 1151
 1152
 1153
 1154
 1155
 1156
 1157
 1158
 1159
 1160
 1161
 1162
 1163
 1164
 1165
 1166
 1167
 1168
 1169
 1170
 1171
 1172
 1173
 1174
 1175
 1176
 1177
 1178
 1179
 1180
 1181
 1182
 1183
 1184
 1185
 1186
 1187
 1188
 1189
 1190
 1191
 1192
 1193
 1194
 1195
 1196
 1197
 1198
 1199
 1200
 1201
 1202
 1203
 1204
 1205
 1206
 1207
 1208
 1209
 1210
 1211
 1212
 1213
 1214
 1215
 1216
 1217
 1218
 1219
 1220
 1221
 1222
 1223
 1224
 1225
 1226
 1227
 1228
 1229
 1230
 1231
 1232
 1233
 1234
 1235
 1236
 1237
 1238
 1239
 1240
 1241
 1242
 1243
 1244
 1245
 1246
 1247
 1248
 1249
 1250
 1251
 1252
 1253
 1254
 1255
 1256
 1257
 1258
 1259
 1260
 1261
 1262
 1263
 1264
 1265
 1266
 1267
 1268
 1269
 1270
 1271
 1272
 1273
 1274
 1275
 1276
 1277
 1278
 1279
 1280
 1281
 1282
 1283
 1284
 1285
 1286
 1287
 1288
 1289
 1290
 1291
 1292
 1293
 1294
 1295
 1296
 1297
 1298
 1299
 1300
 1301
 1302
 1303
 1304
 1305
 1306
 1307
 1308
 1309
 1310
 1311
 1312
 1313
 1314
 1315
 1316
 1317
 1318
 1319
 1320
 1321
 1322
 1323
 1324
 1325
 1326
 1327
 1328
 1329
 1330
 1331
 1332
 1333
 1334
 1335
 1336
 1337
 1338
 1339
 1340
 1341
 1342
 1343
 1344
 1345
 1346
 1347
 1348
 1349
 1350
 1351
 1352
 1353
 1354
 1355
 1356
 1357
 1358
 1359
 1360
 1361
 1362
 1363
 1364
 1365
 1366
 1367
 1368
 1369
 1370
 1371
 1372
 1373
 1374
 1375
 1376
 1377
 1378
 1379
 1380
 1381
 1382
 1383
 1384
 1385
 1386
 1387
 1388
 1389
 1390
 1391
 1392
 1393
 1394
 1395
 1396
 1397
 1398
 1399
 1400
 1401
 1402
 1403
 1404
 1405
 1406
 1407
 1408
 1409
 1410
 1411
 1412
 1413
 1414
 1415
 1416
 1417
 1418
 1419
 1420
 1421
 1422
 1423
 1424
 1425
 1426
 1427
 1428
 1429
 1430
 1431
 1432
 1433
 1434
 1435
 1436
 1437
 1438
 1439
 1440
 1441
 1442
 1443
 1444
 1445
 1446
 1447
 1448
 1449
 1450
 1451
 1452
 1453
 1454
 1455
 1456
 1457
 1458
 1459
 1460
 1461
 1462
 1463
 1464
 1465
 1466
 1467
 1468
 1469
 1470
 1471
 1472
 1473
 1474
 1475
 1476
 1477
 1478
 1479
 1480
 1481
 1482
 1483
 1484
 1485
 1486
 1487
 1488
 1489
 1490
 1491
 1492
 1493
 1494
 1495
 1496

3
 1090
 1100
 1110
 1120
 1130
 1140
 1150
 1160
 1170
 1180
 1190
 1200

K N V O P T J M S C H K I A T K N K L P L P L C C K P V L P N S N S H A S S I C G A
 A P S P S I L D I D J D K K E P F T V E K F V P I L Q A E O A S O L V A N
 L C I A T P A F N I O D K A P I F T M O C S I T M O P S K L M B O A
 A G A A G I G I A G C C C T A C C A G A T T C T G A A G A C G C C A A A G A C C C T T A C A G A T T A G C C T T A A A C T T A A G C C A G C C A G C C A A A
 1090
 1100
 1110
 1120
 1130
 1140
 1150
 1160
 1170
 1180
 1190
 1200

50
 K L D D A V L V C P K C E P A L O D V F K S I C G T S V T R N M D S Y S G S C
 M A I E T L L V M A N P U R K T I L K A L C P A A T L E E P M T A C O G V L
 I C O J E H P C A V K M A T Q I V R L F P W D O L H M K P O M V R E N E
 A A T T C G A T C A C A A C C T T G T C C A A A T G G A A C C G A T C T T A A A G T A T T G G A C C A G C A C T A C A C A G A A N T G A C A C T C A G C A G G C G T C C
 1210 1220 1230 1240 1250 1260 1270 1280 1290 1300 1310 1320

R T R P O G A S F G O S M E P S N K I S Y H U D A K R O F O F P K K D C O V F W
 G P G H A B V L A E A S O V T M S A T I M J R G N F M O K I V K C F N
 O P A I H J F L C P O A K O I L P O C K E A I L G T K E R L S V S I
 A G A C C C G G C C A T A G C A G A G T T T G C T A G C A G C A A T T C A L T A C C A A G A G C A A T T T T G G A C C A A G A G A A T T G T A C T C T T C A A
 1130 1140 1150 1165 1172 1180 1190 1200 1210 1220 1230 1240

[illegible][illegible][illegible][illegible][illegible]

Fig. 5

[illegible]

771248

5.8.9

[illegible]

Q A F H L K T A V Q " A V F I M D F A R K C G I C G V S A C E R I V D I I A T O

N L M I L K O O V K W O Y S S I L K E N W G L C G I V C G N E P T P O O T
 G P T S O S T M G S I M P O F O K M B G D W E V Q C R G K N S R H M S N A H
 C A G G C T C A A C T C T T A A G C A G C A A A T G C G A T T C T C C A C A T T T T A A A G A A A G G G G G C G A T T G C C G G C I A A C T C C A G A A G A A C T A C T A C A C A T T A C C A A G A C
 4210 4220 4230 4240 4250 4260 4270 4280 4290 4300 4310 4320

I O T K E L O R Q I T K I O M F R V Y Y R D S R E D P L M H C P O A K L L V N K E C
 V K L N M Y K M K L O M F R I F C I T C T A O A S H L F C R D T S K A P L E B R G
 T N O R I T K Y M N M S F C L L O Q O A S H L F C R D T S K A P L E B R G
 A T A C A A C A T A A A C A A T A C A A A T T T C G G T T A T C A G G C A C A G A G A C T C C T T G G A A G A C C A G A A C C T C T C G A A G C G A C G C
 4330 4340 4350 4360 4370 4380 4390 4400 4410 4420 4430

A V I D N S D I K V V P R K I I R D Y G K M A G D D C V A S R O D E
 J S Y R I V I K S C U K L K U S L I M E M H A Q V I V C W O N H P
 S M T R I O H K S A K K S D H M C L M T D G B V I C K A G T C G
 : C A L T A G T A C A G A T A A G T A G T C C C A G A A A G C A A G C A I T A G G C A T T G G A A C C G C A T T G C C A G A C A G G A T C A G
 6640 6641 6642 6643 6644 6645 6646 6647 6648 6649 6650 6651 6652 6653 6654 6655 6656 6657 6658 6659 6660

2 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100
 : * M T C A F S K T P V C J R I S - C - V L O T S L O N P S S M N F R S T M
 I E T A K S L V K H M V S C K A N G C F V R M H V E S P H P A I S E V M I S
 L E M K N V O T I C M F O G K L C D G F I T M A L I E V O V M T S
 G A T T A C A C A T G A A A A C C A T A G T G T T T C C G G A A G C I A G G G A T T T A G C A C A T C A T A G C C C C C C C C C C A G C A T A G C A T C A C A T
 4370 4371 4372 4373 4374 4375 4376 4377 4378 4379 4380 4381 4382 4383 4384 4385 4386 4387 4388 4389 4390 4391 4392 4393 4394 4395 4396 4397 4398 4399 4400 4401 4402 4403 4404 4405 4406 4407 4408 4409 4410 4411 4412 4413 4414 4415 4416 4417 4418 4419 4420 4421 4422 4423 4424 4425 4426 4427 4428 4429 4430 4431 4432 4433 4434 4435 4436 4437 4438 4439 4440 4441 4442 4443 4444 4445 4446 4447 4448 4449 4450 4451 4452 4453 4454 4455 4456 4457 4458 4459 4460 4461 4462 4463 4464 4465 4466 4467 4468 4469 4470 4471 4472 4473 4474 4475 4476 4477 4478 4479 4480 4481 4482 4483 4484 4485 4486 4487 4488 4489 4490 4491 4492 4493 4494 4495 4496 4497 4498 4499 4500 4501 4502 4503 4504 4505 4506 4507 4508 4509 4510 4511 4512 4513 4514 4515 4516 4517 4518 4519 4520 4521 4522 4523 4524 4525 4526 4527 4528 4529 4530 4531 4532 4533 4534 4535 4536 4537 4538 4539 4540 4541 4542 4543 4544 4545 4546 4547 4548 4549 4550 4551 4552 4553 4554 4555 4556 4557 4558 4559 4560 4561 4562 4563 4564 4565 4566 4567 4568 4569 4570 4571 4572 4573 4574 4575 4576 4577 4578 4579 4580 4581 4582 4583 4584 4585 4586 4587 4588 4589 4590 4591 4592 4593 4594 4595 4596 4597 4598 4599 4600 4601 4602 4603 4604 4605 4606 4607 4608 4609 4610 4611 4612 4613 4614 4615 4616 4617 4618 4619 4620 4621 4622 4623 4624 4625 4626 4627 4628 4629 4630 4631 4632 4633 4634 4635 4636 4637 4638 4639 4640 4641 4642 4643 4644 4645 4646 4647 4648 4649 4650 4651 4652 4653 4654 4655 4656 4657 4658 4659 4660 4661 4662 4663 4664 4665 4666 4667 4668 4669 4670 4671 4672 4673 4674 4675 4676 4677 4678 4679 4680 4681 4682 4683 4684 4685 4686 4687 4688 4689 4690 4691 4692 4693 4694 4695 4696 4697 4698 4699 4700 4701 4702 4703 4704 4705 4706 4707 4708 4709 4710 4711 4712 4713 4714 4715 4716 4717 4718 4719 4720 4721 4722 4723 4724 4725 4726 4727 4728 4729 4730 4731 4732 4733 4734 4735 4736 4737 4738 4739 4740 4741 4742 4743 4744 4745 4746 4747 4748 4749 4750 4751 4752 4753 4754 4755 4756 4757 4758 4759 4760 4761 4762 4763 4764 4765 4766 4767 4768 4769 4770 4771 4772 4773 4774 4775 4776 4777 4778 4779 4780 4781 4782 4783 4784 4785 4786 4787 4788 4789 4790 4791 4792 4793 4794 4795 4796 4797 4798 4799 4800 4801 4802 4803 4804 4805 4806 4807 4808 4809 4810 4811 4812 4813 4814 4815 4816 4817 4818 4819 4820 4821 4822 4823 4824 4825 4826 4827 4828 4829 4830 4831 4832 4833 4834 4835 4836 4837 4838 4839 4840 4841 4842 4843 4844 4845 4846 4847 4848 4849 4850 4851 4852 4853 4854 4855 4856 4857 4858 4859 4860 4861 4862 4863 4864 4865 4866 4867 4868 4869 4870 4871 4872 4873 4874 4875 4876 4877 4878 4879 4880 4881 4882 4883 4884 4885 4886 4887 4888 4889 4890 4891 4892 4893 4894 4895 4896 4897 4898 4899 4900 4901 4902 4903 4904 4905 4906 4907 4908 4909 4910 4911 4912 4913 4914 4915 4916 4917 4918 4919 4920 4921 4922 4923 4924 4925 4926 4927 4928 4929 4930 4931 4932 4933 4934 4935 4936 4937 4938 4939 4940 4941 4942 4943 4944 4945 4946 4947 4948 4949 4950 4951 4952 4953 4954 4955 4956 4957 4958 4959 4960 4961 4962 4963 4964 4965 4966 4967 4968 4969 4970 4971 4972 4973 4974 4975 4976 4977 4978 4979 4980 4981 4982 4983 4984 4985 4986 4987 4988 4989 4990 4991 4992 4993 4994 4995 4996 4997 4998 4999 5000

[illegible][illegible][illegible]

Fig. 8

11270

30

[illegible]

Fig. 11

Fig 13

77/248

V * G E U E * E H V D P R L E P W K H P G S O P V
T F E S * K * S O * I L D * S P G S I O E V S L
CAACAGAGGAGAGCAAGAAATGGAAGCAGTAGATCCTAGACTAGAGCCCTGGAAGCATCCAGGAAGTCAGCCTAA
5290 5300 5310 5320 5330 5340 5350

P S L F H N K S L R H L L * G E E A E T A T K T S
O V C F T T K A L G I S Y G R K K R R Q R R R P P
K F V S O O K P * A S P H A G R S G D S D E D L
CCAAGTTTGTTCACAACAAAAGCCTTAGGCATCTCCTATGGCAGGAAGCCGGAGACAGCGACGAAGACCTCC
5410 5420 5430 5440 5450 5460 5470

S T C N A T Y T N S N S S I S S S N N N S N S C V
V H V M O P I U I A I A A L V V A I I I A I V V *
Y * C N L Y K * O * O H * * * O * * * O * L C
AGTACATGTAATSCAACCTATACAAATAGCAATAGCAGCATTAGTAGTAGCAATAATAATAGCAATAGTTGTGTG
5530 5540 5550 5560 5570 5580 5590

I * U V N * * T N R K S R R O W O * E * R R N I S
I U K L I O R L I E R A E D S G N E S E G E I S A
* T G * L I O * * K E O K T V A M R V K E K Y U
AATAGACAGGTTAATTGATAGACTAATAGAAAGAGCAGAAGACAGTGGCAATGAGAGTGAAGGAGAAATATCAGC
5650 5660 5670 5680 5690 5700 5710

Y * * S V V L O K N C G S O S I M G Y L C G F K O
I O D L * C Y R K I V G H S L L W G T C V E G S N
L M I C * S A T E K L W V T V Y Y G V P V W K E A
TATTGATGATCTGTAGTGCTACAGAAAAATTGTGGGTACAGTCTATTATGGGGTACCTGTGTGGAAGGAAGCAA
5770 5780 5790 5800 5810 5820 5830

R Y I * F G P H M P V Y P O T P T H K K * Y * *
G T * C L G H T C L C T H R P O P T R S S I G V G
V H N V W A T H A C V P T O P N P O E V V L V *
AGGTACATAATGTTTGGGCCACACATGCCTGTGTACCCACAGACCCCAACCCACAAGAACTAGTATTGGTAAATC
5890 5900 5910 5920 5930 5940 5950

C H R I * S V Y G I K A * S H V * N * P H S V L V
A * G Y N O F M G S K P K A M C K I N P T L C * F
H E D I I S L * D O S L K P C V K L T P L C V S I
TGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAGCCATGTGTAAAAATTAACCCCACTCTGTGTAGTTI
6010 6020 6030 6040 6050 6060 6070

I P I V V A G K * * W R K E R * K T A L S I S A O
Y O * * * K G H D D G E R R D K K I L F O Y O H K
T * S S S G E M M M E K G E I K * N C S F * N T S T
ATACCAATAGTACTACCGGGGAAATGATGATGGAGAAAGGAGAGATAAAAAACTGCTCTTTCAATATCAGCACAAC
6130 6140 6150 6160 6170 6180 6190

L I * Y O * I M I L P A I R * U V V T P O S L H R
* Y N T H R * * Y Y O L Y V O K L * H L S H Y T G
U I I P I O * N D T T S Y T L T S C * N T S V I T O A
TTGATATAATACCAATAGATAATGATACTACCAGCTATACGTTGACAAGTTGTAACACCTCAGTCATTACACAGG
6250 6260 6270 6280 6290 6300 6310

P R L V L R F * N V I I R R S * E O D H V O M S A

Fig 14

111276

D G S D P K T A C T T C Y C K K C C F H C
Q E V S L K L L V P L A I V K S V A F I A
AGGAAGTCAGCCTAAACTGCTTGACCACTTGCTATTGTAAAAAGTTGCTTTTCATTG
5350 5360 5370 5380 5390 5400

A T K T S S R Q S D S S S F S I K A V S
D R R P P Q G S G T H Q V S L S K O * V
S D E D L L K A V R L I K F L Y Q S S K *
AGCGACGAAGACCTCCTCAAGGCAGTCAGACTCATCAAGTTTCTCTATCAAAGCAGTAAGT
5470 5480 5490 5500 5510 5520

S N S C V V H S N H R I * E N I K T K K
I A I V V W S I V I I E Y R K I L R O R K
* Q * L C G P * * S * N I G K Y * D K E K
TAGCAATAGTTGTGGTCCATAGTAATCATAGAATATAGGAAAATATTAAGACAAAGAAA
5590 5600 5610 5620 5630 5640

R R N I S T C G D G G G N G A P C S L G
G E I S A L V E M G V E M G H H A P W D
K E K Y Q H L W R W G W K W G T M L L G I
TAGGAGAAATATCAGCACTTGTTGGAGATGGGGGTGGAAATGGGGCACCATGCTCCTTGGGA
5710 5720 5730 5740 5750 5760

C G F K Q P P L Y F V H Q M L K H M I Q
V E G S N H H S I L C I R C * S I * Y R
V W K E A T T T L F C A S D A K A Y D T E
TGTGGAAGGAAGCAACCACCACTCTATTTTGTGCATCAGATGCTAAAGCATATGATACAG
5830 5840 5850 5860 5870 5880

* Y * * M * O K I L T C G K M T W * N R
V S I G K C D R K F * H V E K * H G R T D
V V L V N V T E N F N M W K N D M V E Q M
TAGTATTGGTAAATGTGACAGAAAATTTTAACATGTGCAAAATGACATGGGTAGAACAGA
5950 5960 5970 5980 5990 6000

H S V L V * S A L T W G * L L I P I V V
T L C * F K V H * F G E C Y * Y O * *
L C V S L K C T D L G N A T N T N S S N
CACTCTGTGTTAGTTTAAAGTGCAGTGAATTTGGGGATGCTACTAATACCAATAGTAGTA
6070 6080 6090 6100 6110 6120

S I S A Q A * E V R C P K N M H F F I N
Q Y Q H K H K R * G A E R I C I F L * T
N I S T S I R G K V G K E Y A F F Y K L
TCAATATCAGCACAAGCATAAGAGGTAAGGTCCAGAAAGAAATATGCATTTTTTATAAAC
6170 6200 6210 6220 6230 6240

U S L H R P V Q R Y P L S Q F P Y I I V
S H Y T G L S K G I L * A N S H T L L C
S V I T O A C P K V S F E P I P I H Y C A
CAGTCATTACACAGGCTGTCCAAAGGTATCCTTTGAGCCAATTCCCATACATTATTGTG
6310 6320 6330 6340 6350 6360

V Q M S A Q Y N V H * F L G Q * Y Q L N

360

Fig 15

771248

P G W F C D S K Y * | * * V J W N R T M Y K C Q
P A G F A I L K C H N K T F N G T G P C T N V S
CCCCGGCTGGTTTTGCGATTCTAAAAATGTAATAAAGACGTTCAATGGAACAGGACCATGTACAAATGTCAGG
6370 6380 6390 6400 6410 6420 6430

C C * N A V * O K K R * * L D L P I S Q T N L K P
A V E W O S S R R R G S N * I C O F H R Q C * N
L L N G S L A E E E V V I R S A N F T D N A K T
TCTGTTCGAATGCCACTCTAGCAGAAGAAGAGGTAGTAATTAGATCTGCCAATTCACAGACAATGCTAAAACC
6490 6500 6510 6520 6530 6540 6550

P T T I Q E K V S V S R G D Q G E H L L Q * E K *
U Q Q Y K K K Y P Y P E G T R E S I C Y N R K N
N N N T R K S I R I O R G P G R A F V T I G K I
CCAACAACAATACAAGAAAAAGTATCCGTATCCAGAGGGGACCAGGGAGAGCATTGTGTTACAATAGGAAAAATA
6610 6620 6630 6640 6650 6660 6670

M P L * N R * L A N * E N N L E I I K Q * S L S N
C H F K T D S * Q I K R T I H K * * N N N L * A
A T L K Q I A S K L R E O F C N N K T I I F K Q
ATGCCACTTTAAACAGATAGCTAGCAAAATTAAGAGAACAATTTGGAATAATAAAACAATAATCTTTAAGCAA
6730 6740 6750 6760 6770 6780 6790

I G N F S T V I O H N C L I V L G L I V L G V L K
H G I F L L * F N T T V * * Y L V * * Y L E Y *
G E F F Y C N S T Q L F N S T W F N S T W S T E
GAGGGGAATTTTCTACTGTAATTCACACAACTGTTAATAGTACTTGGTTAATAGTACTTGGAGTACTGAA
6850 6860 6870 6880 6890 6900 6910

E * N N L * T C G R K * E K Q C M P L P S A D K L
N K T I Y K H V A G S R K S N V C P S H Q R T N
I K O F I N M H O E V G K A M Y A P P I S G Q I
GAATAAAACAATTTATAAACATGTGGCAGGAAGTAGCAAAAGCAATGTATGCCCTCCCATCAGCGGACAAATT
6970 6980 6990 7000 7010 7020 7030

V I T T M G P R S S D L E E E I * G T I G E V N Y
* * O Q W V R D L O T W R R Y E G O L E K * I I
N N N N G S E I F R P G G G D M R O N W R S E L
GTAATAACAACAATGGGTCGAGATCTTCAGACCTGGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTAT
7090 7100 7110 7120 7130 7140 7150

P R Q R E E W C R E K K E Q W E * E L C S L G S W
O G K E K S G A E R K K S S G N R S F V P W V L G
K A K R R V V Q R E K R A V G I G A L F L G F L
CCAAGGCAAGAGAAGAGTGGTGCAGAGAGAAAAAGAGCAGTCCGAATAGGAGCTTTGTTCTTGGTTCTTGG
7210 7220 7230 7240 7250 7260 7270

Y R P O N Y C L V * C S S R T I C * G L L R R N S
T G O T I I V W Y S A A A E Q F A E G Y * G A T A
O A R O L L S G I V O Q O N N L L R A I E A Q O
TACAGGCCAGACAATTATTGTCTGTATAGTGCAGCACCAGAACAAATTTGCTGAGGGCTATTGAGGCGCAACAGC
7330 7340 7350 7360 7370 7380 7390

E S A L H K D T * R I N S S W G F G V A L E N S F

Fig. 16

771248

N R T M Y K C Q H S T M Y T W N * A S S I N S T
 T G P C T N V S T V Q C T M G I R * V V S T U L
 AACAGGACCATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTATCAACTCAAC
 6420 6430 6440 6450 6460 6470 6480

A I S O T M L K P * * Y S * T N L * K L I V U D
 D F H R O C * N H N S T A E P I C R N * L Y K T
 N F T D N A K T I I V Q L N Q S V E I N C T R P
 CAATTTACAGACAATGCTAAAACCATAATAGTAGAGCTGAACCAATCTGTAGAAATTAATTTGTACAAGAC
 6540 6550 6560 6570 6580 6590 6600

F H L L O * E K * E I * D K H I V T L V F O N G
 S I C Y N R K N R K Y E T S T L * H * S K M E
 A F V T I G K I G N * R Q A H C N I S R A K W N
 AGCATTGTGTACATAGGAAAAATAGGAAATATGAGACAAGCACATTGTAAACATTAGTAGAGCAAAATGCA
 6640 6670 6680 6690 6700 6710 6720

I I K Q * S L S N P Q E G T Q K L * R T V L I V
 * * N N V L * A I L R R G P R N C N A O F * L W
 N K T I I F K Q S S G G D P E I V T H S F N C G
 TAATAAAACAATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAAATTGTAACGCACAGTTTAAATTGTG
 6780 6790 6800 6810 6820 6830 6840

L I V L G V L K G Q I T L K E V T O S H S H A
 V * * Y L E Y * R V K * H * R K * H V H T P M Q
 F N S T W S T E G S N N T E G S O T I T L P C R
 TTTAATAGTACTTGGAGTACTGAAGGGTCAATAACACTGAAGGAAGTGACACAATCACACTCCCATGCA
 6900 6910 6920 6930 6940 6950 6960

P L P S A D K L D V H O I L Q G C Y * Q E M V
 C P S H O R T N * M F I K Y Y R A A I N K R W W
 A P P I S G O I R C S S N I T G L L L T R D G G
 TGGCCCTCCCATCAGCGGACAAATAGATGTTTCATCAAAATATTACAGGGCTGCTATTAACAAGAGATGGTG
 7020 7030 7040 7050 7060 7070 7080

G T I G E V N Y I N I K * * K L N H * E * H P
 E G O L E K * I I * I * S S K N * T I R S S T H
 R O N W R S E L Y K Y K V V K I E P L G V A P T
 CAGGCACAATTGGAGAAGTGAATTATATAAATATAAAGTAGTAAAAATTGAACCATAGGAGTAGCACCCA
 7140 7150 7160 7170 7180 7190 7200

E L C S L G S H E O D E A L W A H G O * R * R
 R S F V P W V L G S S R K H Y G R T V N D A D G
 G A L F L G F L G A A G S T M G A R S M T L T V
 AGGAGCTTTGTTCTTGGGTTCTTGGGAGCAGCAGCAAGCACTATGGGGCACGGTCAATGACGCTGACGG
 7260 7270 7280 7290 7300 7310 7320

* G L L R R N S I C C N S O S G A S S S S R O
 A E G Y * G A T A S V A T H S L G H D A A P G K
 L R A I E A O O H L L Q L T V W G I K O L Q A R
 CTGAGCGCTATTGACGGCCAAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAA
 7380 7390 7400 7410 7420 7430 7440

G V A L E N S F A P L L C L G * L V G V I N L 28

Fig 17

77/248

N P C C G K I P K G S T A P G D L G L L W K T M
I L A V E R Y L K D O U L L G I W G C S G K L I
GAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTGGGGTTGCTCTGGAAAACATCAT
7450 7460 7470 7480 7490 7500 7510

W N R F G I T * P G W S G T E K L T I T O A * Y
G T D L E * H D L D G V G O R N * O L M K L N T
E O I W N N H Y W M E W D R E I N N Y T S L I H
TGAACAGATTGGGAATAACATGACCTGGATGGAGTGGGACAGAGAAATTAACAATTACACAAGCTTAATACA
7570 7580 7590 7600 7610 7620 7630

N Y W N * I N G O V C G I G L T * G I G C G I *
I I G I R * M G K F V E L V * H N K L A V V Y K
L L E L D K W A S L W N W F N I T N W L W Y I K
AATTATTGGAATTAGATAAATGGGCAAGTTTGTGGAATTGCTTTAACATAACAAATTGGCTGTGCTATATAAA
7690 7700 7710 7720 7730 7740 7750

L L Y F L * * I E L G R D I H H Y R F R P T S Q I
C C T F Y S E * S * A G G I F T I I V S D P P P N
A V L S I V / N R V R O G Y S P L S F O T H L P T
TTGCTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATATTACCATTATCGTTTCAGACCCACCTCCCAACI
7810 7820 7830 7840 7850 7860 7870

R E T E T D P F D * * T D P * H L S G T I C G A I
E R U P Q I H S I S E R I L S T Y L G R S A E P
R D R D R S I R L V N G S L A L I W D D L R S L
AGAGAGACAGACAGATCCATTGATTAGTGAACGGATCCTTAGCACTTATCTGGGACGATCTGCCGAGCCT
7930 7940 7950 7960 7970 7980 7990

T R I V E L L G R G H E A L K Y W W N L L O Y
R G L W N F W D A G G G K P S N I G G I S Y S I
E D C G T S G T O G V G S P O I L V E S P T V L
ACGAGCATTGTGGAACCTTCTGGGACCCAGGGGGTGGGAAGCCCTCAAAATATTGGTGGAAATCTCTACAGTATT
8050 8060 8070 8080 8090 8100 8110

A I A V A E G T D R V I E V V O G A C R A I R H I
P * J * L R G O I G L * K * Y K E L V E L F A T
H S S S * G D R * G Y K S S T R S L * S Y S P H
GCCATAGCAGTACCTGAGGGGACAGATAGGGTTATAGAAGTAGTACAAGGACCTTGACAGCTATTGCCACAT
8170 8180 8190 8200 8210 8220 8230

G W O V V K K * C G W H A Y C K G K N E T S * A S
G G K W S K S S V V G W P T V R E R M R A E P
V A S G O K V V W L D G L L * G K E * D E L S O
GGGTGGCAAGTGGTCAAAAAGTAGTGTGGTTGGATGGCCTACTGTAAGGGAAGAATGACAGGAGCTGAGCCAG
8290 8300 8310 8320 8330 8340 8350

S N H K * O Y S S Y O C C L C L A R S T R G G G G
A I T S S H T A A T N A A C A W L F A O E E E E
O S O V A I U O L P N L L V P G * K H K R R R
ACCAATCACAAGTAGCAATACAGCAGCTACCAATGCTGCTTGTGCTGGCTTGAAGGACAGAGGAGGAGGAGG
8410 8420 8430 8440 8450 8460 8470

U G S C R S * P L F K R K G G T G
39
15/15

111248

Fig 18

A K T H L H H C G A L E C * L E * * I S
G K L M I C T T A V P W N A S M S N K L
TGGAAACTCATTTCACCACTGCTGTGCCTTGGAAATGCTAGTTGGAGTAATAAATCTC
7510 7520 7530 7540 7550 7560

Q A * Y I P * L K N R K T S K K R M N K
K L N T F L N * R I A K P A R K E * T R
S L I H S L I E E S O V O O E K N E O E
AAGCTTAATACATTCTTAATTGAAGAATCGCAAAACCAGCAAGAAAAGAAATGAACAAG
7630 7640 7650 7660 7670 7680

C G I * K Y S * * * * E A W * V * E * F
V V Y K N I H N D S R R L G R F K N S F
W Y I K I F I M I V G G L V G L / R / I V F
GTGGTATATAAAATATTCATAATGATAGTAGGAGGCTTGCTAGGTTTAAGAATAGTTT
7750 7760 7770 7780 7790 7800

P T S Q P R G D P T G P K E * K K K V E
P P P N P E G T R O A R R N R R R R W R
H L P T P R G P D R P E G I E E E G G E
CCACCTCCCAACCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGGTGGAG
7870 7880 7890 7900 7910 7920

I C G A L C L F S Y H R L R D L L L I V
S A E P C A S S A T T A * E T Y S * L *
L R S L V P L O L P P L E R L T L D C N
TCTGCCGAGCCTTGTGCTCTTCAGTACCACCGCTTGAGAGACTTACTCTTGATTGTA
7990 8000 8010 8020 8030 8040

L L O Y H S O E L K N S A V S L L N A T
S Y S I G V R N * R I V L L A C S M P O
P T V L E S G T K E * C C * L A O C H S
TCCTACAGTATTGGAGTCAGGAACATAAGAATAGTGCTGTTAGCTTGCTCAATGCCACA
8110 8120 8130 8140 8150 8160

A I R H I P R R I R O G L E R I L L * D
L F A T Y L E E * D R A W K G F C Y K M
Y S P H T * K N K T G L G K O F A I R W
CTATTGCCACATACCTAGAAGAATAAGACAGGGCTTGGAAAGGATTTTGCTATAAGAT
8230 8240 8250 8260 8270 8280

T S * A S S R W G G S S I S R P G K T W
R A E P A A D G V G A A S R D L E K H G
E L S O O * G W E O H L E T W K N M E
GAGCTGAGCCAGCAGCAGATGGGGTGGGAGCAGCATCTCGAGACCTGGAAAAACATCG
8350 8360 8370 8380 8390 8400

G G G G G F S S H T S G T F K T N D L
E E E E V G F P V T P C V P L R P M T Y
R R R R Y F S S H L R Y L * D O * L T
AGGACGAGGAGGGTTTCCAGTCACACCTCAGGTAGCTTTAAGACCAATGACTTA
8470 8480 8490 8500 8510 8520

L P T A * S V D L P H T R L L
15/15 B/14

Fig 19

10 20 30 40 50 60
AAGCTTGCTT TGAGTGCTTC AAGTAGTG TGCCCGTCTG TTGTGTGACT CTGGTAACTA
70 80 90 100 110 120
GAGATCCCTC AGACCCTTTT AGTCAGTG TGAAAATCTCT AGCAGTGGCG CCCGAACAGG
130 140 150 160 170 180
GACTTGAAAG CGAAAGGGAA ACCAGAGGAG CTCTCTCGAC GCAGGACTCG GCTTGCTGAA
190 200 210 220 230 240
GCGCGCACGG CAAGAGGCGA GGGGAGGCGA CTGGTGAGTA CGCCAAAAAT TTTGACTAGC
250 260 270 280 290 300
GGAGGCTAGA AGGAGAGAGA TGGGTGCCAG AGCCTCAGTA TTAAGCGGGG CAGAATTAGA
310 320 330 340 350 360
TCGATGGGAA AAAATTCTGGT TAAGGCCAGG GGGAAAGAAA AAATATAAAT TAAAACATAT
370 380 390 400 410 420
AGTATGGGCA AGCAGGGAGC TAGAACGATT CGCTGTTAAT CCTGGCCTGT TAGAAACATC
430 440 450 460 470 480
AGAAGGCTGT AGACAAATAC TGGGACAGCT ACAACCATCC CTTGAGACAG GATCAGAAGA
490 500 510 520 530 540
ACTTAGATCA TTATATAATA CAGTAGCAAC CCTCTATTGT GTGCATCAAA GGATAGAGAT
550 560 570 580 590 600
AAAAGACACC AAGGAAGCTT TAGACAAGAT AGAGGAAGAG CAAAACAAAA GTAAGAAAAA
610 620 630 640 650 660
AGCACAGCAA GCAGCAGCTG ACACAGGACA CAGCAGCCAG GTCAGCCAAA ATTACCCAT
670 680 690 700 710 720
ACTGCAGAAC ATCCAGGGGC AAATGGTACA TCAGGCCATA TCACCTAGAA CTTTAAATGC
730 740 750 760 770 780
ATGGGTAAAA GTAGTAGAAG AGAAGGCTTT CAGCCCAGAA GTGATACCCA TGTTTTCAGC
790 800 810 820 830 840
ATTATCAGAA GGAGCCAACC CACAAGATT AAACACCATG CTAAACACAG TGGGGGGACA
850 860 870 880 890 900
TCAAGCAGCC ATGCAAATGT TAAAAGAGAC CATCAATGAG GAACCTGCAG AATGGGATAG
910 920 930 940 950 960
AGTGCATCCA GTGCATGCAG GGCCTATTGC ACCAGGCCAG ATGAGAGAAC CAAGGGGAAG
970 980 990 1000 1010 1020
TGACATAGCA GGAACACTA GTACCCTTCA GGAACAAATA GGATGGATGA CAAATAATCC
1030 1040 1050 1060 1070 1080
ACCTATCCCA GTAGGAGAAA TTTATAAAG ATGGATAATC CTGGGATTAA ATAAAATAGT
1090 1100 1110 1120 1130 1140

111248

Fig 20

AAATAATGTAT	AGCCCTACCA	GCATTCTGGA	CATAAGAÇAA	GGACCAAAAAG	AACCCCTTTAG
1150	1160	1170	1180	1190	1200
AGACTATGTA	GACCGGTTCT	ATAAAACTCT	AAGAGCCGAG	CAAGCTTCAC	AGGAGGTAAA
1210	1220	1230	1240	1250	1260
AAATTGGATG	ACAGAAACCT	TGTTGGTCCA	AAATGCCAAC	CCAGATTGTA	AGACTATTTT
1270	1280	1290	1300	1310	1320
AAAAGCATTG	GGACCAGCAG	CTACACTAGA	AGAAATGATG	ACAGCATGTC	AGGGAGTGGG
1330	1340	1350	1360	1370	1380
AGGACCCGGC	CATAAGGCAA	CAGTTTTGGC	TGAAGCAATG	AGCCAAGTAA	CAAATTCAGC
1390	1400	1410	1420	1430	1440
TACCATAATG	ATGCAAAGAG	GCAATTTTAG	GAACCAAAGA	AAGATTGTTA	AGTGTTCCTA
1450	1460	1470	1480	1490	1500
TTGTGGCAAA	GAAAGGGACA	TAGCCAGAAA	TTGCAGGGCC	CCTAGGAAAA	AGGGCTGTTG
1510	1520	1530	1540	1550	1560
GAAATGTGGA	AAGGAAGGAC	ACCAAATGAA	AGATTGTACT	GAGAGACAGG	CTAATTTTTT
1570	1580	1590	1600	1610	1620
AGGGAAGATC	TGGCCTTCCT	ACAAGGGAAG	GCCAGGGAAT	TTTCTTCAGA	GCAGACCAGA
1630	1640	1650	1660	1670	1680
GCCAACAGCC	CCACCAGAAG	AGAGCTTCAG	GTCTGGGGTA	GAGACAACAA	CTCCCTCTCA
1690	1700	1710	1720	1730	1740
GAAGCAGGAG	CCGATAGACA	AGGAACGTGA	TCCTTTAACT	TCCCTCAGAT	CACTCTTTGG
1750	1760	1770	1780	1790	1800
CAACGACCCC	TCGTACACAAT	AAAGATAGGG	GGGCAACTAA	AGGAAGCTCT	ATTAGATACA
1810	1820	1830	1840	1850	1860
GGAGCAGATG	ATACAGTATT	AGAAGAAATG	AGTTTGCCAG	GAAGATGGAA	ACCAAAAAATC
1870	1880	1890	1900	1910	1920
ATAGGGGGAA	TTGGAGGTTT	TATCAAAGTA	AGACAGTATG	ATCAGATACT	CATAGAAATC
1930	1940	1950	1960	1970	1980
TGTGGACATA	AAGCTATAGG	TACAGTATTA	GTAGGACCTA	CACCTGTCAA	CATAATTGGA
1990	2000	2010	2020	2030	2040
AGAAATCTGT	TGACTCAGAT	TGGTTGCACT	TTAAATTTTC	CCATTAGTCC	TATTGAAACT
2050	2060	2070	2080	2090	2100
GTACCAGTAA	AATTAAAGCC	AGGAATGGAT	GGCCCAAAAG	TTAAACAATG	CCCATTGACA
2110	2120	2130	2140	2150	2160
GAAGAAAAAA	TAAAGCATT	AGTAGAAAAT	TGTACAGAAA	TGGAAAAGGA	AGGGAAAAAT
2170	2180	2190	2200	2210	2220
TCAAAAATTG	GGCCTGAAAA	TCCATACAAT	ACTCCAGTAT	TTGCCATAAA	GAAAAAAGAC
2230	2240	2250	2260	2270	2280
AGTACTAAAT	GGAGAAAATT	AGTAGATTTT	AGAGAACTTA	ATAAGAGAAC	TCAAGACTTC
2290	2300	2310	2320	2330	2340
TGGGAAGTTC	AATTAGGAAT	ACCACATCCC	GCAGGGTTAA	AAAAGAAAAA	ATCAGTAACA
2350	2360	2370	2380	2390	2400

42

771248

GTCCTGCTATG TGGGTGATGC ATATTTTTC A GTTCCCTTAG ATGAAGACTT CAGGAAGTAT
 2410 2420 2430 2440 2450 2460
 ACTGCATTTA CCATACCTAG TATAAACAAT GAGACACCAG GCATTAGATA TCACTACAAT
 2470 2480 2490 2500 2510 2520
 GTGCTTCCAC AGGGATGGAA AGGATCACCA GCAATATTCC AAAGTAGCAT GACAAAAATC
 2530 2540 2550 2560 2570 2580
 TTAGAGCCTT TTAGAAAAACA AAATCCAGAC ATAGTTATCT ATCAATACAT CGATGATTTG
 2590 2600 2610 2620 2630 2640
 TATGTAGGAT CTGACTTAGA AATAGGGCAG CATAGAACAA AAATAGAGGA GCTGAGACAA
 2650 2660 2670 2680 2690 2700
 CATCTGTTGA GGTGGGGACT TACCACACCA GACAAAAAAC ATCAGAAAGA ACCTCCATTG
 2710 2720 2730 2740 2750 2760
 CTTTGGATGG GTTATGAACT CCATCCTGAT AAATGGACAG TACAGCCTAT AGTGCTGCCA
 2770 2780 2790 2800 2810 2820
 GAAAAAGACA GCTGGACTGT CAATGACATA CAGAAGTTAG TGGGAAAATT GAATTGGGCA
 2830 2840 2850 2860 2870 2880
 AGTCAGATTT ACCCAGGGAT TAAAGTAAGG CAATTATGTA AACTCCTTAG AGGAACCAAA
 2890 2900 2910 2920 2930 2940
 GCACTAACAG AAGTAATACC ACTAACAGAA GAAGCAGAGC TAGAACTGGC AGAAAAACAGA
 2950 2960 2970 2980 2990 3000
 GAGATTCTAA AAGAACCAGT ACATGGAGTG TATTATGACC CATCAAAAAGA CTTAATAGCA
 3010 3020 3030 3040 3050 3060
 GAAATACAGA AGCAGGGGCA AGGCCAATGG ACATATCAAA TTTATCAAQA GCCATTTAAA
 3070 3080 3090 3100 3110 3120
 AATCTGAAAA CAGGAAAAATA TGCAAGAACC AGGGGTGCCC AACTAATGA TGTA AAAACAA
 3130 3140 3150 3160 3170 3180
 TTAACAGAGG CAGTGCAAAA AATAACCACA GAAAGCATAG TAATATGGGG AAAGACTCCT
 3190 3200 3210 3220 3230 3240
 AAATTTAAAC TACCCATACA AAAGGAAACA TGGGAAACAT GGTGGACAGA GTATTGGCAA
 3250 3260 3270 3280 3290 3300
 GCCACCTGGA TTCCTGAGTG GGAGTTTGTC AATACCCCTC CTTTAGTGAA ATTATGGTAC
 3310 3320 3330 3340 3350 3360
 CAGTTAGAGA AAGAACCCAT AGTAGGAGCA GAAACGTTCT ATGTAGATGG GGCAGCTAGC
 3370 3380 3390 3400 3410 3420
 AGGGAGACTA AATTAGGAAA AGCAGGATAT GTTACTAATA GAGGAAGACA AAAAGTTGTC
 3430 3440 3450 3460 3470 3480
 ACCCTAACTG ACACAACAAA TCAGAAGACT GAGTTACAAG CAATTCATCT AGCTTTGCAG
 3490 3500 3510 3520 3530 3540
 GATTGGGGAT TAGAAGTAAA TATAGTAACA GACTCACAAT ATGCATTAGG AATCATTCAA
 3550 3560 3570 3580 3590 3600
 GCACAACCAG ATAAAAGTGA ATCAGAGTTA GTCAATCAAA TAATAGAGCA GTTAATAAAA
 3610 3620 3630 3640 3650 3660

111248

Fig 22

3670 3680 3690 3700 3710 3720
 GTAGATAAAT TAGTCAGTGC TGGCAATCAGG AAAGTACTAT TTTTAGATGG AATAGATAAG
 3730 3740 3750 3760 3770 3780
 GCCCAAGATG AACATGAGAA ATATCACAGT AATTGGAGAG CAATGGCTAG TGATTTTAAC
 3790 3800 3810 3820 3830 3840
 CTGCCACCTG TAGTAGCAAA AGAAATAGTA GCCAGCTGTG ATAAATGTCA GCTAAAAGGA
 3850 3860 3870 3880 3890 3900
 GAAGCCATGC ATGGACAAGT AGACTGTAGT CCAGGAATAT GGCAACTAGA TTGTACACAT
 3910 3920 3930 3940 3950 3960
 TTAGAAGGAA AAGTTATCCT GGTAGCAGTT CATGTAGCCA GTGGATATAT AGAAGCAAGAA
 3970 3980 3990 4000 4010 4020
 GTTATTCCAG CAGAAACAGG GCAGGAAACA GCATACTTTC TTTTAAAATT AGCAGGAAGA
 4030 4040 4050 4060 4070 4080
 TGGCCAGTAA AAACAATACA TACAGACAAAT GGCAGCAATT TCACCAGTAC TACGGTTAAG
 4090 4100 4110 4120 4130 4140
 GCCGCCTGTT GGTGGGCGGG AATCAAGCAG GAATTTGGAA TTCCCTACAA TCCCCAAAGT
 4150 4160 4170 4180 4190 4200
 CAAGGAGTAG TAGAATCTAT GAATAAAGAA TTAAAGAAAA TTATAGGCCA GGTAAGAGAT
 4210 4220 4230 4240 4250 4260
 CAGGCTGAAC ATCTTAAGAC AGCAGTACAA ATGGCAGTAT TCATCCAQAA TTTTAAAAGA
 4270 4280 4290 4300 4310 4320
 AAAGGGGGGA TTGGGGGGTA CAGTGCAAGG GAAAGAATAG TAGACATAAT AGCAACAGAC
 4330 4340 4350 4360 4370 4380
 ATAÇAAACTA AAGAATTACA AAAACAAATT ACAAAAAATC AAAATTTTCG GGTTTATTAC
 4390 4400 4410 4420 4430 4440
 AGGGACAGCA GAGATCCACT TTGGAAAGGA CCAGCAAAGC TCCTCTGGAA AGGTGAAGGG
 4450 4460 4470 4480 4490 4500
 GCAGTAGTAA TACAAGATAA TAGTGACATA AAAGTAGTGC CAAGAAGAAA AGCAAAGATC
 4510 4520 4530 4540 4550 4560
 ATTAGGGATT ATGGAAAACA GATGGCAGGT GATGATTCTG TGGCAAGTAG ACAGGATGAG
 4570 4580 4590 4600 4610 4620
 GATTAGAACA TGGAAAAGTT TAGTAAAACA CCATATGTAT GTTTCAGGGA AAGCTAGGGG
 4630 4640 4650 4660 4670 4680
 ATGGTTTTAT AGACATCACT ATGAAAGCCC TCATCCAAGA ATAAGTTTAC AAGTACACAT
 4690 4700 4710 4720 4730 4740
 CCCACTAGGG GATGCTAGAT TGGTAATAAC AACATATTGG GGTCTGCATA CAGGAGAAAG
 4750 4760 4770 4780 4790 4800
 AGACTGGCAT CTGGGTCAGG GAGTCTCCAT AGAATGGAGG AAAAAGAGAT ATAGCACACA
 4810 4820 4830 4840 4850 4860
 AGTAGACCCT GAACTAGCAG ACCAACTAAT TCATCTGTAT TACTTTGACT GTTTTTCAGA
 4870 4880 4890 4900 4910 4920

44

CTCTCTATA AGAAAGGCTT TATTAGGACA TATAGTTAGC CCTAGGTGTG AATATCAAGC
 4930 4940 4950 4960 4970 4980
 AGGACATAAC AAGGTAGGAT CTCTACAATA CTTGGCACTA GCAGCATTAA TAACACCAAA
 4990 5000 5010 5020 5030 5040
 AAAGATAAAG CCACCTTTGC CTAGTGTTAC GAAACTGACA GAGGATAGAT GGAACAAGCC
 5050 5060 5070 5080 5090 5100
 CCAGAAGACC AAGGGCCACA GAGGGAGCCA CACAATCAAT GGACACTAGA GCTTTTAGAG
 5110 5120 5130 5140 5150 5160
 GAGCTTAAGA ATGAAGCTGT TAGACATTTT CCTAGGATTT GGCTCCATGC CTTAGGGCAA
 5170 5180 5190 5200 5210 5220
 CATATCTATG AAACCTTATGG GGATACTTGG GCAGGAGTGG AAGCCATAAT AAGAATTCTG
 5230 5240 5250 5260 5270 5280
 CAACAACCTGC TGTTTATCCA TTTGAGAAAT GGGTGTGAC ATAGCAGAAT AGGCGTTACT
 5290 5300 5310 5320 5330 5340
 CAACAGAGGA GAGCAAGAAA TGGAGCCAGT AGATCCTAGA CTAGAGCCCT GGAAGCATCC
 5350 5360 5370 5380 5390 5400
 AGGAAGTCAG CCTAAACTG CTTGTACCAC TTGCTATTGT AAAAAAGTGT GCTTTCATTG
 5410 5420 5430 5440 5450 5460
 CCAAGTTTGT TTCACAACAA AAGCCTTAGG CATCTCCTAT GGCAGGAAGA AGCGGAGACA
 5470 5480 5490 5500 5510 5520
 GCGACGAAGA CCTCCTCAAG GCAGTCAGAC TCATCAAGTT TCTCTATCAA AGCAGTAAGT
 5530 5540 5550 5560 5570 5580
 AGTACATGTA ATGCAACCTA TACAAATAGC AATAGCAGCA TTAGTAGTAG CAATAATAAT
 5590 5600 5610 5620 5630 5640
 AGCAATAGTT GTGTGGTCCA TAGTAATCAT AGAATATAGC AAAATATTAA GACAAAGAAA
 5650 5660 5670 5680 5690 5700
 AATAGACAGG TTAATTGATA GACTAATAGA AAGAGCAGAA GACAGTGGCA ATGAGAGTGA
 5710 5720 5730 5740 5750 5760
 AGGAGAAATA TCAGCACTTG TGGAGATGGG GGTGGAAATG GGGCACCATG CTCCTTGGGA
 5770 5780 5790 5800 5810 5820
 TATTGATGAT CTGTAGTGCT ACAGAAAAAT TGTGGGTGAC AGTCTATTAT GGGGTACCTG
 5830 5840 5850 5860 5870 5880
 TGTGGAAGGA AGCAACCACC ACTCTATTTT GTGCATCAGA TGCTAAAGCA TATGATACAG
 5890 5900 5910 5920 5930 5940
 AGGTACATAA TGTTTGGGCC ACACATGCCT GTGTACCCAC AGACCCCAAC CCACAAGAAG
 5950 5960 5970 5980 5990 6000
 TAGTATTGGT AAATGTGACA GAAAAATTTA ACATGTGGAA AAATGACATG GTAGAACAGA
 6010 6020 6030 6040 6050 6060
 TGCATGAGGA TATAATCAGT TTATGGGATC AAAGCCTAAA GCCATGTGTA AAATTAACCC
 6070 6080 6090 6100 6110 6120
 CACTCTGTGT TAGTTTAAAG TGGACTGATT TGGGGAATGC TACTAATACC AATAGTAGTA
 6130 6140 6150 6160 6170 6180

Fig 23

45

7824

ATACCAATAG TAGTAGCGGG GAAATGATGA TGGAGAAAGG AGAGATAAAA AACTGCTCTT
6170 6200 6210 6220 6230 6240
TCAATATCAG CACAAGCATA AGAGGTAAGG TCCAGAAAGA ATATGCCATT TTTTATAAAC
6250 6260 6270 6280 6290 6300
TTGATATAAT ACCAATAGAT AATGATACTA CCAGCTATAC GTTGACAAGT TGTAACACCT
6310 6320 6330 6340 6350 6360
CAGTCATTAC ACAGGCCTGT CCAAAGGTAT CCTTTGAGCC AATTCCCATA CATTATTGTG
6370 6380 6390 6400 6410 6420
CCCCGGCTGG TTTTGGCATT CTAATAATGTA ATAATAAGAC GTTCAATGGA ACAGGACCAT
6430 6440 6450 6460 6470 6480
GTACAAATGT CAGCACAGTA CAATGTACAC ATGGAATTAG GCCAGTAGTA TCAACTCAAC
6490 6500 6510 6520 6530 6540
TGCTGTTGAA TGGCAGTCTA GCAGAAGAAG AGGTAGTAAT TAGATCTGCC AATTTACAG
6550 6560 6570 6580 6590 6600
ACAATGCTAA AACCATAATA GTACAGCTGA ACGAATCTGT AGAAATTAAT TGTACAAGAC
6610 6620 6630 6640 6650 6660
CCAACAACAA TACAAGAAAA AGTATCCGTA TCCAGAGGGG ACCAGGGAGA GCATTTGTTA
6670 6680 6690 6700 6710 6720
CAATAGGAAA AATAGGAAAT ATGAGACAAG CACATTGTAA CATTAGTAGA GCAAAATGCA
6730 6740 6750 6760 6770 6780
ATGCCACTTT AAAACAGATA GCTAGCAAAT TAAGAGAACA ATTTGGAAAT AATAAAACAA
6790 6800 6810 6820 6830 6840
TAATCTTTAA GCAATCCTCA GGAGGGGACC CAGAAATTGT AACGCACAGT TTTAATTGTG
6850 6860 6870 6880 6890 6900
GAGGGGAATT TTTCTACTCT AATTCAACAC AACTGTTTAA TAGTACTTGG TTTAATAGTA
6910 6920 6930 6940 6950 6960
CTTGGAGTAC TGAAGGGTCA AATAACACTG AAGGAAGTGA CACAATCACA CTCCCATGCA
6970 6980 6990 7000 7010 7020
GAATAAAACA ATTTATAAAC ATGTGGCAGG AAGTAGGAAA AGCAATGTAT GCCCCTCCCA
7030 7040 7050 7060 7070 7080
TCAGCGGACA AATTAGATGT TCATCAAATA TTACAGGGCT GCTATTAACA AGAGATGCTG
7090 7100 7110 7120 7130 7140
GTAATAACAA CAATGGGTCC GAGATCTTCA GACCTGGAGG AGGAGATATC AGGGACAATT
7150 7160 7170 7180 7190 7200
GGAGAAGTGA ATTATATAAA TATAAAGTAG TAAAAATTGA ACCATTAGGA GTAGCACCCA
7210 7220 7230 7240 7250 7260
CCAAGGCAAA GAGAAGAGTG GTGCAGAGAG AAAAAAGAGC AGTGGGAATA GGAGCTTTGT
7270 7280 7290 7300 7310 7320
TCCTTGGGTT CTTGGGAGCA GCAGGAAGCA CTATGGGCGC ACGGTCAATG ACGCTGACGG
7330 7340 7350 7360 7370 7380
TACAGGCCAG ACAATTATTG TCTGGTATAG TGCAGCAGCA GAACAATTG CTGAGGGCTA
7390 7400 7410 7420 7430 7440

46

111078

TTGAGGCGCA ACAUCATCTG TTGCAACTCA CAGTCTGGGG CATCAAGCAG CTCCAGGCAA

7450 7460 7470 7480 7490 7500
GAATCCTGGC TGTGGAAAGT TACCTAAAGG ATCAACAGCT CCTGGGGATT TGGGGTTGCT

7510 7520 7530 7540 7550 7560
CTGGAAACT CATTTCACCC ACTGCTGTGC CTTGGAATGC TAGTTGGAGT AATAAATCTC

7570 7580 7590 7600 7610 7620
TGGAACAGAT TTGGAATAAC ATGACCTGGA TGCGAGTGGG CAGAGAAATT AACAATTACA

7630 7640 7650 7660 7670 7680
CAAGCTTAAT ACATTCTTA ATTGAAGAAT CGCAAAACCA GCAAGAAAAG AATGAACAAG

7690 7700 7710 7720 7730 7740
AATTATTGGA ATTAGATAAA TGGGCAAGTT TGTGGAATTG GTTTAACATA ACAAATTGGC

7750 7760 7770 7780 7790 7800
TGTGGTATAT AAAAATATTC ATAATGATAG TAGGAGGCTT GGTAGGTTTA AGAATAGTTT

7810 7820 7830 7840 7850 7860
TTCTGTACT TTCTATAGTG AATAGAGTTA GGCAGGGATA TTCACCATTA TCGTTTCAGA

7870 7880 7890 7900 7910 7920
CCCACCTCCC AACCCCGAGG GGACCCGACA GGCCCGAAGG AATAGAAGAA GAAGGTGGAG

7930 7940 7950 7960 7970 7980
AGAGAGACAG AGACAGATCC ATTCGATTAG TGAACGGATC CTTAGCACTT ATCTGGGACG

7990 8000 8010 8020 8030 8040
ATCTGCGGAG CCTTGTGCCT CTTGAGCTAC CACCGCTTGA GAGACTTACT CTTGATTGTA

8050 8060 8070 8080 8090 8100
ACGAGGATTG TGGAACTTCT GGGACGCAGG GGGTGGGAAG CCCTCAAATA TTGGTGGAAAT

8110 8120 8130 8140 8150 8160
CTCCTACAGT ATTGGAGTCA GGAACATAAG AATAGTGCTG TTAGCTTGCT CAATGCCACA

8170 8180 8190 8200 8210 8220
GCCATAGCAG TAGCTGAGGG GACAGATAGG GTTATAGAAG TAGTACAAGG AGCTTGTAGA

8230 8240 8250 8260 8270 8280
GCTATTCGCC ACATACCTAG AAGAATAAGA CAGGGCTTGG AAAGGATTTT GCTATAAGAT

8290 8300 8310 8320 8330 8340
GGGTGGCAAG TGGTCAAAAA GTAGTGTGGT TGGATGCCCT ACTGTAAGGG AAAGAATGAG

8350 8360 8370 8380 8390 8400
ACGAGCTGAG CCAGCAGCAG ATGGGGTGGG AGCAGCATCT CGAGACCTGG AAAAACATGG

8410 8420 8430 8440 8450 8460
AGCAATCACA AGTAGCAATA CAGCAGCTAC CAATGCTGCT TGTGCCTGGC TAGAAGCACA

8470 8480 8490 8500 8510 8520
AGAGGAGGAG GAGGTGGGTT TTCCAGTCAC ACCTCAGGTA CCTTTAAGAC CAATGACTTA

8530 8540 8550 8560 8570 8580
CAAGGCAGCT GTAGATCTTA GCCACTTTTT AAAAGAAAAG GGGGCACTGG AAGGGCTAAT

8590 8600 8610 8620 8630 8640
TCACTCCCAA CGAAGACAAG ATATCCTTGA TCTGTGGATC TACCACACAC AAGGCTACTT

8650 8660 8670 8680 8690 8700

111476

CCCTGATTGG CAGAACTACA CACCAGGGCC AGGGGTCAQA TATCCACTGA CCTTTGGATG
8710 8720 8730 8740 8750 8760
GTGCTACAAG CTAGTACCAG TTGAGCCAGA TAAGGTAGAA GAGGCCAATA AAGGAGAGAA
8770 8780 8790 8800 8810 8820
CACCAGCTTG TTACACCCTG TGAGCCTGCA TGGAAATGGAT GACCCTGAGA GAGAAGTGTT
8830 8840 8850 8860 8870 8880
AGAGTGGAGG TTTGACAGCC GCCTAGCATT TCATCACCTG GCCCGAGAGC TGCATCCGGA
8890 8900 8910 8920 8930 8940
GTACTTCAAG AACTGCTGAC ATCGAGCTTG CTACAAGGGA CTTTCCGCTG GGCACITTCC
8950 8960 8970 8980 8990 9000
AGGGAGGCGT GGCCTGGGCG GAACTGGGGA GTGGCGAGCC CTCAGATGCT GCATATAAGC
9010 9020 9030 9040 9050 9060
AGCTGCTTTT TGCCTGTACT GGGTCTCTCT GGTTAGACCA GATTTGAGCC TGGGAGCTCT
9070 9080 9090 9100 0 0
CTGGCTAACT AGGGAACCCA CTGCTTAAGC CTCAATAAAG CTT

Fig 2b

48

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.